

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF OHIO
EASTERN DIVISION**

IN RE NATIONAL PRESCRIPTION
OPIATE LITIGATION

This document relates to:

*The County of Summit, Ohio, et al. v. Purdue
Pharma L.P., et al.*, Case No. 18-OP-45090

*The County of Cuyahoga v. Purdue Pharma
L.P., et al.*, Case No. 18-OP-45004

MDL No. 2804

Case No. 17-md-2804

Hon. Dan Aaron Polster

TEVA, CEPHALON AND ACTAVIS'S THIRD AMENDED EXHIBIT LIST

Defendants Teva Pharmaceuticals, USA, Inc. ("Teva"), Cephalon, Inc. ("Cephalon") and Actavis LLC ("Actavis"), hereby submit the following Third Amended Exhibit List¹ for trial in this matter. The Teva, Cephalon and Actavis Defendants submit this trial exhibit list subject to the following reservation of rights:

1. To withdraw at any time any exhibit identified on these lists;
2. To use admissible exhibits identified or used by Plaintiffs or any other party;
3. To supplement and/or amend these lists upon receipt of Plaintiffs' exhibit list(s), witness list(s) and/or amendments and changes to Plaintiffs' or Defendants' deposition designations or counter-designations;
4. To supplement and/or to amend these lists in the event that additional relevant documents or materials are produced in this action, identified in subsequent supplemental expert reports, or are discovered subsequent to the date of service of these exhibit lists;

¹ Pursuant to the parties' practices in this litigation, the Teva, Cephalon and Actavis Defendants' served prior versions of their exhibit list on all parties.

5. To supplement these lists with any medical or scientific literature, other data, or regulatory findings or communications issued or published after the date of this submission;

6. To supplement and/or to amend these exhibit lists to use additional unlisted documents and/or data at trial as required for rebuttal, cross examination, demonstrative purposes, impeachment purposes, or to cure an evidentiary objection, or to the extent Plaintiffs proffer any documents which Plaintiffs have not listed or to the extent that Plaintiffs purport to pursue claims or theories not set forth in their pleadings to date;

7. To object to the introduction and/or admissibility of any document listed on the exhibit lists;

8. That the inclusion of any exhibit on any exhibit list does not waive or affect any prior confidentiality designations in this litigation;

9. That the inclusion of a particular document on the Teva, Cephalon and Actavis Defendants' exhibit list is not intended to be a waiver of the right to object to the introduction and/or admissibility of that document for any purpose;

10. To use alternative copies of exhibits where appropriate, including but not limited to physical, color, redacted, and/or native documents, or copies, without deposition exhibit stickers;

11. To use trial demonstrative exhibits, including without limitation: charts, graphs, photographs, animations, timelines, objects, models, PowerPoint slides, drawings, graphics, and other demonstrative aids;

12. To offer enlargements of any exhibits on the lists or on any party's exhibit lists;

13. To supplement and/or to amend these lists in response to rulings of the Court on pretrial motions, including any Daubert motions, Motions for Summary Judgment, or motions in limine, or any other Court decisions that affect the scope of evidence in this trial; and

14. To supplement and/or amend these lists as necessary based on the Court's order regarding the severing of particular party and/or as necessary based on future severance, settlement, and/or dismissal of any other party.

Dated: October 20, 2019

Respectfully submitted,

/s/ Wendy West Feinstein

Wendy West Feinstein
MORGAN, LEWIS & BOCKIUS LLP
One Oxford Centre
301 Grant Street
Pittsburgh, PA 15219
Telephone: (412) 560-7455
Facsimile: (412) 560-7001
wendy.feinstein@morganlewis.com

Steven A. Reed
Eric W. Sitarchuk
Harvey Bartle IV
Rebecca J. Hillyer
MORGAN, LEWIS & BOCKIUS LLP
1701 Market St.
Philadelphia, PA 19103-2921
Tel: (215) 963-5603
Facsimile: (215) 963-5001
steven.reed@morganlewis.com
eric.sitarchuk@morganlewis.com
harvey.bartle@morganlewis.com
rebecca.hillyer@morganlewis.com

Nancy L. Patterson
MORGAN, LEWIS & BOCKIUS LLP
1000 Louisiana Street, Suite 4000
Houston, TX 77002-5005
Tel : (713) 890-5195
Facsimile : (713) 890-5001
nancy.patterson@morganlewis.com

Brian Ercole
MORGAN, LEWIS & BOCKIUS LLP
200 South Biscayne Boulevard, Suite 5300
Miami, FL 33131
Telephone: (305) 415-3000
Facsimile: (305) 415-3001
brian.ercole@morganlewis.com

*Attorneys for Cephalon, Inc., Teva Pharmaceuticals
USA, Inc., Watson Laboratories, Inc., Actavis LLC,
Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.,
Warner Chilcott Company, LLC, Actavis South
Atlantic LLC, Actavis Elizabeth LLC, Actavis Mid
Atlantic LLC, Actavis Totowa LLC, Actavis Kadian
LLC, Actavis Laboratories UT, Inc. f/k/a Watson
Laboratories, Inc.-Salt Lake City, and Actavis
Laboratories FL, Inc., f/k/a Watson Laboratories,
Inc.-Florida*

CERTIFICATE OF SERVICE

I hereby certify that on October 20, 2019, a copy of the foregoing Teva, Cephalon and Actavis Defendants' Third Amended Exhibit List was filed electronically. Notice of this filing will be sent to all parties by operation of the Court's electronic filing system. If electronic notice is not indicated through the court's e-filing system, a true and correct copy of the foregoing document was delivered via electronic mail or U.S. Mail.

Dated: October 20, 2019

/s/ Wendy West Feinstein
Wendy West Feinstein

CERTIFICATE OF SERVICE

I hereby certify that on October 20, 2019, a copy of the foregoing Teva, Cephalon and Actavis Defendants' Third Amended Exhibit List was filed electronically. Notice of this filing will be sent to all parties by operation of the Court's electronic filing system. If electronic notice is not indicated through the court's e-filing system, a true and correct copy of the foregoing document was delivered via electronic mail or U.S. Mail.

Dated: October 20, 2019

/s/ Wendy West Feinstein
Wendy West Feinstein

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------------|---------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| AC-1 | 09/15/2006 | Watson Infoalert (notification of generic Actiq) | TEVA_MDL_A_00695612 | TEVA_MDL_A_00695615 | | | | | | | |
| AC-2 | 09/10/2018 | Buprenorphine Naloxone Journal Advertisement | TEVA_MDL_A_02914335 | TEVA_MDL_A_02914335 | | | | | | | |
| AC-3 | 07/01/2010 | Fentanyl Reservoir System Mailer | TEVA_MDL_A_02914336 | TEVA_MDL_A_02914339 | | | | | | | |
| AC-4 | 08/01/2014 | Hydrocodone Bitartrate and Acetaminophen Availability Announcement | TEVA_MDL_A_02914340 | TEVA_MDL_A_02914344 | | | | | | | |
| AC-5 | 06/01/2004 | Oxymorphone Hydrochloride availability announcement | TEVA_MDL_A_02914345 | TEVA_MDL_A_02914347 | | | | | | | |
| AC-6 | 01/05/2015 | Attached Action Stat for Oxycodone HCL ER Tablets, CII | Acquired_Actavis_00835648 | Acquired_Actavis_00835648 | | | | | | | |
| AC-7 | | Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2016-Q1.17 | TEVA_MDL_A_02419960 | TEVA_MDL_A_02419960 | | | | | | | |
| AC-8 | | Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2015 | TEVA_MDL_A_02419963 | TEVA_MDL_A_02419963 | | | | | | | |
| AC-9 | | Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2013-2014 | TEVA_MDL_A_02419969 | TEVA_MDL_A_02419969 | | | | | | | |
| AC-10 | | Direct sales data for Jan 2011 to March 2017 | TEVA_MDL_A_02419962 | TEVA_MDL_A_02419962 | | | | | | | |
| AC-11 | | Opioids Direct Sales (2003-2017) | TEVA_MDL_A_02416205 | TEVA_MDL_A_02416205 | | | | | | | |
| AC-12 | | Opioids Indirect Sales (2011-2017) | TEVA_MDL_A_02416206 | TEVA_MDL_A_02416206 | | | | | | | |
| AC-13 | | Actavis/Watson Indirect Sales | TEVA_MDL_A_07869902 | TEVA_MDL_A_07937356 | | | | | | | |
| AC-14 | | SAP Transactional data for Watson 2004-2005 | TEVA_MDL_A_08637278 | TEVA_MDL_A_08637278 | | | | | | | |
| AC-15 | | Direct Sales data 2006 through Q1 2017 | TEVA_MDL_A_08637279 | TEVA_MDL_A_08637279 | | | | | | | |
| AC-16 | | Indirect Sales data (Model N) Q2 2014 though Q1 2017 | TEVA_MDL_A_08637273 | TEVA_MDL_A_08637277 | | | | | | | |
| AC-17 | | QAD data September 1996-April 2013 | TEVA_MDL_A_13742900 | TEVA_MDL_A_13742900 | | | | | | | |
| AC-18 | | SAP transactional data May 2004-March 2017 | TEVA_MDL_A_13742901 | TEVA_MDL_A_13742901 | | | | | | | |
| AC-19 | | SAP Unique Customer & NDC Codes | TEVA_MDL_A_13742989 | TEVA_MDL_A_13742989 | | | | | | | |
| AC-20 | | Actavis/Watson Model N (Chargeback Data) | Acquired_Actavis_01996162 | Acquired_Actavis_02001522 | | | | | | | |
| AC-21 | 03/11/2019 | Actavis Inc. Health Care Compliance Guide | Acquired_Actavis_01169151 | Acquired_Actavis_01169210 | | | | | | | |
| AC-22 | 07/17/2002 | Watson Pharmaceuticals, Inc. Promotional and Marketing Policies | Acquired_Actavis_01648317 | Acquired_Actavis_01648341 | | | | | | | |
| AC-23 | 03/04/2009 | Corporate Structure Operating Procedure | Acquired_Actavis_00211536 | Acquired_Actavis_00211549 | | | | | | | |
| AC-24 | 06/24/2011 | Handling of DEA Controlled Substances | Acquired_Actavis_00477630 | Acquired_Actavis_00477659 | | | | | | | |
| AC-25 | 10/19/2012 | Potential Sources of Medical Inquiries | Acquired_Actavis_00622914 | Acquired_Actavis_00622931 | | | | | | | |
| AC-26 | 01/23/2013 | Glossary of Terms Relating to Adverse Events | Acquired_Actavis_00622941 | Acquired_Actavis_00622955 | | | | | | | |
| AC-27 | 12/30/2011 | Managing Watson Pharmacovigilance Work Instructions | Acquired_Actavis_00623183 | Acquired_Actavis_00623187 | | | | | | | |
| AC-28 | 02/23/2009 | Fentanyl Patch Outsource of SADR, PC and MI to Prosar | Acquired_Actavis_00963852 | Acquired_Actavis_00963858 | | | | | | | |
| AC-29 | 12/07/2019 | Corporate Guidelines for HR Policies | Acquired_Actavis_01167403 | Acquired_Actavis_01167438 | | | | | | | |
| AC-30 | 11/23/2010 | Global Anti-Corruption Policy | Acquired_Actavis_01168623 | Acquired_Actavis_01168636 | | | | | | | |
| AC-31 | 07/11/2019 | Internal Investigation Procedure and Guidelines | Acquired_Actavis_01169131 | Acquired_Actavis_01169138 | | | | | | | |
| AC-32 | 07/11/2019 | Actavis Inc. Compliance and Integrity "Speaking Up" Policy | Acquired_Actavis_01169139 | Acquired_Actavis_01169142 | | | | | | | |
| AC-33 | 09/07/2011 | SOP MA-006 US Medical Affairs - Elizabeth (USMA-E) Exchange of Cases with Pharmacovigilance Drug Safety Europe (PhVDSE/RoW) | Acquired_Actavis_01169213 | Acquired_Actavis_01169213 | | | | | | | |
| AC-34 | 03/27/2009 | Tracking and Trending of Deviations and CAPAs | Acquired_Actavis_01169958 | Acquired_Actavis_01169964 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------------|---------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| AC-35 | 11/13/2019 | Actavis Code of Conduct | Acquired_Actavis_01190118 | Acquired_Actavis_01190144 | | | | | | | |
| AC-36 | 11/01/2013 | Global Ethics & Compliance Charitable Grants and Donations | Acquired_Actavis_01190347 | Acquired_Actavis_01190361 | | | | | | | |
| AC-37 | 01/20/2009 | Actavis General Procedure Quality Organisation | Acquired_Actavis_01344058 | Acquired_Actavis_01344064 | | | | | | | |
| AC-38 | 04/26/2012 | Safety Signal Detection and Risk Management | Acquired_Actavis_01358902 | Acquired_Actavis_01358910 | | | | | | | |
| AC-39 | Undated | Trending of Suspected Adverse Reactions | Acquired_Actavis_01385293 | Acquired_Actavis_01385296 | | | | | | | |
| AC-40 | 01/01/2009 | Actavis Business Conduct Policy | Acquired_Actavis_01389427 | Acquired_Actavis_01389433 | | | | | | | |
| AC-41 | 07/03/2013 | Global Pharmacovigilance Quality System | Acquired_Actavis_01437838 | Acquired_Actavis_01437848 | | | | | | | |
| AC-42 | 05/17/2011 | Management of Suspected Adverse Drug Reaction Reports | Acquired_Actavis_01440105 | Acquired_Actavis_01440134 | | | | | | | |
| AC-43 | 12/10/2013 | Adverse Event and Product Complaint Procedure | Acquired_Actavis_01440558 | Acquired_Actavis_01440567 | | | | | | | |
| AC-44 | 12/13/2013 | Guidelines for Forwarding Adverse Events, Potential Safety Information, and Quality Defect Complaints | Acquired_Actavis_01440569 | Acquired_Actavis_01440589 | | | | | | | |
| AC-45 | 09/03/2013 | Distribution of Medicinal Products | Acquired_Actavis_01444274 | Acquired_Actavis_01444278 | | | | | | | |
| AC-46 | 01/03/2011 | Business Partner - Evaluation & Handling of Pharmacovigilance Performance | Acquired_Actavis_01444371 | Acquired_Actavis_01444373 | | | | | | | |
| AC-47 | 06/07/2012 | CAPAs Related to Inspection and Audit Findings and Compliance Management in Pharmacovigilance | Acquired_Actavis_01444374 | Acquired_Actavis_01444380 | | | | | | | |
| AC-48 | 03/14/2008 | Use of Oracle Adverse Event Reporting System (AERS) in US Medical Affairs | Acquired_Actavis_01444415 | Acquired_Actavis_01444429 | | | | | | | |
| AC-49 | 11/27/2012 | Crisis Management Standard Operating Procedure | Acquired_Actavis_01444438 | Acquired_Actavis_01444444 | | | | | | | |
| AC-50 | 11/27/2012 | Handling of Safety Issues | Acquired_Actavis_01444450 | Acquired_Actavis_01444457 | | | | | | | |
| AC-51 | 02/14/2013 | Documenting GMP Contacts with Regulatory Agencies | Acquired_Actavis_01445237 | Acquired_Actavis_01445239 | | | | | | | |
| AC-52 | 10/31/2006 | Managing Customer Complaints/ Adverse Drug Events | Acquired_Actavis_01445623 | Acquired_Actavis_01445634 | | | | | | | |
| AC-53 | 08/30/2006 | Management of Medical Inquiries | Acquired_Actavis_01447862 | Acquired_Actavis_01447868 | | | | | | | |
| AC-54 | 03/11/2015 | Actavis Compliance: General Training | Acquired_Actavis_01493361 | Acquired_Actavis_01493411 | | | | | | | |
| AC-55 | 10/04/2011 | Actavis Compliance Program: Speak Up Policy/Actavis Alertline | Acquired_Actavis_01501576 | Acquired_Actavis_01501582 | | | | | | | |
| AC-56 | 11/01/2011 | Regional Meetings: Generic Kadian Sales Team Training | Acquired_Actavis_01325827 | Acquired_Actavis_01325827 | | | | | | | |
| AC-57 | 06/16/2011 | Advertisement & Approval Review/Approval – Oxymorphone ER Journal Ad w/ Summary | Acquired_Actavis_01372605 | Acquired_Actavis_01372609 | | | | | | | |
| AC-58 | 07/25/2007 | SOP RA-003 Review and Approval of Drug Advertising for All ANDA Prescription Drug Products (July 25 2007) | Acquired_Actavis_01389540 | Acquired_Actavis_01389544 | | | | | | | |
| AC-59 | 02/27/2012 | Advertisement & Approval Review/Approval – Morphine Sulfate ER Caps – Electronic Sellsheet with PI attached | Acquired_Actavis_02228429 | Acquired_Actavis_02228433 | | | | | | | |
| AC-60 | 06/28/2011 | Advertisement & Approval Review/Approval – Oxymorphone HCL Extended Release Tabs – Sellsheet | Acquired_Actavis_02230003 | Acquired_Actavis_02230005 | | | | | | | |
| AC-61 | 11/05/2012 | Infolert: Watson/Actavis Acquisition | Acquired_Actavis_02231065 | Acquired_Actavis_02231066 | | | | | | | |
| AC-62 | 09/03/2013 | GQP-08-02 Global Quality Policy: Advertising and Promotion | Acquired_Actavis_01444248 | Acquired_Actavis_01444250 | | | | | | | |
| AC-63 | 01/03/2016 | ANDA Approval | TEVA_MDL_A_02922022 | TEVA_MDL_A_02922025 | | | | | | | |
| AC-64 | 07/11/2013 | ANDA Approval | Acquired_Actavis_00677901 | Acquired_Actavis_00677905 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------------|---------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| AC-65 | 11/17/2017 | ANDA Approval | TEVA_MDL_A_08981645 | TEVA_MDL_A_08981651 | | | | | | | |
| AC-66 | 09/14/2011 | SOP RA-003 Review and Approval of Drug Advertising For Prescription Drugs—Actavis—2011 | ALLERGAN_MDL_00626198 | ALLERGAN_MDL_00626203 | | | | | | | |
| AC-67 | 08/01/2011 | Email RE: Generic equivalent to Opana ER now available from Actavis, pp. 3–4 | ALLERGAN_MDL_00401025 | ALLERGAN_MDL_00401029 | | | | | | | |
| AC-68 | 07/11/2019 | Introduction of Oxymorphone Hydrochloride Extended-Release Tablets, CII: Sales Training Class | ALLERGAN_MDL_00401500 | ALLERGAN_MDL_00401518 | | | | | | | |
| AC-69 | 03/08/2012 | Email from M. Killion re Generic Oxymorphone Update | ALLERGAN_MDL_00445923 | ALLERGAN_MDL_00445923 | | | | | | | |
| AC-70 | 11/11/2019 | Availability Announcement for Generic Kadian (morphine sulfate extended-release) | ALLERGAN_MDL_00478888 | ALLERGAN_MDL_00478889 | | | | | | | |
| AC-71 | 06/14/2011 | Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use for Buprenorphine Hydrochloride and Naloxone Hydrochloride - Form FDA 356h | Acquired_Actavis_00187844 | Acquired_Actavis_00187846 | | | | | | | |
| AC-72 | 05/13/2008 | Supplement to ANDA #77-062 for Fentanyl Transderman System with attached Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use - Form FDA 356h | Acquired_Actavis_00188237 | Acquired_Actavis_00188249 | | | | | | | |
| AC-73 | 02/08/2012 | Email from Jinping McCormick, Director of Marketing, Actavis, to Nathalie Leitch and Terrence Fullem | Acquired_Actavis_02472861 | Acquired_Actavis_02472863 | | | | | | | |
| AC-74 | 06/12/2019 | NAM/MSL Engagement Training | Acquired_Actavis_00448595 | Acquired_Actavis_00448609 | | | | | | | |
| AC-75 | 07/25/2007 | SOP RA-003 Review and Approval of Drug Advertising for All ANDA Prescription Drug Products | Acquired_Actavis_00985705 | Acquired_Actavis_00985722 | | | | | | | |
| AC-76 | 07/22/2011 | Full Product Catalog Review, and Generic Return Goods Policy | Acquired_Actavis_01063667 | Acquired_Actavis_01063689 | | | | | | | |
| AC-77 | 12/23/2013 | GCPOL-014US Policy on Contracting with Healthcare Professionals | Acquired_Actavis_01190024 | Acquired_Actavis_01190031 | | | | | | | |
| AC-78 | 05/04/2011 | Compliance Policies on Interacting with Health Care Professionals and Other Customers | Acquired_Actavis_01190039 | Acquired_Actavis_01190109 | | | | | | | |
| AC-79 | 12/23/2013 | U.S. Policy on Promotion, Non-Promotional, and Off-Label Interactions and Materials | Acquired_Actavis_01190436 | Acquired_Actavis_01190449 | | | | | | | |
| AC-80 | 03/06/2009 | SOP C0-001 Product Recall Procedure | Acquired_Actavis_01403294 | Acquired_Actavis_01403312 | | | | | | | |
| AC-81 | 07/07/2005 | Corporate Quality Policy: Drug Product Recalls and Market Withdrawals | Acquired_Actavis_01495263 | Acquired_Actavis_01495270 | | | | | | | |
| AC-82 | 01/07/2019 | C-260 Watson Pharmaceuticals, Inc. Human Resources Policy and Procedures Manual: Speaking Engagements | Acquired_Actavis_01495791 | Acquired_Actavis_01495791 | | | | | | | |
| AC-83 | 01/28/2013 | Actavis - SOM System Logic | TEVA_MDL_A_01038898 | TEVA_MDL_A_01038942 | | | | | | | |
| AC-84 | 03/21/2016 | Actavis - Power Point re SOM Program | TEVA_MDL_A_01038978 | TEVA_MDL_A_01038993 | | | | | | | |
| AC-85 | 10/18/2013 | Actavis - Controlled SOM Procedure | TEVA_MDL_A_01039097 | TEVA_MDL_A_01039100 | | | | | | | |
| AC-86 | 03/11/2014 | Actavis - SOM program overview after merger with Watson. | TEVA_MDL_A_01039190 | TEVA_MDL_A_01039190 | | | | | | | |
| AC-87 | 10/04/2011 | Watson - Investigation Summary Suspicious Order TOP RX, Inc. | TEVA_MDL_A_01039670 | TEVA_MDL_A_01039671 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------------|---------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| AC-88 | 05/17/2012 | Watson - PowerPoint titled Global Security & DEA Affairs Audit Summary: Top RX, Inc. | TEVA_MDL_A_01039672 | TEVA_MDL_A_01039672 | | | | | | | |
| AC-89 | 05/30/2012 | Watson - Letter to Top RX, Inc. re Restoration of Business Relationship After Audit | TEVA_MDL_A_01039673 | TEVA_MDL_A_01039673 | | | | | | | |
| AC-90 | 07/19/2011 | Watson - cSOP – 11-004 – Revision 004 – Suspicious Orders of Controlled Drugs (July 19 2011) | TEVA_MDL_A_01130615 | TEVA_MDL_A_01130619 | | | | | | | |
| AC-91 | | Watson - DEA Affairs Organizational Overview (2009-2010) | TEVA_MDL_A_01159593 | TEVA_MDL_A_01159603 | | | | | | | |
| AC-92 | 09/27/2012 | Email RE: Order(s) on Hold - Cardinal SD# 574340 | ALLERGAN_MDL_04173111 | ALLERGAN_MDL_04173113 | | | | | | | |
| AC-93 | 01/11/2016 | Email RE: Bell Medical | ALLERGAN_MDL_03431731 | ALLERGAN_MDL_03431739 | | | | | | | |
| AC-94 | 01/31/2011 | E-mail from Rachelle Galant to Kelly Smith (re: Ox., IR Tabs Suspicious Order SOP revised 1-28-2011). | ALLERGAN_MDL_00493795 | ALLERGAN_MDL_00493795 | | | | | | | |
| AC-95 | 09/12/2012 | E-mail from Rachelle Grant to Nancy Baran (re: Last question I promise). | Acquired_Actavis_00099564 | Acquired_Actavis_00099564 | | | | | | | |
| AC-96 | 09/25/2012 | E-mail from Michael Clarke to Nancy Baran, et. al (re: SOM meeting). | ALLERGAN_MDL_01641955 | ALLERGAN_MDL_01641956 | | | | | | | |
| AC-97 | 02/14/2012 | E-mail from Jinping McCormick to Michael Perfetto and Rachelle Galant (re: RE: safe and secure). | ALLERGAN_MDL_01725016 | ALLERGAN_MDL_01725019 | | | | | | | |
| AC-98 | 03/08/2012 | E-mail from Nancy Baran to Michael Clarke, et. al (re: SOM PROJECT TEAM WEEKLY STATUS- Following our meeting on Tuesday, 3/6). | ALLERGAN_MDL_01719862 | ALLERGAN_MDL_01719862 | | | | | | | |
| AC-99 | 06/25/2015 | E-mail from Thomas Napoli to Tara Brolly re: (ACTION REQUIRED: Information Request from Pinney Associates). | Acquired_Actavis_00930887 | Acquired_Actavis_00930890 | | | | | | | |
| AC-100 | 05/06/2011 | E-mail from Nancy Baran to Beth Zelnick-Kaufman, et. al (re: FW: Actavis / BuzzeoPDMA - Customer Services Agreement - SOM Services). | ALLERGAN_MDL_01860386 | ALLERGAN_MDL_01860387 | | | | | | | |
| AC-101 | 09/30/2013 | Email from T. Napoli to ABC requesting DEA/SOM Compliance materials and information | TEVA_MDL_A_01037632 | TEVA_MDL_A_01037632 | | | | | | | |
| AC-102 | 09/30/2013 | Letter from T. Napoli to ABC requesting DEA/SOM Compliance materials and information | TEVA_MDL_A_01037633 | TEVA_MDL_A_01037634 | | | | | | | |
| AC-103 | 09/30/2013 | Actaivs / ABC - Compliance Acknowledgement Form | TEVA_MDL_A_01037635 | TEVA_MDL_A_01037635 | | | | | | | |
| AC-104 | 09/30/2013 | Overview of ABC's Diversion Control Program | TEVA_MDL_A_01037636 | TEVA_MDL_A_01037638 | | | | | | | |
| AC-105 | 02/26/2013 | Email from Ed. Hazewski to Tom Napoli Attaching Completed Due Diligence Documents | TEVA_MDL_A_01037639 | TEVA_MDL_A_01037640 | | | | | | | |
| AC-106 | 12/27/2011 | Correspondence with DEA Re: Procurement Quota | Acquired_Actavis_00220379 | Acquired_Actavis_00220380 | | | | | | | |
| AC-107 | 12/27/2011 | Actavis Elizabeth, LLC Quota Approval - RK0146806 12-27-2011.pdf | Acquired_Actavis_00456460 | Acquired_Actavis_00456461 | | | | | | | |
| AC-108 | 07/17/2009 | Correspondence with DEA Re: Procurement Quota | Acquired_Actavis_01378198 | Acquired_Actavis_01378198 | | | | | | | |
| AC-109 | 07/17/2009 | Watson Laboratories Inc Quota Approval - RW0117261 07-17-09.PDF | Acquired_Actavis_01378199 | Acquired_Actavis_01378199 | | | | | | | |
| AC-110 | 12/31/2009 | Correspondence with DEA Re: Procurement Quota | Acquired_Actavis_01378389 | Acquired_Actavis_01378389 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------------|---------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| AC-111 | 12/31/2009 | Watson Laboratories Inc Quota Approval RW0331885 12-23-2009.pdf | Acquired_Actavis_01378390 | Acquired_Actavis_01378390 | | | | | | | |
| AC-112 | 12/31/2009 | Watson Laboratories Inc Quota Approval- Florida RA0279946 12-23-2009.pdf | Acquired_Actavis_01378391 | Acquired_Actavis_01378391 | | | | | | | |
| AC-113 | 12/31/2009 | Watson Laboratories Inc Quota Approval - Florida RA0297033 12-23-2009.pdf | Acquired_Actavis_01378392 | Acquired_Actavis_01378392 | | | | | | | |
| AC-114 | 12/31/2009 | Watson Laboratories Inc Quota Approval - Florida RA0352663 12-23-2009.pdf | Acquired_Actavis_01378393 | Acquired_Actavis_01378393 | | | | | | | |
| AC-115 | 12/31/2009 | Watson Laboratories Inc Quota Approval RD0118150 12-23-2009.pdf | Acquired_Actavis_01378394 | Acquired_Actavis_01378394 | | | | | | | |
| AC-116 | 12/31/2009 | Watson Laboratories Inc Quota Approval RW0117261 12-23-2009.pdf | Acquired_Actavis_01378395 | Acquired_Actavis_01378395 | | | | | | | |
| AC-117 | 12/31/2009 | Watson Laboratories Inc Quota Approval RW0288933 12-23-2009.pdf | Acquired_Actavis_01378396 | Acquired_Actavis_01378396 | | | | | | | |
| AC-118 | 12/30/2010 | Correspondence with DEA Re: Procurement Quota | Acquired_Actavis_01378409 | Acquired_Actavis_01378409 | | | | | | | |
| AC-119 | 12/30/2010 | Andrx dba Watson Quota Approval RA0279946 12-29-10.PDF | Acquired_Actavis_01378410 | Acquired_Actavis_01378410 | | | | | | | |
| AC-120 | 12/30/2010 | Andrx dba Watson Quota Approval RA0297033 12-29-10.PDF | Acquired_Actavis_01378411 | Acquired_Actavis_01378411 | | | | | | | |
| AC-121 | 12/30/2010 | Andrx dba Watson Quota Approval RA0352663 12-29-10.PDF | Acquired_Actavis_01378412 | Acquired_Actavis_01378412 | | | | | | | |
| AC-122 | 12/30/2010 | Watson Quota Approval RW0117261 12-29-10.PDF | Acquired_Actavis_01378413 | Acquired_Actavis_01378413 | | | | | | | |
| AC-123 | 12/30/2010 | Watson Quota Approval RW0259893 12-2910.PDF | Acquired_Actavis_01378414 | Acquired_Actavis_01378414 | | | | | | | |
| AC-124 | 12/30/2010 | Watson Quota Approval RW0288933 12-29-10.PDF | Acquired_Actavis_01378415 | Acquired_Actavis_01378415 | | | | | | | |
| AC-125 | 06/10/2014 | Actavis Laboratories Fl, Inc. Quota Approval RA0297033 6-9-2014.pdf | Acquired_Actavis_01378873 | Acquired_Actavis_01378873 | | | | | | | |
| AC-126 | 06/10/2014 | Actavis Laboratories, FL, Inc. Quota Approval RA0279946 6-9-2014.pdf | Acquired_Actavis_01378874 | Acquired_Actavis_01378874 | | | | | | | |
| AC-127 | 08/12/2014 | Actavis Laboratories Fl, Inc. Quota Approval RS0297033_8-12-2014.pdf | Acquired_Actavis_01379145 | Acquired_Actavis_01379145 | | | | | | | |
| AC-128 | 12/28/2011 | Watson Laboratories_Quota Approval RA0297033_12-27-2011pdf.pdf | Acquired_Actavis_01379672 | Acquired_Actavis_01379672 | | | | | | | |
| AC-129 | 12/28/2011 | Watson laboratories Quota Approval RA0279946 12-28-2011.pdf | Acquired_Actavis_01379673 | Acquired_Actavis_01379673 | | | | | | | |
| AC-130 | 07/19/2011 | DEA Quota Letter.msg | Acquired_Actavis_01379850 | Acquired_Actavis_01379850 | | | | | | | |
| AC-131 | 07/19/2011 | Watson Quota Approval RW0117261 7-18-11.PDF | Acquired_Actavis_01379851 | Acquired_Actavis_01379851 | | | | | | | |
| AC-132 | 08/05/2011 | DEA Quota Letters.msg | Acquired_Actavis_01379900 | Acquired_Actavis_01379900 | | | | | | | |
| AC-133 | 08/05/2011 | Andrx Pharmaceuticals Inc-FL Quota Approval RA0279946 08-05-11.PDF | Acquired_Actavis_01379901 | Acquired_Actavis_01379901 | | | | | | | |
| AC-134 | 08/05/2011 | Andrx Pharmaceuticals Inc-FL Quota Approval RA035266 08-05-11.PDF | Acquired_Actavis_01379902 | Acquired_Actavis_01379902 | | | | | | | |
| AC-135 | 09/30/2014 | Actavis Laboratories, Inc.-Florida Quota Approval RA0279946_9-26-2014.pdf | Acquired_Actavis_01379975 | Acquired_Actavis_01379975 | | | | | | | |
| AC-136 | 04/28/2016 | Correspondence with DEA Re: Procurement Quota | Acquired_Actavis_01842692 | Acquired_Actavis_01842692 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------------|---------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| AC-137 | 04/28/2016 | Actavis Laboratories FL, Inc. Quota Approval RA0352663_4-28-2016.pdf | Acquired_Actavis_01842693 | Acquired_Actavis_01842693 | | | | | | | |
| AC-138 | 04/25/2016 | Correspondence with DEA Re: Procurement Quota | Acquired_Actavis_01842907 | Acquired_Actavis_01842907 | | | | | | | |
| AC-139 | 04/25/2016 | Actavis Elizabeth LLC Quota Approval RK0146806_04-25-2016.pdf | Acquired_Actavis_01842908 | Acquired_Actavis_01842908 | | | | | | | |
| AC-140 | 05/16/2006 | Correspondence with DEA Re: Procurement Quota | Acquired_Actavis_01843751 | Acquired_Actavis_01843751 | | | | | | | |
| AC-141 | 05/16/2016 | Warner Chilcott Company, LLC Quota Approval RW0456865_5-16-2016.pdf | Acquired_Actavis_01843752 | Acquired_Actavis_01843752 | | | | | | | |
| AC-142 | 09/21/2010 | Correspondence with DEA Re: Procurement Quota | Acquired_Actavis_01673258 | Acquired_Actavis_01673258 | | | | | | | |
| AC-143 | 09/20/2010 | Watson Laboratories, Inc. Quota Approval (RW0117261) 09-20-2010.pdf | Acquired_Actavis_01673259 | Acquired_Actavis_01673259 | | | | | | | |
| AC-144 | 02/11/2011 | Correspondence with DEA Re: Procurement Quota | Acquired_Actavis_01673272 | Acquired_Actavis_01673272 | | | | | | | |
| AC-145 | 02/11/2011 | Watson Laboratories Inc Quota Approval RW0331885 02-11-11.PDF | Acquired_Actavis_01673273 | Acquired_Actavis_01673273 | | | | | | | |
| AC-146 | 12/27/2011 | Watson Laboratories Quota Approval _RW0117261_12-27-2011.pdf | Acquired_Actavis_01674724 | Acquired_Actavis_01674724 | | | | | | | |
| AC-147 | 08/09/2002 | Watson Laboratories Inc-FL Quota Approval RA0279946 -08-09-12.pdf | Acquired_Actavis_01674898 | Acquired_Actavis_01674898 | | | | | | | |
| AC-148 | 09/10/2014 | Actavis Elizabeth, LLC Quota Approval RK0146806_9-10-2014.pdf | Acquired_Actavis_01674917 | Acquired_Actavis_01674917 | | | | | | | |
| AC-149 | 08/09/2012 | Watson Laboratories Inc- Quota Approval FL RA0352663 -08-09-12.pdf | Acquired_Actavis_01674947 | Acquired_Actavis_01674947 | | | | | | | |
| AC-150 | 10/01/2012 | Watson Laboratories Quota Approval RW0117261 10-01-2012.pdf | Acquired_Actavis_01675117 | Acquired_Actavis_01675117 | | | | | | | |
| AC-151 | 08/06/2012 | Watson Quota Approval RW0117261 8-6-2012.pdf | Acquired_Actavis_01675146 | Acquired_Actavis_01675146 | | | | | | | |
| AC-152 | 09/19/2014 | Correspondence with DEA Re: Procurement Quota | Acquired_Actavis_01675402 | Acquired_Actavis_01675402 | | | | | | | |
| AC-153 | 10/22/2014 | Actavis Laboratories FL, Inc. Quota Approval RA0352663_10-22-2014.pdf | Acquired_Actavis_01675450 | Acquired_Actavis_01675450 | | | | | | | |
| AC-154 | 09/25/2014 | Actavis Laboratories Florida, Inc. Quota Approval RA0352663_9-25-2014.pdf | Acquired_Actavis_01675486 | Acquired_Actavis_01675486 | | | | | | | |
| AC-155 | 09/25/2014 | Watson Laboratories, Inc. Quota Approval RW0288933_9-25-2014.pdf | Acquired_Actavis_01675547 | Acquired_Actavis_01675547 | | | | | | | |
| AC-156 | 09/10/2014 | Actavis, LLC Quota Approval RA0419552_9-10-2014.pdf | Acquired_Actavis_01675562 | Acquired_Actavis_01675562 | | | | | | | |
| AC-157 | 12/27/2011 | Actavis Elizabeth, LLC Quota Approval RK0146806 12-27-2011.pdf | Acquired_Actavis_01696447 | Acquired_Actavis_01696448 | | | | | | | |
| AC-158 | 12/27/2011 | Watson Laboratories_Quota Approval RW0117261_12-27-2011.pdf | ALLERGAN_MDL_03737793 | ALLERGAN_MDL_03737794 | | | | | | | |
| AC-159 | 11/30/2012 | Watson Laboratories Quota Approval RW0117261 11-30-2012.pdf | ALLERGAN_MDL_03740473 | ALLERGAN_MDL_03740473 | | | | | | | |
| AC-160 | 08/06/2012 | Watson Quota Approval RW0117261 8-6-2012.pdf | ALLERGAN_MDL_03740683 | ALLERGAN_MDL_03740684 | | | | | | | |
| AC-161 | 07/30/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03953857 | ALLERGAN_MDL_03953857 | | | | | | | |
| AC-162 | 07/29/2008 | Watson DEA Approval letter for Hydrocodone 7-29-08.PDF | ALLERGAN_MDL_03953858 | ALLERGAN_MDL_03953858 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------------|---------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| AC-163 | 09/23/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03953866 | ALLERGAN_MDL_03953866 | | | | | | | |
| AC-164 | 09/22/2008 | Andrx Pharmaceuticals hydrocodone letter - FL.PDF | ALLERGAN_MDL_03953867 | ALLERGAN_MDL_03953867 | | | | | | | |
| AC-165 | 12/30/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03953868 | ALLERGAN_MDL_03953868 | | | | | | | |
| AC-166 | 12/29/2008 | Watson Laboratories RW0288933 12-29-08.PDF | ALLERGAN_MDL_03953869 | ALLERGAN_MDL_03953869 | | | | | | | |
| AC-167 | 12/29/2008 | Watson Laboratories RD0118150 12-29-08.PDF | ALLERGAN_MDL_03953870 | ALLERGAN_MDL_03953870 | | | | | | | |
| AC-168 | 12/29/2008 | Watson Laboratories RW0117261 12-2908.PDF | ALLERGAN_MDL_03953871 | ALLERGAN_MDL_03953872 | | | | | | | |
| AC-169 | 12/29/2008 | Watson Laboratories RW0259893 12-29-08.PDF | ALLERGAN_MDL_03953873 | ALLERGAN_MDL_03953873 | | | | | | | |
| AC-170 | 12/29/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03953881 | ALLERGAN_MDL_03953881 | | | | | | | |
| AC-171 | 12/29/2008 | Andrx Pharmaceuticals Inc dba Watson Laboratories(FL) RA0297033 12-29-08.PDF | ALLERGAN_MDL_03953882 | ALLERGAN_MDL_03953882 | | | | | | | |
| AC-172 | 12/29/2008 | Andrx Pharmaceuticals Inc RA0279946 12-29-08.PDF | ALLERGAN_MDL_03953883 | ALLERGAN_MDL_03953884 | | | | | | | |
| AC-173 | 11/17/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03954097 | ALLERGAN_MDL_03954097 | | | | | | | |
| AC-174 | 11/14/2008 | Watson Laboratories Inc RD0118150 11-14-08.PDF | ALLERGAN_MDL_03954098 | ALLERGAN_MDL_03954098 | | | | | | | |
| AC-175 | 11/14/2008 | Andrx Pharmaceuticals Inc RA0279946 11-14-08.PDF | ALLERGAN_MDL_03954099 | ALLERGAN_MDL_03954099 | | | | | | | |
| AC-176 | 11/14/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03954259 | ALLERGAN_MDL_03954259 | | | | | | | |
| AC-177 | 11/13/2008 | Watson Laboratories Inc RW0117261 11-13-08.PDF | ALLERGAN_MDL_03954260 | ALLERGAN_MDL_03954260 | | | | | | | |
| AC-178 | 11/13/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03954938 | ALLERGAN_MDL_03954938 | | | | | | | |
| AC-179 | 04/14/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03955344 | ALLERGAN_MDL_03955344 | | | | | | | |
| AC-180 | 04/14/2008 | Sales to DEA.xls | ALLERGAN_MDL_03955345 | ALLERGAN_MDL_03955345 | | | | | | | |
| AC-181 | 11/25/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03956249 | ALLERGAN_MDL_03956249 | | | | | | | |
| AC-182 | 11/25/2008 | Watson Laboratories RW0117261 11-25-08.PDF | ALLERGAN_MDL_03956250 | ALLERGAN_MDL_03956250 | | | | | | | |
| AC-183 | 08/20/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03962766 | ALLERGAN_MDL_03962766 | | | | | | | |
| AC-184 | 08/20/2008 | Andrx Pharmaceuticals hydrocodone letter.PDF | ALLERGAN_MDL_03962767 | ALLERGAN_MDL_03962767 | | | | | | | |
| AC-185 | 08/20/2008 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_03966301 | ALLERGAN_MDL_03966301 | | | | | | | |
| AC-186 | 05/19/2016 | Correspondence with DEA Re: Procurement Quota | ALLERGAN_MDL_04018690 | ALLERGAN_MDL_04018690 | | | | | | | |
| AC-187 | 05/19/2016 | Actavis Laboratories FL, Inc. RA0279946_5-19-2016.pdf | ALLERGAN_MDL_04018691 | ALLERGAN_MDL_04018691 | | | | | | | |
| AC-188 | 12/08/2017 | Actavis Labs FL Inc RA0279946 12-8-17.pdf | Acquired_Actavis_02340018 | Acquired_Actavis_02340018 | | | | | | | |
| AC-189 | 12/08/2017 | Actavis Labs FL Inc RA0352663 12-8-17.pdf | Acquired_Actavis_02340020 | Acquired_Actavis_02340020 | | | | | | | |
| AC-190 | 03/17/2011 | Oxy IR Tabs Suspicious Order SOP revised 3-17-2011.doc | ALLERGAN_MDL_00490306 | ALLERGAN_MDL_00490307 | | | | | | | |
| AC-192 | 11/03/2010 | Suspicious Order Report-082009.doc | ALLERGAN_MDL_02128514 | ALLERGAN_MDL_02128514 | | | | | | | |
| AC-199 | 10/18/2013 | Know Your Customer Policy.docx | ALLERGAN_MDL_02176554 | ALLERGAN_MDL_02176557 | | | | | | | |
| AC-205 | 09/26/2011 | Watson Laboratories Inc RA0352663 - 09-23-11.PDF | TEVA_MDL_A_13737062 | TEVA_MDL_A_13737062 | | | | | | | |
| AC-206 | 09/26/2011 | Watson Laboratories Inc RA0279946 - 09-23-11.PDF | TEVA_MDL_A_13737063 | TEVA_MDL_A_13737063 | | | | | | | |
| AC-207 | 05/03/2004 | Watson Call Center Operations Master Data / License Admin. Operational Procedure – CII Schedule Drugs and SOMS Blocks Procedure | ALLERGAN_MDL_01175574 | ALLERGAN_MDL_01175585 | | | | | | | |
| AC-209 | 04/25/2012 | Email from Nancy Baran re SOM Project Team Status/Upcoming Steering Committee Meeting | ALLERGAN_MDL_01729077 | ALLERGAN_MDL_01729081 | | | | | | | |
| AC-210 | 06/12/2013 | User Requirement Specification | ALLERGAN_MDL_01767369 | ALLERGAN_MDL_01767371 | | | | | | | |
| AC-214 | 11/13/2013 | Actavis - Letter to Supply Chain Customer re Actavis DEA Affairs Efforts To Prevent Diversion | TEVA_MDL_A_01037413 | TEVA_MDL_A_01037414 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------------|---------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| AC-215 | Undated | Actavis - Compliance Acknowledgement Form to Customers | TEVA_MDL_A_01037415 | TEVA_MDL_A_01037415 | | | | | | | |
| AC-217 | 02/17/2010 | Email Re: REMS – Contact person | Acquired_Actavis_00657205 | Acquired_Actavis_00657207 | | | | | | | |
| AC-219 | 10/16/2012 | Letter from Actavis Elizabeth LLC to FDA: REMS Amendment | Acquired_Actavis_01383113 | Acquired_Actavis_01383114 | | | | | | | |
| AC-220 | 12/13/2012 | Email RE: Investigation Summary Capital Wholesale | ALLERGAN_MDL_02187194 | ALLERGAN_MDL_02187194 | | | | | | | |
| AC-221 | 11/21/2011 | FW: Approved (Not Released) – Buprenorphine Naloxone A303 | Acquired_Actavis_01662177 | Acquired_Actavis_01662185 | | | | | | | |
| AC-222 | 04/30/2012 | SOM Presentation to Cardinal Health | ALLERGAN_MDL_00277101 | ALLERGAN_MDL_00277110 | | | | | | | |
| AC-223 | 01/01/2012 | Opioid REMS Program Agreement | ALLERGAN_MDL_02823086 | ALLERGAN_MDL_02823109 | | | | | | | |
| AC-224 | Undated | Actavis Customer Due Diligence Documents | TEVA_MDL_A_01037239 | TEVA_MDL_A_01042706 | | | | | | | |
| AC-225 | Undated | IMS Xponent | ALLERGAN_MDL_03320305 | ALLERGAN_MDL_03320305 | | | | | | | |
| AC-226 | Undated | IMS Xponent | ALLERGAN_MDL_03320303 | ALLERGAN_MDL_03320303 | | | | | | | |
| AC-227 | 02/02/2013 | Approval Letter Buprenorphine HCI and Naloxone HCI Dihydrate Sublingual Tablets | Acquired_Actavis_01373545 | Acquired_Actavis_01373584 | | | | | | | |
| AC-228 | 11/10/2011 | Watson Pharmaceuticals Press Release: Watson Launches Generic Kadian | Acquired_Actavis_01935615 | Acquired_Actavis_01935616 | | | | | | | |
| AC-229 | 06/00/2011 | Oxymorphone Hydrochloride Extended Release Tablets, CII Availability Announcement | ALLERGAN_MDL_01040653 | ALLERGAN_MDL_01040681 | | | | | | | |
| AC-230 | 9/3/2001 | Letter from L. DaCunha to Customer Support Services re DEA Excess/ Max Qty. - Suspicious Orders of Controlled Drugs | ALLERGAN_MDL_01844864 | ALLERGAN_MDL_01844865 | | | | | | | |
| AC-231 | 6/14/2002 | Letter from E. David to Call Center Operation re DEA Excess/ Controlled Substance New Product Launch and Suspicious Orders of Controlled Drugs | ALLERGAN_MDL_01844724 | ALLERGAN_MDL_01844725 | | | | | | | |
| AC-232 | 5/3/2004 | Watson Pharma, Inc. Call Center Operations - Call Center Operational Procedure of Suspicious Orders of Controlled Drugs | ALLERGAN_MDL_01839001 | ALLERGAN_MDL_01839002 | | | | | | | |
| AC-233 | 9/22/2004 | Email from E. David to J. Wobeser, D. Grimm and S. Guzman re cSOP Training | ALLERGAN_MDL_01838989 | ALLERGAN_MDL_01838990 | | | | | | | |
| AC-234 | 9/19/2005 | Watson Pharmaceuticals, Inc. Corporate Standard Operating Procedure of Suspicious Orders of Controlled Drugs, No. CSOP 11-004 | ALLERGAN_MDL_03951885 | ALLERGAN_MDL_03951888 | | | | | | | |
| AC-235 | 9/23/2005 | Watson Pharma, Inc. Call Center Operations - Call Center Operational Procedure for Suspicious Orders of Controlled Drugs | Acquired_Actavis_01495929 | Acquired_Actavis_01495930 | | | | | | | |
| AC-236 | 11/17/2005 | Watson Pharma, Inc. Call Center Operations Licenses Administrator Operational Procedure of SAP License Maintenance, Create, Change License or Create, Change, Change Listing/ Exclusion for Controlled and Non-Controlled Substance License | ALLERGAN_MDL_03953044 | ALLERGAN_MDL_03953065 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|-----------------------|-----------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| AC-237 | 4/4/2007 | Watson Pharma, Inc. Call Center Operations Licenses Administrator Operational Procedure of License Maintenance, Create, Change License or Create, Change, Change Listing/ Exclusion for Controlled and Non-Controlled Substance License | ALLERGAN_MDL_03952774 | ALLERGAN_MDL_03952793 | | | | | | | |
| AC-238 | 4/7/2009 | Watson Pharmaceuticals, Inc. Corporate Standard Operating Procedure for Suspicious Orders of Controlled Drugs, No. CSOP 011-004 | ALLERGAN_MDL_03641386 | ALLERGAN_MDL_03641389 | | | | | | | |
| AC-239 | 6/28/2009 | Process for Suspicious Orders of Controlled Drugs | ALLERGAN_MDL_02467151 | ALLERGAN_MDL_02467154 | | | | | | | |
| AC-240 | 8/18/2009 | Email from N. Baran to J. LaRocca re Suspicious Orders | ALLERGAN_MDL_02081243 | ALLERGAN_MDL_02081245 | | | | | | | |
| AC-241 | 11/3/2010 | Email from U. Solanki to J. McCormick re Suspicious Order Logic | ALLERGAN_MDL_02128513 | ALLERGAN_MDL_02128513 | | | | | | | |
| AC-244 | 7/19/2011 | Watson Pharmaceuticals, Inc. Corporate Standard Operating Procedure for Suspicious Orders of Controlled Drugs, Document No. CSOP 011-004 | ALLERGAN_MDL_02146521 | ALLERGAN_MDL_02146525 | | | | | | | |
| AC-245 | 1/5/2012 | Watson Pharma, Inc. Call Center Operations, Master Data / License Admin. Operational Procedure for License Maintenance, Create, Change License or Create, Change Listing/ Exclusion for Controlled and Non-Controlled Substance License | ALLERGAN_MDL_01175574 | ALLERGAN_MDL_01175585 | | | | | | | |
| AC-246 | 10/26/2012 | Actavis Suspicious Order Monitoring - Direct Customer Sales SOP | ALLERGAN_MDL_01684748 | ALLERGAN_MDL_01684752 | | | | | | | |
| AC-247 | 6/5/2014 | Actavis Pharma Inc. US Order Management, Master Data / License Admin. Operational Procedure | ALLERGAN_MDL_03750135 | ALLERGAN_MDL_03750146 | | | | | | | |
| AC-248 | 10/26/2015 | Actavis Suspicious Order Monitoring - Indirect Customer Sales SOP | ALLERGAN_MDL_01979834 | ALLERGAN_MDL_01979838 | | | | | | | |
| AC-249 | 1/6/2016 | Actavis Standard Operating Procedure for Controlled Substance Order Monitoring Policy | ALLERGAN_MDL_02146301 | ALLERGAN_MDL_02146307 | | | | | | | |
| AC-250 | 1/6/2016 | Watson: Controlled Substance Compliance SOMS System Flow | ALLERGAN_MDL_02146308 | ALLERGAN_MDL_02146309 | | | | | | | |
| AC-251 | 1/11/2016 | Actavis DEA Affairs, Controlled Substance Suspicious Order Monitoring: ' Order of Interest' Evaluation | ALLERGAN_MDL_02146077 | ALLERGAN_MDL_02146080 | | | | | | | |
| AC-252 | 1/11/2016 | Actavis Suspicious Order Monitoring Program Overview | ALLERGAN_MDL_02146081 | ALLERGAN_MDL_02146081 | | | | | | | |
| AC-253 | 1/11/2016 | Actavis Suspicious Order Monitoring Program, Customer Due Diligence Overview | ALLERGAN_MDL_02146314 | ALLERGAN_MDL_02146315 | | | | | | | |
| AC-254 | 1/11/2016 | Actavis DEA Affairs re Controlled Substance Customer Knowledge Policy (Know Your Customer) | ALLERGAN_MDL-02176554 | ALLERGAN_MDL-02176557 | | | | | | | |
| AC-255 | 5/26/2016 | Actavis Corporate Standard Operating Procedure, Controlled Substance Order Monitoring Policy (No. CSOP 001-163) | TEVA_MDL_A_01037228 | TEVA_MDL_A_01037235 | | | | | | | |
| AC-256 | 5/26/2016 | Actavis Corporate Standard Operating Procedure, Controlled Substance Compliance Policy (No. CSOP 001-165) | TEVA_MDL_A_06619234 | TEVA_MDL_A_06619242 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|-----------------------|-----------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| AC-257 | 1/17/2019 | Email from M. Woods to T. Napoli re Call Center SOP | ALLERGAN_MDL_02467143 | ALLERGAN_MDL_02467154 | | | | | | | |
| CE-1 | 01/01/2017 | ACT039 - Overall Efficacy of ACTIQ in Opioid-Tolerant Patients with Breakthrough Cancer Pain | TEVA_MDL_A_01088915 | TEVA_MDL_A_01088921 | | | | | | | |
| CE-4 | 09/00/2011 | ACT011 - Use of ACTIQ in Opioid-Tolerant Patients with Chronic Non-Cancer Pain | TEVA_MDL_A_00705148 | TEVA_MDL_A_00705151 | | | | | | | |
| CE-5 | 08/00/2011 | FENT008 - Overall Efficacy of FENTORA | TEVA_MDL_A_00705333 | TEVA_MDL_A_00705337 | | | | | | | |
| CE-6 | 04/28/2008 | Review Process for Investigator Sponsored Studies | TEVA_MDL_A_00552592 | TEVA_MDL_A_00552602 | | | | | | | |
| CE-28 | Undated | Table of Clinical Studies: Table 2: Fentora (fentanyl buccal tablet) | TEVA_MDL_A_08235305 | TEVA_MDL_A_08235315 | | | | | | | |
| CE-30 | 12/06/2010 | HCP Website ACTIQ 2010 (Re-approval 1) | TEVA_MDL_A_01151384 | TEVA_MDL_A_01151412 | | | | | | | |
| CE-32 | 12/06/2010 | Patient Website ACTIQ 2010 (Re-approval 1) | TEVA_MDL_A_01151450 | TEVA_MDL_A_01151470 | | | | | | | |
| CE-33 | 02/28/2011 | Actiq Media Fact Sheet | TEVA_MDL_A_01152460 | TEVA_MDL_A_01152464 | | | | | | | |
| CE-41 | 09/01/2011 | Actiq.com | TEVA_MDL_A_01154573 | TEVA_MDL_A_01154593 | | | | | | | |
| CE-44 | 00/00/2006 | Actiq A Pain Primer: A Reference for the Rest of Us (2006) | TEVA_MDL_A_00514270 | TEVA_MDL_A_00514280 | | | | | | | |
| CE-45 | 08/31/2005 | Actiq Marketing Materials – Promotional | TEVA_MDL_A_02968522 | TEVA_MDL_A_02968522 | | | | | | | |
| CE-46 | 07/28/2005 | Actiq Montage Sales Aid | TEVA_MDL_A_01491886 | TEVA_MDL_A_01491894 | | | | | | | |
| CE-47 | 01/17/2019 | ACT002 - Analgesic Potency of ACTIQ | TEVA_MDL_A_01088893 | TEVA_MDL_A_01088896 | | | | | | | |
| CE-48 | 01/17/2019 | ACT022 - Dosage and Administration of ACTIQ | TEVA_MDL_A_01088907 | TEVA_MDL_A_01088914 | | | | | | | |
| CE-52 | 07/00/2005 | Reimbursement Direct Mail | TEVA_MDL_A_00266356 | TEVA_MDL_A_00266367 | | | | | | | |
| CE-55 | 11/00/2006 | www.Actiq.com posting generic PI & Med Guide to site | TEVA_MDL_A_00514338 | TEVA_MDL_A_00514354 | | | | | | | |
| CE-56 | 11/00/2000 | Pharmacologic Treatment of Cancer Pain - Levy | TEVA_MDL_A_00514736 | TEVA_MDL_A_00514749 | | | | | | | |
| CE-57 | 01/00/2006 | Commercial Operations SF Notifications | TEVA_MDL_A_00695218 | TEVA_MDL_A_00695224 | | | | | | | |
| CE-58 | 01/00/2005 | ACTIQ E-Detail (Medsite) Wave B | TEVA_MDL_A_00695225 | TEVA_MDL_A_00695260 | | | | | | | |
| CE-59 | 04/00/2003 | 2003 BTP Counter Card | TEVA_MDL_A_01583982 | TEVA_MDL_A_01583999 | | | | | | | |
| CE-61 | 04/00/2002 | Pocket Dosing Guide | TEVA_MDL_A_11115489 | TEVA_MDL_A_11115492 | | | | | | | |
| CE-62 | 4/11/2005 | Letter RE: Actiq Promotional Material | TEVA_MDL_A_00266011 | TEVA_MDL_A_00266181 | | | | | | | |
| CE-63 | 01/00/2005 | Product Return Sheet (Tear Pad) | TEVA_MDL_A_00266209 | TEVA_MDL_A_00266215 | | | | | | | |
| CE-64 | 5/16/2005 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00266216 | TEVA_MDL_A_00266266 | | | | | | | |
| CE-65 | 9/22/2005 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00266319 | TEVA_MDL_A_00266346 | | | | | | | |
| CE-68 | 07/00/2006 | ACTIQ DAW Journal Ad | TEVA_MDL_A_00695596 | TEVA_MDL_A_00695605 | | | | | | | |
| CE-70 | 11/00/2003 | Promotional Slide Kit 2004 | TEVA_MDL_A_01583675 | TEVA_MDL_A_01583973 | | | | | | | |
| CE-71 | 03/00/2002 | www.actiq.com revised | TEVA_MDL_A_01584015 | TEVA_MDL_A_01584439 | | | | | | | |
| CE-72 | 10/00/2004 | 2005 Promotional Slide Kit | TEVA_MDL_A_01584765 | TEVA_MDL_A_01584793 | | | | | | | |
| CE-74 | 11/00/2004 | BTP Assessment Poster with Folder | TEVA_MDL_A_04250081 | TEVA_MDL_A_04250085 | | | | | | | |
| CE-75 | 4/10/2006 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00695346 | TEVA_MDL_A_00695595 | | | | | | | |
| CE-83 | 02/00/2001 | Updated Regular PI (3 pg.) | TEVA_MDL_A_11121362 | TEVA_MDL_A_11121438 | | | | | | | |
| CE-84 | 04/00/2003 | New Formulation Press Materials for Trade Magazines | TEVA_MDL_A_11121688 | TEVA_MDL_A_11121692 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-85 | 6/29/2001 | DDMAC letter RE: NDA 20-747 Actiq® (oral transmucosal fentanyl citrate, OTFC®) Promotional Material | TEVA_MDL_A_11110212 | TEVA_MDL_A_11110363 | | | | | | | |
| CE-86 | 7/6/2001 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_11110449 | TEVA_MDL_A_11110535 | | | | | | | |
| CE-89 | 4/12/2001 | DDMAC letter RE: NDA 20-747 Actiq® (oral transmucosal fentanyl citrate, OTFC®) Promotional Material | TEVA_MDL_A_11114488 | TEVA_MDL_A_11114503 | | | | | | | |
| CE-90 | 8/9/2002 | Revised Patient Leaflet | TEVA_MDL_A_11117171 | TEVA_MDL_A_11117181 | | | | | | | |
| CE-93 | 1/14/2003 | DDMAC letter RE: NDA 20-747 Actiq® (oral transmucosal fentanyl citrate, OTFC®) Promotional Material | TEVA_MDL_A_11121064 | TEVA_MDL_A_11121170 | | | | | | | |
| CE-95 | 01/31/2006 | Pain Notebook- American Pain Foundation | TEVA_MDL_A_00695261 | TEVA_MDL_A_00695297 | | | | | | | |
| CE-104 | 12/21/2009 | ACT 2001 HCP Website | TEVA_MDL_A_00695698 | TEVA_MDL_A_00695742 | | | | | | | |
| CE-109 | 03/26/2012 | ACT-2-26 ACTIQ.com Update/ACT-2026a Patient Child Safety Kit Request/ACT-2026b HCP Child Safety Kit Request | TEVA_MDL_A_00696717 | TEVA_MDL_A_00696739 | | | | | | | |
| CE-110 | 05/25/2012 | FEN/ACT-0005 RTL-Actiq Conversions | TEVA_MDL_A_00696740 | TEVA_MDL_A_00696762 | | | | | | | |
| CE-115 | 07/01/2010 | New Dimen Dialog MD Workshop: Speaker Deck | TEVA_MDL_A_01150009 | TEVA_MDL_A_01150052 | | | | | | | |
| CE-116 | 01/06/2010 | Dinner Meeting Fax Invite | TEVA_MDL_A_01150053 | TEVA_MDL_A_01150053 | | | | | | | |
| CE-120 | 07/07/2010 | YEARLY REVIEW: Weinstein reprint | TEVA_MDL_A_01150090 | TEVA_MDL_A_01150098 | | | | | | | |
| CE-121 | 07/07/2010 | YEARLY REVIEW: 2009 Patient FAQ | TEVA_MDL_A_01150099 | TEVA_MDL_A_01150116 | | | | | | | |
| CE-122 | 01/06/2010 | FENTORA flyer | TEVA_MDL_A_01150117 | TEVA_MDL_A_01150117 | | | | | | | |
| CE-123 | 07/08/2010 | YEARLY REVIEW: FENTORA ITC CVA DVD Workshop | TEVA_MDL_A_01150118 | TEVA_MDL_A_01150165 | | | | | | | |
| CE-126 | 01/07/2010 | Patient/ Dosing Workshop, ITC | TEVA_MDL_A_01150184 | TEVA_MDL_A_01150200 | | | | | | | |
| CE-135 | 07/26/2010 | YEARLY REVIEW: FEN-2009P-PM-00231 CVA | TEVA_MDL_A_01150240 | TEVA_MDL_A_01150246 | | | | | | | |
| CE-136 | 01/07/2010 | CSP Invite | TEVA_MDL_A_01150250 | TEVA_MDL_A_01150251 | | | | | | | |
| CE-138 | 01/08/2010 | Customer Question Workshop, ITC | TEVA_MDL_A_01150254 | TEVA_MDL_A_01150258 | | | | | | | |
| CE-139 | 08/02/2010 | Quantia Wave 3 | TEVA_MDL_A_01150259 | TEVA_MDL_A_01150275 | | | | | | | |
| CE-143 | 08/01/2010 | PCS August Managers' Meeting FENTORA Workshop | TEVA_MDL_A_01150279 | TEVA_MDL_A_01150309 | | | | | | | |
| CE-144 | 08/01/2010 | FENTORA Scenario Resource Cards | TEVA_MDL_A_01150310 | TEVA_MDL_A_01150316 | | | | | | | |
| CE-145 | 08/02/2010 | TRAINING GUIDE: FENTORA Dosing Flash Card | TEVA_MDL_A_01150436 | TEVA_MDL_A_01150436 | | | | | | | |
| CE-146 | 03/25/2010 | Revised FENTORA Brief Summary | TEVA_MDL_A_01150443 | TEVA_MDL_A_01150446 | | | | | | | |
| CE-150 | 08/09/2010 | Yearly Review: Tick Tock Approp Patient Table Top | TEVA_MDL_A_01150467 | TEVA_MDL_A_01150467 | | | | | | | |
| CE-153 | 08/09/2010 | TRAINING GUIDE: FENTORABreakthrough Pain Flash Card | TEVA_MDL_A_01150470 | TEVA_MDL_A_01150470 | | | | | | | |
| CE-154 | 08/09/2010 | TRAINING GUIDE: FENTORA Efficacy Flash Card | TEVA_MDL_A_01150471 | TEVA_MDL_A_01150472 | | | | | | | |
| CE-155 | 08/09/2010 | TRAINING GUIDE: FENTORA PK Flash Card | TEVA_MDL_A_01150473 | TEVA_MDL_A_01150473 | | | | | | | |
| CE-156 | 08/11/2010 | Yearly Review:Secure Reprint Carrier Content | TEVA_MDL_A_01150474 | TEVA_MDL_A_01150487 | | | | | | | |
| CE-157 | 08/11/2010 | Yearly Review:Secure Reprint Carrier | TEVA_MDL_A_01150488 | TEVA_MDL_A_01150498 | | | | | | | |
| CE-159 | 08/16/2010 | PPLS Annotated PI Cert Exam | TEVA_MDL_A_01150500 | TEVA_MDL_A_01150513 | | | | | | | |
| CE-160 | 08/16/2010 | PPLS Module 6: Risk Minimization Action Plan | TEVA_MDL_A_01150514 | TEVA_MDL_A_01150557 | | | | | | | |
| CE-161 | 08/16/2010 | New Dimen in Pain: Allied Health Training Deck Revised | TEVA_MDL_A_01150558 | TEVA_MDL_A_01150597 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-162 | 08/18/2010 | Risk Map Mod 6 Cert Exam | TEVA_MDL_A_01150598 | TEVA_MDL_A_01150600 | | | | | | | |
| CE-164 | 08/22/2010 | PPLS Module 1: Intro to Pain | TEVA_MDL_A_01150603 | TEVA_MDL_A_01150668 | | | | | | | |
| CE-165 | 08/22/2010 | PPLS Module 2: Cancer Pain | TEVA_MDL_A_01150669 | TEVA_MDL_A_01150700 | | | | | | | |
| CE-172 | 08/26/2010 | Fentora Reimbursement Kit - Reimbursement Guide | TEVA_MDL_A_01150837 | TEVA_MDL_A_01150845 | | | | | | | |
| CE-174 | 08/26/2010 | Fentora Reimbursement Program - Flashcard | TEVA_MDL_A_01150849 | TEVA_MDL_A_01150849 | | | | | | | |
| CE-175 | 08/30/2010 | PPLS Module 4: Assessment | TEVA_MDL_A_01150850 | TEVA_MDL_A_01150860 | | | | | | | |
| CE-176 | 09/03/2010 | Y&F: Fentora Intro Letter | TEVA_MDL_A_01150956 | TEVA_MDL_A_01150958 | | | | | | | |
| CE-179 | 09/13/2010 | HCP Web-based Speaker Training Invitation | TEVA_MDL_A_01150971 | TEVA_MDL_A_01150971 | | | | | | | |
| CE-194 | 09/27/2010 | TRAINING GUIDE: Weinstein et al | TEVA_MDL_A_01151008 | TEVA_MDL_A_01151009 | | | | | | | |
| CE-195 | 01/19/2010 | PDR Prescribing Guide Content | TEVA_MDL_A_01151010 | TEVA_MDL_A_01151021 | | | | | | | |
| CE-196 | 10/01/2010 | 2011 Core Visual Aid | TEVA_MDL_A_01151022 | TEVA_MDL_A_01151029 | | | | | | | |
| CE-197 | 10/04/2010 | CSP Promotional Slide Deck | TEVA_MDL_A_01151030 | TEVA_MDL_A_01151075 | | | | | | | |
| CE-199 | 10/15/2010 | Dosing Leave Behind | TEVA_MDL_A_01151083 | TEVA_MDL_A_01151086 | | | | | | | |
| CE-200 | 10/15/2010 | Stop Look and Listen Leave Behind | TEVA_MDL_A_01151087 | TEVA_MDL_A_01151090 | | | | | | | |
| CE-201 | 10/21/2010 | Efficacy Leave Behind | TEVA_MDL_A_01151091 | TEVA_MDL_A_01151094 | | | | | | | |
| CE-202 | 10/21/2010 | PK Leave behind | TEVA_MDL_A_01151095 | TEVA_MDL_A_01151098 | | | | | | | |
| CE-204 | 10/27/2010 | HCP Dinner invite for Sales Reps | TEVA_MDL_A_01151101 | TEVA_MDL_A_01151101 | | | | | | | |
| CE-210 | 11/10/2010 | FENTORA Annotated CVA eLearning Module | TEVA_MDL_A_01151144 | TEVA_MDL_A_01151204 | | | | | | | |
| CE-211 | 11/10/2010 | Facilitator Guide - Section 1: Engaging the Customer | TEVA_MDL_A_01151205 | TEVA_MDL_A_01151258 | | | | | | | |
| CE-212 | 11/10/2010 | Facilitator Guide - Section 2: Aligning Solutions | TEVA_MDL_A_01151259 | TEVA_MDL_A_01151287 | | | | | | | |
| CE-213 | 11/10/2010 | Facilitator Guide - Section 3: Committing to Action | TEVA_MDL_A_01151288 | TEVA_MDL_A_01151309 | | | | | | | |
| CE-214 | 11/10/2010 | Facilitator Guide - Section 4: Putting it All Together | TEVA_MDL_A_01151310 | TEVA_MDL_A_01151336 | | | | | | | |
| CE-219 | 12/14/2010 | FENTORA.com Renewal | TEVA_MDL_A_01151471 | TEVA_MDL_A_01151704 | | | | | | | |
| CE-221 | 12/21/2010 | Appropriate Patient Selection and Dosing | TEVA_MDL_A_01151715 | TEVA_MDL_A_01151734 | | | | | | | |
| CE-225 | 01/09/2011 | Promotional Slide Deck | TEVA_MDL_A_01151741 | TEVA_MDL_A_01151778 | | | | | | | |
| CE-226 | 01/09/2011 | REMS Slide Deck | TEVA_MDL_A_01151779 | TEVA_MDL_A_01151833 | | | | | | | |
| CE-227 | 02/25/2011 | Patient Case Study Detailer - FOLDER (Re-approval 1) | TEVA_MDL_A_01151834 | TEVA_MDL_A_01151838 | | | | | | | |
| CE-228 | 01/09/2011 | Annotated CVA (print version) | TEVA_MDL_A_01151839 | TEVA_MDL_A_01151854 | | | | | | | |
| CE-229 | 02/25/2011 | Patient Case Study Detailer - Case Study #1 (Re-approval 1) | TEVA_MDL_A_01151855 | TEVA_MDL_A_01151858 | | | | | | | |
| CE-230 | 02/25/2011 | Patient Case Study Detailer - Case Study #2 (Re-approval 1) | TEVA_MDL_A_01151859 | TEVA_MDL_A_01151860 | | | | | | | |
| CE-237 | 01/18/2011 | FENTORA Participant Guide Tab 1 | TEVA_MDL_A_01151907 | TEVA_MDL_A_01151935 | | | | | | | |
| CE-238 | 01/18/2011 | FENTORA Participant's Guide Tab 2 | TEVA_MDL_A_01151936 | TEVA_MDL_A_01151946 | | | | | | | |
| CE-239 | 01/18/2011 | FENTORA Participant's Guide Tab 3 | TEVA_MDL_A_01151947 | TEVA_MDL_A_01151957 | | | | | | | |
| CE-241 | 01/18/2011 | FENTORA Participants Guide - Tab 4 | TEVA_MDL_A_01151961 | TEVA_MDL_A_01151968 | | | | | | | |
| CE-242 | 01/20/2011 | FENTORA Frequently Asked Questions and Responses | TEVA_MDL_A_01151969 | TEVA_MDL_A_01151983 | | | | | | | |
| CE-245 | 01/24/2011 | Rep Triggered Letter: Dosing | TEVA_MDL_A_01152118 | TEVA_MDL_A_01152121 | | | | | | | |
| CE-246 | 01/24/2011 | Rep Triggered Letter: Efficacy | TEVA_MDL_A_01152122 | TEVA_MDL_A_01152124 | | | | | | | |
| CE-247 | 01/24/2011 | Rep Triggered Letter: PK | TEVA_MDL_A_01152125 | TEVA_MDL_A_01152127 | | | | | | | |
| CE-248 | 01/24/2011 | Rep triggered Letter: Stop, Look and Listen | TEVA_MDL_A_01152128 | TEVA_MDL_A_01152130 | | | | | | | |
| CE-251 | 01/28/2011 | Rep Triggered Letter:Dosing Actiq convert | TEVA_MDL_A_01152135 | TEVA_MDL_A_01152138 | | | | | | | |
| CE-253 | 02/09/2011 | Fentora Convention Panel: ISI and Black Box | TEVA_MDL_A_01152170 | TEVA_MDL_A_01152170 | | | | | | | |
| CE-254 | 02/09/2011 | Training Guide – Dosing Leave-Behind | TEVA_MDL_A_01152171 | TEVA_MDL_A_01152173 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-255 | 01/27/2010 | Pain Products Learning System - M4 Update | TEVA_MDL_A_01152176 | TEVA_MDL_A_01152287 | | | | | | | |
| CE-257 | 01/27/2010 | FENTORA Annotated PI | TEVA_MDL_A_01152289 | TEVA_MDL_A_01152370 | | | | | | | |
| CE-258 | 02/23/2011 | FENTORA Medication Guide | TEVA_MDL_A_01152382 | TEVA_MDL_A_01152384 | | | | | | | |
| CE-267 | 03/03/2011 | Training Guide - Stop, Look, Listen Leave-Behind | TEVA_MDL_A_01152470 | TEVA_MDL_A_01152471 | | | | | | | |
| CE-268 | 03/04/2011 | FENTORA Teleconference Series Invitation | TEVA_MDL_A_01152472 | TEVA_MDL_A_01152475 | | | | | | | |
| CE-270 | 03/04/2011 | FENTORA Teleconference Series Workbook Cover Letter for Attendees | TEVA_MDL_A_01152477 | TEVA_MDL_A_01152477 | | | | | | | |
| CE-271 | 02/01/2010 | FENTORA NSMM Workshop | TEVA_MDL_A_01152478 | TEVA_MDL_A_01152518 | | | | | | | |
| CE-273 | 03/13/2011 | FENTORA Phase II Customer Questions & Responses Workshop | TEVA_MDL_A_01152605 | TEVA_MDL_A_01152627 | | | | | | | |
| CE-276 | 03/18/2011 | FENTORA Phase II Marketplace Workshop Facilitator Guide | TEVA_MDL_A_01152914 | TEVA_MDL_A_01152932 | | | | | | | |
| CE-279 | 03/28/2011 | Attendee Workbook for FENTORA Teleconference Series | TEVA_MDL_A_01152937 | TEVA_MDL_A_01152972 | | | | | | | |
| CE-284 | 03/31/2011 | FENTORA Patient Profile 1 | TEVA_MDL_A_01152991 | TEVA_MDL_A_01152995 | | | | | | | |
| CE-285 | 03/31/2011 | FENTORA Patient Profile 2 | TEVA_MDL_A_01152996 | TEVA_MDL_A_01153000 | | | | | | | |
| CE-286 | 03/31/2011 | FENTORA Reprint Compendium | TEVA_MDL_A_01153001 | TEVA_MDL_A_01153009 | | | | | | | |
| CE-288 | 04/14/2011 | Facilitator Guide: Putting it All Together Workshop: May 2011 Area Manager and June 2011 POA Meetings | TEVA_MDL_A_01153023 | TEVA_MDL_A_01153065 | | | | | | | |
| CE-289 | 04/28/2011 | TRAINING GUIDE: FENTORA Patient Profile 1 Case Study Leave-Behind (FEN-2286) | TEVA_MDL_A_01153074 | TEVA_MDL_A_01153076 | | | | | | | |
| CE-290 | 04/28/2011 | TRAINING GUIDE: FENTORA Patient Profile #2 Case Study Leave-Behind (FEN-2287) | TEVA_MDL_A_01153077 | TEVA_MDL_A_01153079 | | | | | | | |
| CE-291 | 04/30/2011 | Facilitator Guide: Applying the Patient Focused Selling Approach (PFSA) to Clinical Papers Workshop | TEVA_MDL_A_01153080 | TEVA_MDL_A_01153119 | | | | | | | |
| CE-292 | 05/02/2011 | Participant Guide: Applying Patient Focused Selling Approach (PFSA) to Clinical Reprint Selling Workshop | TEVA_MDL_A_01153120 | TEVA_MDL_A_01153137 | | | | | | | |
| CE-293 | 05/04/2011 | Participant Guide: Putting it All Together Workshop: May 2011 Area Manager and June 2011 POA Meetings | TEVA_MDL_A_01153138 | TEVA_MDL_A_01153159 | | | | | | | |
| CE-295 | 05/10/2011 | REMS NAMs Slide Deck | TEVA_MDL_A_01153165 | TEVA_MDL_A_01153180 | | | | | | | |
| CE-296 | 05/19/2011 | Pain Product Learning System: Disease State Module | TEVA_MDL_A_01153203 | TEVA_MDL_A_01153282 | | | | | | | |
| CE-299 | 05/19/2011 | FENTORA/Actiq REMS FAQ Document | TEVA_MDL_A_01153401 | TEVA_MDL_A_01153410 | | | | | | | |
| CE-304 | 06/07/2011 | FENTORA PHASE II PI Workshop | TEVA_MDL_A_01153466 | TEVA_MDL_A_01153511 | | | | | | | |
| CE-306 | 06/13/2011 | FENTORA Teleconference Series, Wave #2 | TEVA_MDL_A_01153529 | TEVA_MDL_A_01153532 | | | | | | | |
| CE-308 | 06/16/2011 | Convention Program Ad | TEVA_MDL_A_01153534 | TEVA_MDL_A_01153537 | | | | | | | |
| CE-309 | 06/20/2011 | Fentora Speaker Reduction Letter | TEVA_MDL_A_01153538 | TEVA_MDL_A_01153538 | | | | | | | |
| CE-312 | 06/29/2011 | ACTIQ and FENTORA REMS Graphic for Media | TEVA_MDL_A_01153560 | TEVA_MDL_A_01153560 | | | | | | | |
| CE-313 | 06/29/2011 | ACTIQ and FENTORA REMS Media Fact Sheet | TEVA_MDL_A_01153561 | TEVA_MDL_A_01153564 | | | | | | | |
| CE-314 | 02/10/2010 | FENTORA NSMM Workshop - CVA | TEVA_MDL_A_01153565 | TEVA_MDL_A_01153598 | | | | | | | |
| CE-315 | 07/10/2011 | PCS PHASE II FENTORA Post-Exam | TEVA_MDL_A_01153599 | TEVA_MDL_A_01153622 | | | | | | | |
| CE-317 | 07/18/2011 | REMS Approval Speaker Letter | TEVA_MDL_A_01153630 | TEVA_MDL_A_01153633 | | | | | | | |
| CE-319 | 07/27/2011 | Actiq and FENTORA REMS Enrollment Kit: Housing Unit | TEVA_MDL_A_01153638 | TEVA_MDL_A_01153643 | | | | | | | |
| CE-320 | 07/27/2011 | REMS Dear HCP Letter | TEVA_MDL_A_01153644 | TEVA_MDL_A_01153647 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-321 | 07/27/2011 | REMS Dear Outpatient Pharmacy Letter | TEVA_MDL_A_01153648 | TEVA_MDL_A_01153651 | | | | | | | |
| CE-322 | 07/28/2011 | REMS Patient Perscriber Agreement Form | TEVA_MDL_A_01153652 | TEVA_MDL_A_01153653 | | | | | | | |
| CE-323 | 07/28/2011 | REMS Dear Inpatient Pharmacy Letter | TEVA_MDL_A_01153654 | TEVA_MDL_A_01153657 | | | | | | | |
| CE-324 | 07/28/2011 | REMS Dear Distributor Letter | TEVA_MDL_A_01153658 | TEVA_MDL_A_01153659 | | | | | | | |
| CE-330 | 07/29/2011 | Lesson 1: ACTIQ and FENTORA REMS | TEVA_MDL_A_01153889 | TEVA_MDL_A_01153973 | | | | | | | |
| CE-331 | 07/29/2011 | Lesson 2: Follow the Patient | TEVA_MDL_A_01153974 | TEVA_MDL_A_01154020 | | | | | | | |
| CE-332 | 07/29/2011 | Lesson 3: Presenting ACTIQ and FENTORA REMS to HCPs | TEVA_MDL_A_01154021 | TEVA_MDL_A_01154122 | | | | | | | |
| CE-333 | 08/02/2011 | REMS Enrollment Communication Letters:Wave 1 | TEVA_MDL_A_01154123 | TEVA_MDL_A_01154126 | | | | | | | |
| CE-334 | 08/02/2011 | REMS Enrollment Communication Letters:Wave 2 | TEVA_MDL_A_01154127 | TEVA_MDL_A_01154130 | | | | | | | |
| CE-335 | 08/02/2011 | REMS Enrollment Communication Letters:Wave 3 | TEVA_MDL_A_01154131 | TEVA_MDL_A_01154134 | | | | | | | |
| CE-339 | 08/03/2011 | Convention Panel REMS Update: ISI Panel | TEVA_MDL_A_01154143 | TEVA_MDL_A_01154143 | | | | | | | |
| CE-342 | 08/05/2011 | Table Top Panel Summary: REMS update | TEVA_MDL_A_01154208 | TEVA_MDL_A_01154208 | | | | | | | |
| CE-357 | 08/16/2011 | REMS Reference Guide | TEVA_MDL_A_01154464 | TEVA_MDL_A_01154563 | | | | | | | |
| CE-359 | 08/26/2011 | Fentora Media Fact Sheet | TEVA_MDL_A_01154565 | TEVA_MDL_A_01154568 | | | | | | | |
| CE-360 | 08/26/2011 | ACTIQ and FENTORA REMS Media Fact Sheet | TEVA_MDL_A_01154569 | TEVA_MDL_A_01154572 | | | | | | | |
| CE-365 | 09/07/2011 | Disease State Awareness: Pain Evaluation and Diagnosis Phase II Facilitator Guide-Wkshp (FENTORA) | TEVA_MDL_A_01154686 | TEVA_MDL_A_01154713 | | | | | | | |
| CE-366 | 09/13/2011 | FENTORA PHASE II Dosing, Titration & Administration Workshop | TEVA_MDL_A_01154716 | TEVA_MDL_A_01154752 | | | | | | | |
| CE-367 | 09/16/2011 | Patient Breakthrough Pain Waiting Room Brochure | TEVA_MDL_A_01154753 | TEVA_MDL_A_01154766 | | | | | | | |
| CE-372 | 09/30/2011 | Pain Products Learning System: FENTORA Annotated PI | TEVA_MDL_A_01154782 | TEVA_MDL_A_01154895 | | | | | | | |
| CE-374 | 10/10/2011 | Enrollment Kit: PPAF Tear Pad | TEVA_MDL_A_01154900 | TEVA_MDL_A_01154901 | | | | | | | |
| CE-375 | 10/17/2011 | Revised REMS Transition Slide Deck | TEVA_MDL_A_01154902 | TEVA_MDL_A_01154956 | | | | | | | |
| CE-386 | 04/05/2010 | FENTORA Core Visual Aid Coaching Guide | TEVA_MDL_A_01157892 | TEVA_MDL_A_01157909 | | | | | | | |
| CE-387 | 04/05/2010 | Oncology Leave Behind Implementation Guide | TEVA_MDL_A_01157993 | TEVA_MDL_A_01157997 | | | | | | | |
| CE-389 | 04/09/2010 | FENTORA Oncology Leave Behind Training | TEVA_MDL_A_01158002 | TEVA_MDL_A_01158049 | | | | | | | |
| CE-399 | 12/28/2009 | PI Workshop | TEVA_MDL_A_01158288 | TEVA_MDL_A_01158290 | | | | | | | |
| CE-401 | 05/10/2010 | FENTORA Annual Assessment | TEVA_MDL_A_01158325 | TEVA_MDL_A_01158340 | | | | | | | |
| CE-404 | 12/01/2011 | Fentora Frequently Asked Questions | TEVA_MDL_A_00982822 | TEVA_MDL_A_00982836 | | | | | | | |
| CE-405 | 06/29/2006 | FDA letter approving labeling for Fentora | TEVA_MDL_A_00263638 | TEVA_MDL_A_00263678 | | | | | | | |
| CE-406 | 05/06/2009 | May 2008 Letter providing FENT008 | TEVA_MDL_A_01083635 | TEVA_MDL_A_01083640 | | | | | | | |
| CE-407 | 10/14/2019 | FENT002 General Information | TEVA_MDL_A_01085033 | TEVA_MDL_A_01085044 | | | | | | | |
| CE-409 | 08/27/2010 | Direct Mail Appeal in Advance of Pain Week Conference | TEVA_MDL_A_01149905 | TEVA_MDL_A_01149910 | | | | | | | |
| CE-410 | 01/22/2010 | Fentora Brochure | TEVA_MDL_A_01151339 | TEVA_MDL_A_01151344 | | | | | | | |
| CE-411 | 03/29/2011 | Fentora Brochure | TEVA_MDL_A_01152980 | TEVA_MDL_A_01152990 | | | | | | | |
| CE-412 | 03/29/2011 | Promotional Letter re Fentora | TEVA_MDL_A_01153539 | TEVA_MDL_A_01153541 | | | | | | | |
| CE-413 | 08/11/2019 | FENT009 - Safety Profile of FENTORA | TEVA_MDL_A_00704700 | TEVA_MDL_A_00704712 | | | | | | | |
| CE-415 | 00/00/2009 | How Do I Request Additional Information About FENTORA? | TEVA_MDL_A_00539204 | TEVA_MDL_A_00539221 | | | | | | | |
| CE-417 | 06/01/2010 | FENTORA Sales Simulation Project | TEVA_MDL_A_01149671 | TEVA_MDL_A_01149676 | | | | | | | |
| CE-419 | 06/02/2010 | New Dimensions in Pain Dialogues: Presenter Guide | TEVA_MDL_A_01149717 | TEVA_MDL_A_01149766 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-420 | 06/16/2010 | New Dimensions in Pain Dialogues: Nurse Peer to Peer Brochure | TEVA_MDL_A_01149832 | TEVA_MDL_A_01149847 | | | | | | | |
| CE-422 | 06/22/2010 | FEN2009PMC00060 - Yearly review - BTP Education brochure | TEVA_MDL_A_01149871 | TEVA_MDL_A_01149880 | | | | | | | |
| CE-423 | 06/22/2010 | FEN2009PPM00164 - Yearly Review - FENTORA BTP Flashcard | TEVA_MDL_A_01149881 | TEVA_MDL_A_01149882 | | | | | | | |
| CE-424 | 06/22/2010 | FEN2009PPM00371 - Yearly Review - FENTORA Efficacy Flashcard | TEVA_MDL_A_01149883 | TEVA_MDL_A_01149884 | | | | | | | |
| CE-425 | 06/22/2010 | FEN2009PPM00373 - Yearly Review - FENTORA HCP FAQ Brochure | TEVA_MDL_A_01149885 | TEVA_MDL_A_01149902 | | | | | | | |
| CE-426 | 06/22/2010 | FEN2009PPM00375 - Yearly Review - FENTORA PK Flashcard | TEVA_MDL_A_01149903 | TEVA_MDL_A_01149904 | | | | | | | |
| CE-433 | 07/00/2006 | Fentora Full Promotional Slide Kit | TEVA_MDL_A_00025496 | TEVA_MDL_A_00025577 | | | | | | | |
| CE-434 | 03/00/2007 | Fentora Revised Journal Ad -Optimize Onset | TEVA_MDL_A_00025865 | TEVA_MDL_A_00025871 | | | | | | | |
| CE-439 | 10/12/2006 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00025238 | TEVA_MDL_A_00025279 | | | | | | | |
| CE-440 | 10/20/2006 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00025280 | TEVA_MDL_A_00025339 | | | | | | | |
| CE-442 | 10/31/2006 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00025378 | TEVA_MDL_A_00025405 | | | | | | | |
| CE-443 | 11/28/2006 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00025406 | TEVA_MDL_A_00025424 | | | | | | | |
| CE-444 | 12/19/2006 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00025425 | TEVA_MDL_A_00025495 | | | | | | | |
| CE-446 | 1/26/2007 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00025578 | TEVA_MDL_A_00025693 | | | | | | | |
| CE-447 | 2/7/2007 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00025746 | TEVA_MDL_A_00025805 | | | | | | | |
| CE-448 | 2/16/2007 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00025806 | TEVA_MDL_A_00025843 | | | | | | | |
| CE-451 | 6/22/2007 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00026080 | TEVA_MDL_A_00026087 | | | | | | | |
| CE-454 | 8/24/2007 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00026240 | TEVA_MDL_A_00026329 | | | | | | | |
| CE-455 | 8/31/2007 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00026330 | TEVA_MDL_A_00026339 | | | | | | | |
| CE-460 | 11/9/2007 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00026566 | TEVA_MDL_A_00026617 | | | | | | | |
| CE-461 | 11/16/2007 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00026618 | TEVA_MDL_A_00026627 | | | | | | | |
| CE-464 | 2/22/2008 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00026715 | TEVA_MDL_A_00026761 | | | | | | | |
| CE-465 | 3/14/2008 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00026773 | TEVA_MDL_A_00026793 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-468 | 06/00/2008 | Revised Pocket Dosing Guide | TEVA_MDL_A_00027637 | TEVA_MDL_A_00027645 | | | | | | | |
| CE-469 | 4/11/2008 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00027116 | TEVA_MDL_A_00027147 | | | | | | | |
| CE-472 | 5/2/2008 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00027170 | TEVA_MDL_A_00027215 | | | | | | | |
| CE-482 | 07/00/2006 | Direct Mail #1 -Now Available | TEVA_MDL_A_00550961 | TEVA_MDL_A_00550966 | | | | | | | |
| CE-483 | 07/00/2006 | Direct Mail #2 - Enhanced Bioavailability | TEVA_MDL_A_00550967 | TEVA_MDL_A_00550972 | | | | | | | |
| CE-484 | 07/00/2006 | Direct Mail #3 - A pharmacokinetic difference | TEVA_MDL_A_00550973 | TEVA_MDL_A_00550980 | | | | | | | |
| CE-485 | 07/00/2006 | Direct Mail #4 -Simple Administration | TEVA_MDL_A_00550981 | TEVA_MDL_A_00550988 | | | | | | | |
| CE-490 | 6/19/2009 | Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use | TEVA_MDL_A_00027916 | TEVA_MDL_A_00028076 | | | | | | | |
| CE-496 | 6/22/2009 | SECURE Access Pharmacy Quick Reference Card (FEN-2009P-PM-00161) | TEVA_MDL_A_00028216 | TEVA_MDL_A_00028264 | | | | | | | |
| CE-504 | 12/00/2006 | PharmAlert Mailing Revised | TEVA_MDL_A_00551030 | TEVA_MDL_A_00551031 | | | | | | | |
| CE-507 | 08/00/2006 | Fentora Formulary Kit | TEVA_MDL_A_00551137 | TEVA_MDL_A_00551172 | | | | | | | |
| CE-516 | 11/00/2006 | PDR Pain Mgmt Prescribing Guide | TEVA_MDL_A_00551369 | TEVA_MDL_A_00551395 | | | | | | | |
| CE-517 | 11/00/2006 | Fentora Dose Conversion Cling Poster | TEVA_MDL_A_00551396 | TEVA_MDL_A_00551400 | | | | | | | |
| CE-518 | 01/00/2007 | "Gap" Core Sales Aid | TEVA_MDL_A_00551447 | TEVA_MDL_A_00551466 | | | | | | | |
| CE-522 | 01/00/2007 | AAPM 20 Second Tower Animation | TEVA_MDL_A_00551502 | TEVA_MDL_A_00551511 | | | | | | | |
| CE-526 | 10/00/2010 | Starting Fentora | TEVA_MDL_A_00551587 | TEVA_MDL_A_00551590 | | | | | | | |
| CE-527 | 03/00/2007 | AMCP Booth Panels - What is BTP | TEVA_MDL_A_00551591 | TEVA_MDL_A_00551591 | | | | | | | |
| CE-528 | 03/00/2007 | AMCP Booth Panels - Optimize onset with FENTORA | TEVA_MDL_A_00551592 | TEVA_MDL_A_00551592 | | | | | | | |
| CE-532 | 03/00/2007 | Patient FAQs - Revised | TEVA_MDL_A_00551596 | TEVA_MDL_A_00551616 | | | | | | | |
| CE-536 | 04/00/2007 | Fentora Catalina Newsletter | TEVA_MDL_A_00551635 | TEVA_MDL_A_00551635 | | | | | | | |
| CE-537 | 07/00/2007 | 3039 4-page Journal Ad - redosing line removed | TEVA_MDL_A_00551664 | TEVA_MDL_A_00551665 | | | | | | | |
| CE-541 | 05/00/2007 | 3039 DM #2 - Optimize Onset with Fentora | TEVA_MDL_A_00551760 | TEVA_MDL_A_00551767 | | | | | | | |
| CE-542 | 05/00/2007 | 3039 Efficacy Flashcard | TEVA_MDL_A_00551768 | TEVA_MDL_A_00551773 | | | | | | | |
| CE-543 | 05/00/2007 | 3039 Physician FAQ | TEVA_MDL_A_00551774 | TEVA_MDL_A_00551793 | | | | | | | |
| CE-544 | 5/7/2007 | RiskMAP Speaker Training Slides | TEVA_MDL_A_00551636 | TEVA_MDL_A_00551661 | | | | | | | |
| CE-546 | 06/00/2007 | Fentora Pocket Folder (new logo) | TEVA_MDL_A_00551815 | TEVA_MDL_A_00551822 | | | | | | | |
| CE-548 | 6/7/2007 | 3039 3pg Journal Ad - revised Aes | TEVA_MDL_A_00551744 | TEVA_MDL_A_00551746 | | | | | | | |
| CE-561 | 2/9/2009 | SECURE Access Institution Enrollment Form (FEN-2009P-PM-00214) | TEVA_MDL_A_00551930 | TEVA_MDL_A_00551943 | | | | | | | |
| CE-570 | 08/08/2011 | FEN-2320: REMS Fact Sheet/FEN-2321: REMS Approval Speaker Letter | TEVA_MDL_A_00695824 | TEVA_MDL_A_00695852 | | | | | | | |
| CE-572 | 10/23/2006 | FENT 023 Fentora Website/FENT 054 Launch Announcement Email/FENT 043 Pharmacy Corporate Email | TEVA_MDL_A_00025340 | TEVA_MDL_A_00025374 | | | | | | | |
| CE-573 | 10/30/2006 | FENT 056 Convention Tote/FENT 048 Element Convention Pen | TEVA_MDL_A_00025375 | TEVA_MDL_A_00025377 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-578 | 02/02/2007 | FENT 025a Direct Mail to Health Care Providers/FENT 026a Direct Mail to Actiq Prescribers/FENT 045 Promotional Reprint-Darwish-"Comparison of Equivalent Doses of FEBT and Ateriovenous Differences in Fentanyl Pharmacokinetics"/FENT 049 Promotional Reprint-Darwish-"Pharmacokinetic Properties of Fentanyl Effervescent Buccal Tablets: A Phase I, Open-Label, Crossover Study of Single-Dose 100, 200, 400, and 800 mg in Healthy Adult Volunteers/FENT 108 Promotional Reprint- Darwish "Comparison of Equiveland Doses of FEBT and Arteriovenous Differences in Fentanyl Pharmacokinetics." | TEVA_MDL_A_00025694 | TEVA_MDL_A_00025745 | | | | | | | |
| CE-581 | 02/26/2007 | FENT 025d Direct Mail to Health Care Providers/FENT 026d Direct Mail to Actiq Prescribers | TEVA_MDL_A_00025844 | TEVA_MDL_A_00025864 | | | | | | | |
| CE-582 | 04/06/2007 | FENT 061 FENTORA Reimbursement Kit/FENT 069 FENTORA Abbreviated Formulary Kit and CD_ROM/FENT 137a FENTORA Corporate Booth Panel/FENT 137b FENTORA Corporate Booth Panel | TEVA_MDL_A_00025872 | TEVA_MDL_A_00025941 | | | | | | | |
| CE-583 | 04/20/2007 | FENT 138a Convention Booth Panel "What is breakthrough pain?"/FENT 138b FENTORA Convention Booth Panel "Optimizing Onset"/FENT 138c FENTORA Convention Booth Panel "Black Box Warning"/FENT 142a FENTORA "Optimizing Onset" 3-page Journal Ad. | TEVA_MDL_A_00025983 | TEVA_MDL_A_00025989 | | | | | | | |
| CE-584 | 05/02/2007 | WLF-FENT 001 WLF Article "Fentanyl Buccal Tablets for the relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study"/FENT 115 Patient Privacy Sign-in Clopboard/FENT 121 FENTORA Core Sales Aid/FENT 141 FENTORA Pharmacy Flashcard | TEVA_MDL_A_00025990 | TEVA_MDL_A_00026027 | | | | | | | |
| CE-585 | 05/18/2007 | FENT 107 Promotional Reprint-Relative and Absoltue Bioavailability of FEBT-Darwish/FENT 108 Promotional Reprint- Single-Dose and Steady-State Pharmacokinetics of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers-Darwish/FENT 132a FENTORA case studies booklet includes 132b FENTORA case studies DVD FENT 132c, d, e, f, FENTORA case study leave behinds. | TEVA_MDL_A_00026028 | TEVA_MDL_A_00026079 | | | | | | | |
| CE-587 | 06/29/2007 | FENT 150a FENTORA 4pg Journal Ad- August pubs/FENT 152a FENTORA 3pg Journal Ad- August Pubs | TEVA_MDL_A_00026088 | TEVA_MDL_A_00026097 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-588 | 07/02/2007 | FENT 144 Triple I Prescription Pad/144a Triple I Prescription Pad Ad/FENT 144b Triple I Prescription Pad Ad. | TEVA_MDL_A_00026098 | TEVA_MDL_A_00026106 | | | | | | | |
| CE-589 | 07/06/2007 | FENT 154 FENTORA Efficacy Flashcard | TEVA_MDL_A_00026107 | TEVA_MDL_A_00026117 | | | | | | | |
| CE-590 | 07/20/2007 | FENT 023b FENTORA.com (Revised website with updated physician and patient information)/FENT 135 FENTORA Professional E-mail/FENT 147 Fentora Newsletter/FENT 153a FENTORA Direct Mail/FENT 1543b FENTORA Direct Mail | TEVA_MDL_A_00026118 | TEVA_MDL_A_00026170 | | | | | | | |
| CE-591 | 07/30/2007 | FENT 143b FENTORA patient placebo pak desk top holder/FENT 143e FENTORA patient placebo pak carton | TEVA_MDL_A_00026171 | TEVA_MDL_A_00026180 | | | | | | | |
| CE-592 | 08/03/2007 | FENT 159 FENTORA Pocket Folder | TEVA_MDL_A_00026181 | TEVA_MDL_A_00026189 | | | | | | | |
| CE-593 | 08/10/2007 | FENT 156 FENTORA Patient FAQ/FENT 162 FENTORA Enlarged PI | TEVA_MDL_A_00026190 | TEVA_MDL_A_00026223 | | | | | | | |
| CE-594 | 08/17/2007 | FENT 163 FENTORA Slatkin Reprint "FBT for relief of BTP in cancer-related chronic pain"/FENT 178 FENTORA Epocrates Email Alert. | TEVA_MDL_A_00026224 | TEVA_MDL_A_00026239 | | | | | | | |
| CE-597 | 09/26/2007 | FENT 185 FENTORA Prescription pad contains: FENT 185a Optimize Onset Ad, FENT 185b Successful Titration Ad/FENT 185c Sales Representatives Ordering Materials | TEVA_MDL_A_00026340 | TEVA_MDL_A_00026356 | | | | | | | |
| CE-598 | 10/06/2017 | FENT 127a FENTORA 3-D Animation Video/FENT 151 FENTORA Promotional Slide Kit/FENT 194 FENTORA Animated Convention Booth Panels | TEVA_MDL_A_00026357 | TEVA_MDL_A_00026462 | | | | | | | |
| CE-599 | 10/25/2007 | FENT 204 Epocrates E-mail Alert Fentora Reminders | TEVA_MDL_A_00026463 | TEVA_MDL_A_00026472 | | | | | | | |
| CE-600 | 11/01/2007 | FENT 186a FENTORA Medsite E-Detail Wave B/FENT 186b FENTORA Medsite E-Detail Wave C/FENT 186c FENTORA E-detail Invitation | TEVA_MDL_A_00026473 | TEVA_MDL_A_00026565 | | | | | | | |
| CE-603 | 01/25/2008 | FENT 214 FENTORA Promotional Slide Kit | TEVA_MDL_A_00026628 | TEVA_MDL_A_00026706 | | | | | | | |
| CE-604 | 02/08/2008 | FENT 232 FENTORA Journal Advertisement | TEVA_MDL_A_00026707 | TEVA_MDL_A_00026714 | | | | | | | |
| CE-606 | 03/07/2008 | FENT 226 FENTORA Voucher FENT 219 Medication Guide | TEVA_MDL_A_00026762 | TEVA_MDL_A_00026772 | | | | | | | |
| CE-608 | 03/21/2008 | FENT 150 FENTORA Managed Care Speaker Slide Kit/FENT 190 Nexcura E-Mail to Cancer Pain Patients/FENT 242 Debit Card IVR Hotline Script. | TEVA_MDL_A_00026794 | TEVA_MDL_A_00026902 | | | | | | | |
| CE-609 | 03/28/2008 | FENT 233a FENTORA Reimbursement Kit-Folder/FENT 233b FENTORA Reimbursement Kit-Brochure/FENT 233c FENTORA Reimbursement Kit- Consent Form/FENT 233d FENTORA Reimbursement Kit- Magnet/FENT 233f FENTORA Reimbursement Kit- CD-ROM/ FENT 239 FENTORA PDR addendum/FENT 243 FENTORA Pharmacy Flashcard | TEVA_MDL_A_00026903 | TEVA_MDL_A_00026951 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-610 | 04/03/2008 | Transmittal of Advertisements and Promotional Labeling for Fentora, FENT 200 FENTORA.com (HCP and Patient Content). | TEVA_MDL_A_00026952 | TEVA_MDL_A_00027115 | | | | | | | |
| CE-612 | 04/11/2008 | Transmittal of Advertisements and Promotional Labeling for Fentora, FENT 216d placebo pack/FENT 143 e holder for placebo pack. | TEVA_MDL_A_00027148 | TEVA_MDL_A_00027151 | | | | | | | |
| CE-613 | 04/25/2008 | Transmittal of Advertisements and Promotional Labeling for Fentora, FENT 241 FENTORA Enlarged PI/FENT 257 FENTORA Boat Tote. | TEVA_MDL_A_00027152 | TEVA_MDL_A_00027169 | | | | | | | |
| CE-615 | 05/02/2008 | FENT 224 FENTORA Tamperproof RX Pads/FENT 246 FENTORA 5 Minute Animation/FENT 247 PDR Pain Management Prescribing Guide/FENT 254 FENTORA Booth Challenge Game/FENT 255a-c Convention booth panel[s]/FENT 258 Interactive Touchscreen Panels | TEVA_MDL_A_00027216 | TEVA_MDL_A_00027231 | | | | | | | |
| CE-616 | 05/09/2008 | FENT 250 FENTORA SECURE Slim Jim Brochure. | TEVA_MDL_A_00027232 | TEVA_MDL_A_00027238 | | | | | | | |
| CE-617 | 05/12/2008 | FENT 208 FENTORA SECURE Visual Aid. | TEVA_MDL_A_00027239 | TEVA_MDL_A_00027250 | | | | | | | |
| CE-618 | 05/23/2008 | FENT 251 FENTORA Making Pain Talk Painless - Patient Brochure. | TEVA_MDL_A_00027251 | TEVA_MDL_A_00027261 | | | | | | | |
| CE-619 | 05/23/2008 | FENT 249 FENTORA Portenoy Reprint Carrier/FENT 259 FENTORA Spanish PI/FENT 260 FENTORA Spanish Medication Guide. | TEVA_MDL_A_00027262 | TEVA_MDL_A_00027289 | | | | | | | |
| CE-620 | 05/30/2008 | Transmittal of Advertisements and Promotional Labeling for Fentora, EDU 262 Abuse, Addiction & Diversion Slide Kit. | TEVA_MDL_A_00027290 | TEVA_MDL_A_00027415 | | | | | | | |
| CE-621 | 06/13/2008 | FENT 264 FENTORA Practice Management Slide Kit. | TEVA_MDL_A_00027416 | TEVA_MDL_A_00027473 | | | | | | | |
| CE-622 | 07/18/2008 | FENT 262 FENTORA E-detail Website. | TEVA_MDL_A_00027474 | TEVA_MDL_A_00027555 | | | | | | | |
| CE-623 | 07/31/2008 | FENT 266 FENTORA PK Flashcard. | TEVA_MDL_A_00027556 | TEVA_MDL_A_00027562 | | | | | | | |
| CE-624 | 08/08/2008 | FENT 265 FENTORA Promotional Slide Kit. | TEVA_MDL_A_00027563 | TEVA_MDL_A_00027636 | | | | | | | |
| CE-625 | 08/28/2008 | FENT 269 FENTORA Dosing and Administration Guide. | TEVA_MDL_A_00027637 | TEVA_MDL_A_00027645 | | | | | | | |
| CE-626 | 09/12/2008 | FENT 263 FENTORA Interactive Dosing Guide. | TEVA_MDL_A_00027646 | TEVA_MDL_A_00027652 | | | | | | | |
| CE-627 | 10/31/2008 | FENT 275 PK DocAlert & email. | TEVA_MDL_A_00027653 | TEVA_MDL_A_00027661 | | | | | | | |
| CE-628 | 11/21/2008 | FENT 276 FENTORA 2009 Wall Calendar. | TEVA_MDL_A_00027662 | TEVA_MDL_A_00027668 | | | | | | | |
| CE-629 | 01/15/2009 | Fentora, FENT 277a FENTORA Voucher. | TEVA_MDL_A_00027669 | TEVA_MDL_A_00027681 | | | | | | | |
| CE-630 | 01/30/2009 | FENT 280 Epocrates Certificates. | TEVA_MDL_A_00027682 | TEVA_MDL_A_00027688 | | | | | | | |
| CE-631 | 02/20/2009 | Transmittal of Advertisements and Promotional Labeling for Fentora, FENT 2009P-PMC-00001 Assistance Cards. | TEVA_MDL_A_00027689 | TEVA_MDL_A_00027701 | | | | | | | |
| CE-632 | 02/27/2009 | FENT 2009P-PMC-00080 Website Banner. | TEVA_MDL_A_00027702 | TEVA_MDL_A_00027709 | | | | | | | |
| CE-633 | 04/03/2009 | Transmittal of Advertisements and Promotional Labeling for Fentora, FEN 2009P-PMC-00003 Patient profiler | TEVA_MDL_A_00027710 | TEVA_MDL_A_00027726 | | | | | | | |
| CE-634 | 04/08/2009 | Response to DDMAC re FENT 023a/FENT 200. | TEVA_MDL_A_00027727 | TEVA_MDL_A_00027728 | | | | | | | |
| CE-635 | 04/13/2009 | FENT 200a Website update. | TEVA_MDL_A_00027729 | TEVA_MDL_A_00027836 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-636 | 04/29/2009 | FEN-2009P-PM 00165 Prescribing Guide. | TEVA_MDL_A_00027837 | TEVA_MDL_A_00027849 | | | | | | | |
| CE-637 | 05/06/2009 | FEN-2009P-PM-00388 Interactive Touch Screens. | TEVA_MDL_A_00027850 | TEVA_MDL_A_00027869 | | | | | | | |
| CE-638 | 05/29/2009 | FEN-2009P-PM-00231 Core Visual Aid. | TEVA_MDL_A_00027870 | TEVA_MDL_A_00027886 | | | | | | | |
| CE-639 | 06/19/2009 | FEN-2009P-PMC-00377 Card Holder/FEN-2009P-PMC-00399 Patient FAQ. | TEVA_MDL_A_00027887 | TEVA_MDL_A_00027915 | | | | | | | |
| CE-641 | 06/26/2009 | FENT-279a Tear Sheet/FEN-2009P-PMC-00060 Brochure/FEN-2009P-PMC-00376 Voucher. | TEVA_MDL_A_00028077 | TEVA_MDL_A_00028100 | | | | | | | |
| CE-642 | 07/10/2009 | FENT-2009P-PM-00599 Fax Invitation/FENT-2009P-PM-00600 Fax Flyer. | TEVA_MDL_A_00028101 | TEVA_MDL_A_00028115 | | | | | | | |
| CE-643 | 07/17/2009 | FEN-2009P-PM-00523 Table Top Panel/FEN-2009PM-00524 Table Top Panel/FEN-2009P-PM-00525 Table Top Panel/FEN-2009P-PM-00526 Table Top Panel/FEN-2009P-PM-00573 Email | TEVA_MDL_A_00028116 | TEVA_MDL_A_00028128 | | | | | | | |
| CE-644 | 07/28/2009 | FEN-2009P-PM-00059 Education Station/FEN-2009P-PM-00520 Convention Panel/FEN-2009P-PM-00521 Convention Panel/FEN-2009P-PM-00574 Convention Panel/FEN-2009P-PM-00575 Convention Panel/FEN-2009P-PM-00576 Convention Panel/FEN-2009P-PM-00577 Convention Panel/FEN-2009P-PM-00308 Workbook | TEVA_MDL_A_00028129 | TEVA_MDL_A_00028184 | | | | | | | |
| CE-645 | 08/05/2009 | FEN-2009P-PM-00426 Invitation. | TEVA_MDL_A_00028185 | TEVA_MDL_A_00028191 | | | | | | | |
| CE-646 | 08/14/2009 | FEN-2009P-PM-00797 Workbook. | TEVA_MDL_A_00028192 | TEVA_MDL_A_00028215 | | | | | | | |
| CE-648 | 08/21/2009 | FEN-2009P-PM-00681 Website/FEN-2009P-PM-00643 DVD/FEN-2009P-PM-00644 DVD/FEN-2009P-PM-00645 DVD | TEVA_MDL_A_00028265 | TEVA_MDL_A_00028333 | | | | | | | |
| CE-649 | 08/28/2009 | FEN-2009P-PM-00794 Screensaver/FEN-2009P-PM-00795 Room Drop/FEN-2009P-PM-00886 Belly Band | TEVA_MDL_A_00028334 | TEVA_MDL_A_00028347 | | | | | | | |
| CE-650 | 09/04/2009 | FEN-2009P-PM-00715 Sign/FEN-2009P-PM-00716 Room Drop/FEN-2009P-PM-00757 Flashcard/FEN-2009P-PM-00766 Touchscreens/FEN-2009P-PM-00936 E-mail/FEN-2009P-PM-00937 Screenshots | TEVA_MDL_A_00028348 | TEVA_MDL_A_00028374 | | | | | | | |
| CE-651 | 09/18/2009 | FEN-2009P-PMC-00480 CD | TEVA_MDL_A_00028375 | TEVA_MDL_A_00028380 | | | | | | | |
| CE-652 | 09/25/2009 | FEN-2009P-PMC-00898 Leave Behind | TEVA_MDL_A_00028381 | TEVA_MDL_A_00028387 | | | | | | | |
| CE-653 | 10/15/2009 | FEN-2009P-PM-01153 Letter/FEN-2009P-PM-01154 Letter/FEN-2009P-PM-01155 Letter/FEN-2009P-PM-01179 | TEVA_MDL_A_00028388 | TEVA_MDL_A_00028396 | | | | | | | |
| CE-654 | 11/13/2009 | FEN-2009P-PM-01265 Email/FEN-2009P-PM-01266 Letter | TEVA_MDL_A_00028397 | TEVA_MDL_A_00028404 | | | | | | | |
| CE-655 | 01/05/2010 | FEN-2009P-PMC-00377 | TEVA_MDL_A_00028405 | TEVA_MDL_A_00028417 | | | | | | | |
| CE-656 | 01/19/2010 | FEN-2001 Quantia Slide Deck/FEN-2013 Dinner Meeting Rep Invite/FEN-2014 DM Fax Invite/FEN-2015 DM Confirmation Fax/FEN-2016 DM Flyer | TEVA_MDL_A_00028418 | TEVA_MDL_A_00028449 | | | | | | | |
| CE-657 | 01/28/2010 | FEN 2024 Flash storyboards | TEVA_MDL_A_00028450 | TEVA_MDL_A_00028455 | | | | | | | |
| CE-658 | 02/12/2010 | FEN 2027 Promotional P.I. | TEVA_MDL_A_00028456 | TEVA_MDL_A_00028462 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-659 | 02/19/2010 | FEN 2019 Hospital Invitation | TEVA_MDL_A_00028463 | TEVA_MDL_A_00028471 | | | | | | | |
| CE-660 | 03/25/2010 | FEN 2005 Fact Sheet | TEVA_MDL_A_00028472 | TEVA_MDL_A_00028481 | | | | | | | |
| CE-661 | 04/20/2010 | FEN 2043 Email Invitation/FEN 2043a Fax Invitation | TEVA_MDL_A_00028482 | TEVA_MDL_A_00028491 | | | | | | | |
| CE-662 | 04/23/2010 | FEN 2044 Confirmation Email/FEN 2044a Confirmation Fax/FEN 2056 eDetail Email | TEVA_MDL_A_00028492 | TEVA_MDL_A_00028502 | | | | | | | |
| CE-663 | 04/30/2010 | FEN 2025 PDR Content Converter/FEN 2026 Oncology Leave Behind | TEVA_MDL_A_00028503 | TEVA_MDL_A_00028527 | | | | | | | |
| CE-664 | 05/05/2010 | FEN-2038 Convention Booth Quiz | TEVA_MDL_A_00028528 | TEVA_MDL_A_00028536 | | | | | | | |
| CE-665 | 05/12/2010 | FEN-2028 Detailer-Case Study Folder/FEN-2028a Detailer-Case Study #1/FEN-2028b Detailer-Case Study #2/FEN-2028c Detailer-Tearsheets/FEN-2037 Fentora Brief Summary/FEN-2040 Slide Deck with Speaker Notes/FEN-2040b CD/FEN-2045 Workshop Sign/FEN-2048 Banner/FEN-2054a ONS Booth Sign/FEN-2057 Response Card/FEN-2040a Workbook/FEN-2046 BTP Survey/FEN-2047 Attendee Survey | TEVA_MDL_A_00028537 | TEVA_MDL_A_00028650 | | | | | | | |
| CE-666 | 06/28/2010 | FEN-2041 Post Convention Mailer | TEVA_MDL_A_00028651 | TEVA_MDL_A_00028657 | | | | | | | |
| CE-667 | 07/23/2010 | FEN-2067 Flashcard | TEVA_MDL_A_00028658 | TEVA_MDL_A_00028666 | | | | | | | |
| CE-668 | 08/05/2010 | FEN-2098 Cephalon.com patient section/FEN-2099 HCP section of Cephalon.com | TEVA_MDL_A_00028667 | TEVA_MDL_A_00028681 | | | | | | | |
| CE-669 | 08/13/2010 | FEN-2072 Brochure/FEN-2087 Registration Email/FEN-2087a Confirmation Email/FEN-2087b Registration Fax/FEN-2087c Sales Rep Invitation Letter/FEN-2087d Invitation Fax/FEN-2087e Confirmation Fax/FEN-2106 Registration Fax/FEN-2108 Invitation Letter/FEN-2109 Booth Handout/FEN-2110 Confirmation Letter | TEVA_MDL_A_00028682 | TEVA_MDL_A_00028715 | | | | | | | |
| CE-670 | 08/26/2010 | FEN-2080 PainWeek Mailer/FEN-2101 Floor Clings/FEN-2082a Pain Week Tweets | TEVA_MDL_A_00028716 | TEVA_MDL_A_00028732 | | | | | | | |
| CE-671 | 09/02/2010 | FEN-2069 Slide Deck/FEN-2082 Pain Week e-survey/FEN-2088 MD Slide Deck | TEVA_MDL_A_00028733 | TEVA_MDL_A_00028824 | | | | | | | |
| CE-672 | 09/09/2010 | FEN-2088a Worksheet/FEN-2089-PM-00374 Workbook/FEN-2104a E-Newsletter/FEN-2124 Signage | TEVA_MDL_A_00028825 | TEVA_MDL_A_00028894 | | | | | | | |
| CE-673 | 10/01/2010 | FEN-2164 ETC Invite/FEN-2165 ETC Fax Confirmation/FEN-2166 ETC Confirmation | TEVA_MDL_A_00028895 | TEVA_MDL_A_00028904 | | | | | | | |
| CE-674 | 10/08/2010 | FEN-2069a Worksheets/FEN-2086 Workbook/FEN-2156 Introduction Letter/FEN-2157 Direct Mail Material Letter/FEN-2159 Co-pay Assistance Card Letter/FEN-2170 HCP Dinner Email Invitation/FEN-2171 HCP Dinner Email Confirmation/FEN-2172 HCP Dinner Fax Invitation/FEN-2173 HCP Dinner Fax Confirmation/FEN-2174 HCP Dinner Sales Rep Invitation/FEN-2168 ETC Sales Rep Invitation | TEVA_MDL_A_00028905 | TEVA_MDL_A_00028984 | | | | | | | |
| CE-675 | 10/29/2010 | FEN-2177 Promotional Slide Deck | TEVA_MDL_A_00028985 | TEVA_MDL_A_00029031 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-676 | 11/05/2010 | FEN-2179 Workbook/FEN-2193 Rep Invitation/FEN-2194 Fax Invitation/FEN-2195 Confirmation Letter/FEN-2196 Evaluation Form | TEVA_MDL_A_00029032 | TEVA_MDL_A_00029049 | | | | | | | |
| CE-677 | 11/12/2010 | FEN-2155 Folder/FEN-2155a Prior Authorization CD Guide/FEN-2155b Prior Authorization CD/FEN-2155c Forms/FEN-2155d Flashcard | TEVA_MDL_A_00029050 | TEVA_MDL_A_00029070 | | | | | | | |
| CE-678 | 11/23/2010 | FEN-2200 HCP Slide Deck | TEVA_MDL_A_00029071 | TEVA_MDL_A_00029110 | | | | | | | |
| CE-679 | 12/10/2010 | FEN-2107 Quantia Slide Deck - Wave 2/FEN-2107a Quantia Slide Deck - Wave 3 | TEVA_MDL_A_00029111 | TEVA_MDL_A_00029152 | | | | | | | |
| CE-680 | 01/07/2011 | FEN-2122 Fentora.com | TEVA_MDL_A_00029153 | TEVA_MDL_A_00029393 | | | | | | | |
| CE-681 | 01/10/2011 | FEN-2201 FENTORA Voucher | TEVA_MDL_A_00029394 | TEVA_MDL_A_00029406 | | | | | | | |
| CE-682 | 01/14/2011 | FEN-2176 Core Visual Aid | TEVA_MDL_A_00029407 | TEVA_MDL_A_00029421 | | | | | | | |
| CE-683 | 01/28/2011 | FEN-2207 Assistance Card/FEN-2207a Assistance Card Holder | TEVA_MDL_A_00029422 | TEVA_MDL_A_00029431 | | | | | | | |
| CE-684 | 02/18/2011 | FEN-2225 Weinstein Reprint 2009/FEN-2226 Darwish Reprint 2007/FEN-2227 Portenoy Reprint 2006/FEN-2228 Darwish Reprint 2006/FEN-2229 Darwish Reprint 2006 | TEVA_MDL_A_00029432 | TEVA_MDL_A_00029483 | | | | | | | |
| CE-685 | 03/04/2011 | FEN-2183 Dosing Leave Behind | TEVA_MDL_A_00029484 | TEVA_MDL_A_00029494 | | | | | | | |
| CE-686 | 03/11/2011 | FEN-2236: Rep-triggered Letter - Efficacy/FEN-2236a: Rep-Triggered Letter Envelope/FEN-2237: Rep-triggered Letter - PK/FEN-2238: Rep-triggered Letter - STL | TEVA_MDL_A_00029495 | TEVA_MDL_A_00029511 | | | | | | | |
| CE-687 | 03/18/2011 | FEN-2242: Fentora Summary Panel/FEN-2249: Fentora Efficacy Panel | TEVA_MDL_A_00029512 | TEVA_MDL_A_00029520 | | | | | | | |
| CE-688 | 03/21/2011 | FEN-2250: Fentora ISI & Black Box Panel | TEVA_MDL_A_00029521 | TEVA_MDL_A_00029528 | | | | | | | |
| CE-689 | 03/22/2011 | FEN-2276: Fentora.com - Update | TEVA_MDL_A_00029529 | TEVA_MDL_A_00029774 | | | | | | | |
| CE-690 | 03/23/2011 | FEN-2259: Cephalon.com - Our Products | TEVA_MDL_A_00029775 | TEVA_MDL_A_00029797 | | | | | | | |
| CE-691 | 03/23/2011 | FEN-2260: Cephalon.com - Our Products | TEVA_MDL_A_00029798 | TEVA_MDL_A_00029819 | | | | | | | |
| CE-692 | 03/25/2011 | FEN-2186: Efficacy Leave Behind/FEN-2187: PK Leave Behind/FEN-2235: RTM Dosing/FEN-2244: RTM Dosing Actiq Convert | TEVA_MDL_A_00029820 | TEVA_MDL_A_00029842 | | | | | | | |
| CE-693 | 04/01/2011 | FEN-2220: Promotional Slide Deck/FEN-2220a: Abbr. Promotional Slide Deck | TEVA_MDL_A_00029843 | TEVA_MDL_A_00029914 | | | | | | | |
| CE-694 | 04/15/2011 | FEN-2264: Convention Fabric Ring | TEVA_MDL_A_00029915 | TEVA_MDL_A_00029922 | | | | | | | |
| CE-695 | 04/22/2011 | FEN-2271: Teleconference Series Invite | TEVA_MDL_A_00029923 | TEVA_MDL_A_00029933 | | | | | | | |
| CE-696 | 05/04/2011 | FEN-2220b: Telecon Series Workbook/FEN-2273: Telecon Series Cover Letter/FEN-2281: Telecon Series Evaluation Form/FEN-2284: Placebo for demonstration | TEVA_MDL_A_00029934 | TEVA_MDL_A_00029983 | | | | | | | |
| CE-697 | 05/26/2011 | FEN-2285: FENTORA HCP Leave Behind/FEN-2286: Patient Profile #1/FEN-2287: Patient Profile #2/FEN-2184: Stop Look Listen Leave Behind | TEVA_MDL_A_00029984 | TEVA_MDL_A_00030015 | | | | | | | |
| CE-698 | 06/09/2011 | FEN-2288: FENTORA Reprint Compend./FEN-2289: FENTORA Promotional Pl | TEVA_MDL_A_00030016 | TEVA_MDL_A_00030028 | | | | | | | |
| CE-699 | 06/23/2011 | FEN-2233 - HCP Product Website Update | TEVA_MDL_A_00030029 | TEVA_MDL_A_00030093 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-700 | 07/05/2011 | FEN-2234 - Consumer Product Website | TEVA_MDL_A_00030094 | TEVA_MDL_A_00030170 | | | | | | | |
| CE-701 | 07/15/2011 | FEN-2271a: Teleconference Series, Wave 2 | TEVA_MDL_A_00030171 | TEVA_MDL_A_00030178 | | | | | | | |
| CE-702 | 07/21/2011 | FEN-2316: REMS Media Fact Sheet | TEVA_MDL_A_00030179 | TEVA_MDL_A_00030202 | | | | | | | |
| CE-703 | 07/28/2011 | FEN-2312: RTL Assessing SAOs/FEN-2313: RTL Assessing LAOs | TEVA_MDL_A_00030203 | TEVA_MDL_A_00030212 | | | | | | | |
| CE-704 | 08/08/2011 | FEN-2320: REMS Fact Sheet/FEN-2321: REMS Approval Speaker Letter | TEVA_MDL_A_00030213 | TEVA_MDL_A_00030241 | | | | | | | |
| CE-705 | 08/10/2011 | FEN-2322: KOL REMS Approval Email | TEVA_MDL_A_00030242 | TEVA_MDL_A_00030270 | | | | | | | |
| CE-706 | 08/10/2011 | Transmittal of advertisements and promotional labeling for Fentora: FEN-2241a: Pain Week Program Ad | TEVA_MDL_A_00030271 | TEVA_MDL_A_00030278 | | | | | | | |
| CE-707 | 09/01/2011 | Transmittal of advertisements and promotional labeling for Fentora: FEN-2337 - Convention Panel: Summary/FEN-2338 - Convention Panel: Efficacy/FEN-2339 - Convention Panel: ISI | TEVA_MDL_A_00030279 | TEVA_MDL_A_00030299 | | | | | | | |
| CE-708 | 09/01/2011 | FEN-2324 - Dear HCP Letter/FEN-2325 - Dear Outpatient Pharmacy/FEN-2326 - Dear Inpatient Pharmacy/FEN-2327 - Dear Distributer Letter/FEN-2342 - Dear Stakeholder Envelope | TEVA_MDL_A_00030300 | TEVA_MDL_A_00030353 | | | | | | | |
| CE-709 | 09/08/2011 | Transmittal of advertisements and promotional labeling for Fentora: FEN-2323: Enrollment Kit Housing Unit/FEN-2323a: PPAF Tear Pad/FEN-2323b: Overview/FAQ/FEN-2328: REMS Enrollment Info Sheet | TEVA_MDL_A_00030354 | TEVA_MDL_A_00030375 | | | | | | | |
| CE-710 | 09/09/2011 | FEN-2337a: Table Top Panel - Summary/FEN-2338a: Table Top Panel - Efficacy/FEN-2339a: Table Top Panel - ISI | TEVA_MDL_A_00030376 | TEVA_MDL_A_00030396 | | | | | | | |
| CE-711 | 09/16/2011 | FEN-2220c: Full Promotional Slide Deck/FEN-2220d: Abbreviated Promo Slide Deck/FEN-2352: FENTORA Media Fact Sheet | TEVA_MDL_A_00030397 | TEVA_MDL_A_00030485 | | | | | | | |
| CE-712 | 09/16/2011 | FEN-2221: REMS Slide Deck/FEN-2353 REMS Media Fact Sheet | TEVA_MDL_A_00030486 | TEVA_MDL_A_00030583 | | | | | | | |
| CE-713 | 10/07/2011 | FEN-2334: REMS Enroll Letter-Wave 1/FEN-2357: REMS Inpatient Pharmacy/FEN-2358: REMS Outpatient Pharmacy/FEN-2365: NCPA pre-show email | TEVA_MDL_A_00030584 | TEVA_MDL_A_00030644 | | | | | | | |
| CE-714 | 10/13/2011 | FEN-2355: Fentora.com (Professional site) | TEVA_MDL_A_00030645 | TEVA_MDL_A_00030740 | | | | | | | |
| CE-715 | 10/13/2011 | FEN-2323c: Enrollment Kit/PPAF Tear Pad | TEVA_MDL_A_00030741 | TEVA_MDL_A_00030781 | | | | | | | |
| CE-716 | 11/04/2011 | FEN-2366: RTL [Representative Triggered Letter] Reminder REMS 3 Steps/FEN-2369: RTL Reminder Enroll is Open | TEVA_MDL_A_00030782 | TEVA_MDL_A_00030828 | | | | | | | |
| CE-717 | 11/11/2011 | FEN: 2221b: Rev. REMS Transition Deck | TEVA_MDL_A_00030829 | TEVA_MDL_A_00030901 | | | | | | | |
| CE-718 | 12/02/2011 | FEN-2373: Prescription Savings Brochure/FEN-2377: Prescription Savings Card | TEVA_MDL_A_00030902 | TEVA_MDL_A_00030929 | | | | | | | |
| CE-719 | 12/02/2011 | FEN-2221a: Rems NAMs Slide Deck | TEVA_MDL_A_00030930 | TEVA_MDL_A_00030984 | | | | | | | |
| CE-720 | 12/09/2011 | FEN-2377a: Prescription Savings Website | TEVA_MDL_A_00030985 | TEVA_MDL_A_00031008 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-721 | 01/06/2012 | FEN-2221c: REMS Transition Deck/FEN-2367: You're Enrolled, Int. ino Pract. | TEVA_MDL_A_00031056 | TEVA_MDL_A_00031170 | | | | | | | |
| CE-722 | 01/13/2012 | FEN-2376: REMS Webcast Invitation | TEVA_MDL_A_00031171 | TEVA_MDL_A_00031213 | | | | | | | |
| CE-723 | 01/26/2012 | FEN-2382: Core Visual Aid (Update) | TEVA_MDL_A_00031214 | TEVA_MDL_A_00031245 | | | | | | | |
| CE-724 | 01/26/2012 | FEN-2376b: REMS Webcast Invite (e-mail)/FEN/ACT-0002: PPAF Leave-Behind | TEVA_MDL_A_00031246 | TEVA_MDL_A_00031295 | | | | | | | |
| CE-725 | 02/17/2012 | FEN-2370: Pharmacy REMS Reminder/FEN-2371: Inpatient Pharm. REMS letter/FEN-2371a: REMS Letters Envelope/FEN-2372: Outpatient Pharm. REMS Letter/FEN-2376c: REMS On-Demand Webcast | TEVA_MDL_A_00031296 | TEVA_MDL_A_00031403 | | | | | | | |
| CE-726 | 02/24/2012 | FEN-2370: Pharmacy REMS Reminder/FEN-2376c: REMS Webcast Registration | TEVA_MDL_A_00031404 | TEVA_MDL_A_00031449 | | | | | | | |
| CE-727 | 03/02/2012 | FEN-2405: BTP Speaker Program Invite/FEN-2408: REMS Speaker Program Invite | TEVA_MDL_A_00031450 | TEVA_MDL_A_00031472 | | | | | | | |
| CE-728 | 03/09/2012 | FEN-2401 WIP Table Display/FEN-2409 FENTORA.com Update | TEVA_MDL_A_00031473 | TEVA_MDL_A_00031491 | | | | | | | |
| CE-729 | 03/15/2012 | FEN-2415 BTP Speaker Program Invite/FEN-2416 REMS Speaker Program Invite | TEVA_MDL_A_00031492 | TEVA_MDL_A_00031514 | | | | | | | |
| CE-730 | 03/19/2012 | FEN-2409 FENTORA.com Update | TEVA_MDL_A_00031515 | TEVA_MDL_A_00031532 | | | | | | | |
| CE-731 | 03/26/2012 | FEN-2409 FENTORA.com Update | TEVA_MDL_A_00031533 | TEVA_MDL_A_00031550 | | | | | | | |
| CE-732 | 03/26/2012 | FEN-2409 FENTORA.com Update/FEN-2401 WIP Table Display | TEVA_MDL_A_00031551 | TEVA_MDL_A_00031569 | | | | | | | |
| CE-733 | 04/06/2012 | FEN-2417 Efficacy Leave Behind Update | TEVA_MDL_A_00031570 | TEVA_MDL_A_00031590 | | | | | | | |
| CE-734 | 04/13/2012 | FEN-2411 Rx Savings Brochure/FEN-2411a Rx Savings Brochure Holder | TEVA_MDL_A_00031591 | TEVA_MDL_A_00031615 | | | | | | | |
| CE-735 | 04/20/2012 | FEN-2411 Rx Savings Brochure/FEN-2410 Rx Savings Card/FEN-2412 65 & Over Program Ltr & Cert/FEN-2414 Rx Savings Program Envelope | TEVA_MDL_A_00031616 | TEVA_MDL_A_00031652 | | | | | | | |
| CE-736 | 04/20/2012 | FEN-2441 FENTORA ISI Panel | TEVA_MDL_A_00031653 | TEVA_MDL_A_00031670 | | | | | | | |
| CE-737 | 04/27/2012 | FEN-2421 Rx Savings Rep Triggered Mail | TEVA_MDL_A_00031671 | TEVA_MDL_A_00031690 | | | | | | | |
| CE-738 | 05/03/2012 | FEN-2429 Touch Screen Panels | TEVA_MDL_A_00031691 | TEVA_MDL_A_00031725 | | | | | | | |
| CE-739 | 05/18/2012 | FEN-2418 Dosing Leave Behind/FEN-2447 Hotline Card Update | TEVA_MDL_A_00031726 | TEVA_MDL_A_00031746 | | | | | | | |
| CE-740 | 05/25/2012 | FEN-2442 Portenoy Reprint Carrier/FEN-2443 Weinstein Reprint Carrier/FEN/ACT-0005 RTL-Actiq Conversions | TEVA_MDL_A_00031747 | TEVA_MDL_A_00031782 | | | | | | | |
| CE-741 | 06/01/2012 | FEN-2464 ISI Panel Update/FEN-2446 HCP Brochure Update | TEVA_MDL_A_00031783 | TEVA_MDL_A_00031820 | | | | | | | |
| CE-742 | 07/06/2012 | FEN-2456 FentoraSavings.com | TEVA_MDL_A_00031821 | TEVA_MDL_A_00031838 | | | | | | | |
| CE-743 | 07/06/2012 | FEN-2456 FentoraSavings.com | TEVA_MDL_A_00031839 | TEVA_MDL_A_00031856 | | | | | | | |
| CE-744 | 07/20/2012 | FEN-2362 Patient Brochure | TEVA_MDL_A_00031857 | TEVA_MDL_A_00031887 | | | | | | | |
| CE-745 | 07/27/2012 | FEN-2455 FENTORA Digital Sales Aid for iPad (July Pilot)/FEN-2457 FENTORA Dosing Digital Sales Aid for iPad (July Pilot) | TEVA_MDL_A_00031888 | TEVA_MDL_A_00031973 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-746 | 09/18/2012 | Case-Based Promotional Slide Deck/Breakthrough Cancer Pain Speaker Program Invite Template | TEVA_MDL_A_00031974 | TEVA_MDL_A_00032058 | | | | | | | |
| CE-747 | 09/20/2012 | FEN-2438/FEN-2444 FENTORA.com Website Pages (Consumer) | TEVA_MDL_A_00032059 | TEVA_MDL_A_00032085 | | | | | | | |
| CE-748 | 09/20/2012 | FEN-2437/FEN-2444 FENTORA.com Website Pages (HCP) | TEVA_MDL_A_00032086 | TEVA_MDL_A_00032111 | | | | | | | |
| CE-749 | 10/03/2012 | FEN-2484 Digital Sales Aid for iPad/FEN-2508 Fingertip Formulary for iPad | TEVA_MDL_A_00032112 | TEVA_MDL_A_00032218 | | | | | | | |
| CE-750 | 10/19/2012 | FEN-2490 Sales Aid/FEN-2491 HCP Slim Jim/FEN-2497 Hotline Form | TEVA_MDL_A_00032219 | TEVA_MDL_A_00032280 | | | | | | | |
| CE-751 | 11/16/2012 | FEN-2509 BTP Speaker Program Invite Template/FEN-2509a BTP Speaker Program Invite Envelope | TEVA_MDL_A_00032281 | TEVA_MDL_A_00032300 | | | | | | | |
| CE-752 | 12/07/2012 | FEN-2493 Dosing Leave Behind | TEVA_MDL_A_00032301 | TEVA_MDL_A_00032319 | | | | | | | |
| CE-753 | 12/20/2012 | FEN-2492 Tri-fold Leave Behind | TEVA_MDL_A_00032320 | TEVA_MDL_A_00032338 | | | | | | | |
| CE-754 | 01/04/2013 | FEN-2452a FENTORA abbreviated case-based promotional slide deck | TEVA_MDL_A_00032339 | TEVA_MDL_A_00032398 | | | | | | | |
| CE-755 | 01/10/2013 | FEN-2484a Digital Sales Aid for iPad | TEVA_MDL_A_00032399 | TEVA_MDL_A_00032500 | | | | | | | |
| CE-756 | 02/01/2013 | FEN-2510 Rx Savings Brochure/FEN-2519 Rx Savings Card | TEVA_MDL_A_00032501 | TEVA_MDL_A_00032524 | | | | | | | |
| CE-757 | 01/15/2013 | FEN-2522 Table Top Panels/FEN-2522a Table Cloth for Table Top Display | TEVA_MDL_A_00032525 | TEVA_MDL_A_00032546 | | | | | | | |
| CE-758 | 01/22/2013 | FEN-2526 Rx Savings RTM/FEN-2527 Clinical Data RTM/FEN-2534 Dosing RTM | TEVA_MDL_A_00032547 | TEVA_MDL_A_00032573 | | | | | | | |
| CE-759 | 03/01/2013 | FEN-2535 Digital Sales Aid for iPad/PAIN-2094 Breakthrough Pain Animation/FEN-2523 Webkey Splash Page/FEN-2532 Webkey RTM/FEN-2533 Webkey Card/FEN-2526a RTM Envelope/FEN-2533a Webkey Brochure | TEVA_MDL_A_00032574 | TEVA_MDL_A_00032694 | | | | | | | |
| CE-760 | 03/08/2013 | FEN-2529 Touchscreen Convention Panels/FEN-2530 Convention ISI Panel | TEVA_MDL_A_00032695 | TEVA_MDL_A_00032760 | | | | | | | |
| CE-761 | 04/02/2013 | FEN-40019 AAPM Backlit logo/AMR-40006 AAPM Hanging Sign | TEVA_MDL_A_00032761 | TEVA_MDL_A_00032779 | | | | | | | |
| CE-762 | 04/03/2013 | FEN-2516 eNewsletter 1 | TEVA_MDL_A_00032780 | TEVA_MDL_A_00032783 | | | | | | | |
| CE-763 | 04/05/2013 | FEN-2536a Copay Coupon | TEVA_MDL_A_00032784 | TEVA_MDL_A_00032803 | | | | | | | |
| CE-764 | 04/19/2013 | FEN-40007 Horizontal Touchscreen Panels/FEN-40009 ISI Poster | TEVA_MDL_A_00032804 | TEVA_MDL_A_00032915 | | | | | | | |
| CE-765 | 04/24/2013 | ONC-40163 Multi Brand Projection Screen Full Version | TEVA_MDL_A_00032916 | TEVA_MDL_A_00032943 | | | | | | | |
| CE-766 | 04/26/2013 | FEN-40011 30x40 Backlit Panel/FEN-40017 eNewsletter 2 | TEVA_MDL_A_00032944 | TEVA_MDL_A_00032950 | | | | | | | |
| CE-767 | 05/03/2013 | FEN-40028 Vertical Convention Panel Update/FEN-40021 Sublingual Administration Leave Behind | TEVA_MDL_A_00032951 | TEVA_MDL_A_00033008 | | | | | | | |
| CE-768 | 05/10/2013 | FEN-40005 Digital Sales Aid for iPad | TEVA_MDL_A_00033009 | TEVA_MDL_A_00033092 | | | | | | | |
| CE-769 | 06/21/2013 | FEN-40047 Over 65 Program Letter and Certification Update/FEN-40048 BTP Patient Brochure | TEVA_MDL_A_00033093 | TEVA_MDL_A_00033117 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-770 | 07/12/2013 | FEN-40044 FENTORA.com HCP Site | TEVA_MDL_A_00033118 | TEVA_MDL_A_00033126 | | | | | | | |
| CE-771 | 07/19/2013 | FEN-40050 Managing Breakthrough Pain in the Oncology Setting Slide Deck | TEVA_MDL_A_00033127 | TEVA_MDL_A_00033166 | | | | | | | |
| CE-772 | 08/23/2013 | TEVA_MDL_A_00033167 | TEVA_MDL_A_00033167 | TEVA_MDL_A_00033214 | | | | | | | |
| CE-773 | 09/06/2013 | FEN-40074 Perspectives in Oncology: Managing Breakthrough Pain (Participant Guide) | TEVA_MDL_A_00033215 | TEVA_MDL_A_00033252 | | | | | | | |
| CE-774 | 09/13/2013 | FEN-40066 Oncology Speaker Program Invite 7x7 size | TEVA_MDL_A_00033253 | TEVA_MDL_A_00033257 | | | | | | | |
| CE-775 | 09/27/2013 | FEN-40056 Rx Savings RTL with Brochure and Copay Coupons/FEN-40078 Speaker Program Invite/FEN-40084 eNewsletter | TEVA_MDL_A_00033263 | TEVA_MDL_A_00033275 | | | | | | | |
| CE-776 | 10/18/2013 | FEN-40029 Fentora eDetail | TEVA_MDL_A_00033276 | TEVA_MDL_A_00033328 | | | | | | | |
| CE-777 | 11/08/2013 | FEN-40102 HCP Connect Program Invitation/FEN-40037 Cover My Meds Landing Page | TEVA_MDL_A_00033329 | TEVA_MDL_A_00033343 | | | | | | | |
| CE-778 | 11/22/2013 | FEN-40101 Reimbursement Form/FEN-40114 Reimbursement Form (fax version) | TEVA_MDL_A_00033344 | TEVA_MDL_A_00033362 | | | | | | | |
| CE-780 | 12/04/2013 | FEN-40111 Pain Program Guidebook/FEN-40110 Oncology Program Guidebook | TEVA_MDL_A_00033372 | TEVA_MDL_A_00033466 | | | | | | | |
| CE-790 | 07/06/2010 | ShareYourPain.com Article_MayoClinic_Prescription Drug Abuse | TEVA_MDL_A_01150054 | TEVA_MDL_A_01150073 | | | | | | | |
| CE-791 | 07/06/2010 | YEARLY REVIEW: BTP Patient Education Brochure | TEVA_MDL_A_01150080 | TEVA_MDL_A_01150089 | | | | | | | |
| CE-801 | 01/27/2010 | Breakthrough Pain in Patients with Cancer Fact Sheet | TEVA_MDL_A_01152140 | TEVA_MDL_A_01152140 | | | | | | | |
| CE-802 | 01/27/2010 | Drug Scheduling Fact Sheet | TEVA_MDL_A_01152168 | TEVA_MDL_A_01152168 | | | | | | | |
| CE-818 | 06/21/2011 | RTL 6: Assessing Long Acting Opioids | TEVA_MDL_A_01153542 | TEVA_MDL_A_01153544 | | | | | | | |
| CE-824 | 04/14/2010 | Breakthrough Cancer Pain Podcast Series Interview #6: Clinical Perspective | TEVA_MDL_A_01158059 | TEVA_MDL_A_01158064 | | | | | | | |
| CE-827 | 04/23/2010 | ShareYourPain.com Article: National Cancer Institute - Addiction and Chronic Pain Myths | TEVA_MDL_A_01158119 | TEVA_MDL_A_01158119 | | | | | | | |
| CE-828 | 04/23/2010 | ShareYourPain.com Article: National Cancer Institute - Pain(PDQ) | TEVA_MDL_A_01158120 | TEVA_MDL_A_01158126 | | | | | | | |
| CE-829 | 04/26/2010 | ShareYourPain.com Article: Leukemia and Lymphoma Society - Pain Management | TEVA_MDL_A_01158132 | TEVA_MDL_A_01158145 | | | | | | | |
| CE-830 | 04/26/2010 | ShareYourPain.com Article: National Cancer Institute - Cancer Pain Can Be Managed | TEVA_MDL_A_01158146 | TEVA_MDL_A_01158146 | | | | | | | |
| CE-836 | 03/02/2006 | Email from Michael Richardson, Senior Director, Worldwide Product Planning, Cephalon, to Terrence Terifay, Associate Product Director, Pain Franchise, (re: Pain as the Fifth Vital Sign campaign language) | TEVA_MDL_A_01488890 | TEVA_MDL_A_01488892 | | | | | | | |
| CE-838 | 07/00/2006 | Revised Abuse, Addiction & Diversion Speaker Slide Kit Module 1 | TEVA_MDL_A_00514038 | TEVA_MDL_A_00514094 | | | | | | | |
| CE-839 | 07/00/2006 | Revised Abuse, Addiction & Diversion Speaker Slide Kit Module 2 | TEVA_MDL_A_00514095 | TEVA_MDL_A_00514137 | | | | | | | |
| CE-848 | 11/00/2005 | BTP Catalina Newsletter - You may have BTP | TEVA_MDL_A_01400560 | TEVA_MDL_A_01400560 | | | | | | | |
| CE-858 | 00/00/2008 | Cephalon Corporate Integrity Agreement (2008) | TEVA_MDL_A_06380925 | TEVA_MDL_A_06380989 | | | | | | | |
| CE-859 | 00/00/2012 | Speakers Bureau Business Rationale Application | TEVA_MDL_A_00702968 | TEVA_MDL_A_00702968 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-860 | 12/16/2004 | Cephalon Board of Directors Meeting (Annual Compliance Update Section included) | TEVA_MDL_A_00667543 | TEVA_MDL_A_00667754 | | | | | | | |
| CE-861 | 01/20/2010 | Compliance Overview Initial Training Class Presentation conducted by Karen Lowney, Compliance Senior Director (Jan. 2010) | TEVA_MDL_A_00381967 | TEVA_MDL_A_00381989 | | | | | | | |
| CE-862 | 07/01/2018 | Cephalon Employee Conduct Policy (HR-510) | TEVA_MDL_A_00552247 | TEVA_MDL_A_00552248 | | | | | | | |
| CE-863 | 01/26/2009 | Field Force Ride-Along Program (GC-220), (Jan. 2009) | TEVA_MDL_A_00552273 | TEVA_MDL_A_00552275 | | | | | | | |
| CE-864 | 06/01/2008 | Cephalon Good Business Practices Field Guide ("GBP") (June 2008) | TEVA_MDL_A_00552305 | TEVA_MDL_A_00552363 | | | | | | | |
| CE-865 | 01/26/2009 | Cephalon Incident Management (GC-300) (Jan. 2009) | TEVA_MDL_A_00552368 | TEVA_MDL_A_00552373 | | | | | | | |
| CE-866 | 02/09/2007 | Cephalon Patient Safety Policy | TEVA_MDL_A_00552453 | TEVA_MDL_A_00552453 | | | | | | | |
| CE-867 | 07/01/2008 | Cephalon Reporting and Investigations of Misconduct (C-150) (July 1 2008) | TEVA_MDL_A_00552585 | TEVA_MDL_A_00552588 | | | | | | | |
| CE-868 | 01/26/2009 | Targeting Assessment and Call Activity (GPO-130) | TEVA_MDL_A_00552695 | TEVA_MDL_A_00552698 | | | | | | | |
| CE-869 | 07/01/2008 | US Sales and Marketing Policy (GPO-100) | TEVA_MDL_A_00552786 | TEVA_MDL_A_00552818 | | | | | | | |
| CE-870 | 10/06/2006 | Adverse Drug Experience, Product Complaint, and MIRF to PSMI | TEVA_MDL_A_00552829 | TEVA_MDL_A_00552839 | | | | | | | |
| CE-871 | 03/07/2019 | Policy on Gifts, Meals, and Entertainment for Physicians and Other Healthcare Practitioners | TEVA_MDL_A_00552891 | TEVA_MDL_A_00552900 | | | | | | | |
| CE-872 | 10/06/2019 | Policy re Sample Management | TEVA_MDL_A_00552901 | TEVA_MDL_A_00552901 | | | | | | | |
| CE-873 | 10/06/2019 | Policy on Preceptorships | TEVA_MDL_A_00553012 | TEVA_MDL_A_00553026 | | | | | | | |
| CE-874 | 06/01/2007 | Marketing Policy, WLF: Dissemination of Peer-Reviewed Reprints and Reference Textbooks | TEVA_MDL_A_00553036 | TEVA_MDL_A_00553047 | | | | | | | |
| CE-875 | 11/22/2013 | Cephalon CIA Annual Report Year 5 | TEVA_MDL_A_00559116 | TEVA_MDL_A_00559117 | | | | | | | |
| CE-876 | 11/21/2012 | Cephalon CIA Annual Report Year 4 | TEVA_MDL_A_00560833 | TEVA_MDL_A_00560834 | | | | | | | |
| CE-877 | 11/20/2009 | Cephalon CIA Annual Report Year 1 | TEVA_MDL_A_00561764 | TEVA_MDL_A_00561765 | | | | | | | |
| CE-878 | 11/23/2010 | Cephalon CIA Annual Report Year 2 | TEVA_MDL_A_00562291 | TEVA_MDL_A_00562292 | | | | | | | |
| CE-879 | 11/18/2011 | Cephalon CIA Annual Report Year 3 | TEVA_MDL_A_00562862 | TEVA_MDL_A_00562863 | | | | | | | |
| CE-880 | 01/21/2009 | Compliance Overview Initial Training Class Presentation conducted by Karen Lowney, Compliance Senior Director | TEVA_MDL_A_00801578 | TEVA_MDL_A_00801603 | | | | | | | |
| CE-881 | 01/09/2019 | Charter of Cephalon's Global Compliance Committee | TEVA_MDL_A_00819644 | TEVA_MDL_A_00819645 | | | | | | | |
| CE-882 | 01/27/2010 | 2009 Global Compliance Report Summary | TEVA_MDL_A_00820941 | TEVA_MDL_A_00820947 | | | | | | | |
| CE-883 | 04/06/2006 | Training Process for Members of the Sales Organization | TEVA_MDL_A_01249224 | TEVA_MDL_A_01249228 | | | | | | | |
| CE-884 | 10/04/2007 | Cephalon Standards of Business Conduct | TEVA_MDL_A_06880695 | TEVA_MDL_A_06880710 | | | | | | | |
| CE-885 | 01/28/2009 | 2008 Global Compliance Report Executive Summary | TEVA_MDL_A_04321674 | TEVA_MDL_A_04321676 | | | | | | | |
| CE-886 | 07/30/2009 | Effectiveness of Cephalon's Global Compliance Program Board Update | TEVA_MDL_A_04321682 | TEVA_MDL_A_04321687 | | | | | | | |
| CE-887 | 10/06/2019 | Policy on Gifts, Meals, and Entertainment for Physicians and Other Healthcare Practitioners | TEVA_MDL_A_04756815 | TEVA_MDL_A_04756821 | | | | | | | |
| CE-888 | 00/00/2000 | Cephalon Corporate Compliance Program Policy (2000) | TEVA_MDL_A_05508657 | TEVA_MDL_A_05508678 | | | | | | | |
| CE-889 | 07/29/2004 | Memorandum: Mid-Year Compliance Update | TEVA_MDL_A_06377159 | TEVA_MDL_A_06377181 | | | | | | | |
| CE-890 | 06/13/2011 | Year Two CIA Specific New Hire Course | TEVA_MDL_A_00007783 | TEVA_MDL_A_00007864 | | | | | | | |
| CE-891 | 07/01/2008 | Cephalon Political Activities and Lobbying Policy | TEVA_MDL_A_00552458 | TEVA_MDL_A_00552460 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-892 | 09/30/2009 | Training Summary | TEVA_MDL_A_00561907 | TEVA_MDL_A_00561909 | | | | | | | |
| CE-893 | 11/02/2009 | Ernst & Young Report on Independent Review Organization's Engagement | TEVA_MDL_A_00561910 | TEVA_MDL_A_00562007 | | | | | | | |
| CE-894 | 11/17/2010 | Ernst & Young Report on Independent Review Organization's Engagement | TEVA_MDL_A_00562363 | TEVA_MDL_A_00562428 | | | | | | | |
| CE-895 | 01/01/2008 | Cephalon MIRF Monitoring Procedure | TEVA_MDL_A_01086224 | TEVA_MDL_A_01086225 | | | | | | | |
| CE-896 | 04/23/2007 | Cephalon Management Readiness Program | TEVA_MDL_A_01105624 | TEVA_MDL_A_01105632 | | | | | | | |
| CE-897 | 08/21/2009 | Submission of Medical Information Requests WMRO 116 | TEVA_MDL_A_00770359 | TEVA_MDL_A_00770362 | | | | | | | |
| CE-898 | 04/03/2013 | April 2013 Letter from OIG to Tricia Glover re: Site Inspection Summary | TEVA_MDL_A_00782034 | TEVA_MDL_A_00782037 | | | | | | | |
| CE-899 | 07/29/2008 | Cephalon Global Compliance New Employee Orientation | TEVA_MDL_A_00786858 | TEVA_MDL_A_00786858 | | | | | | | |
| CE-900 | 00/00/2008 | Cephalon Global Compliance Department | TEVA_MDL_A_01251327 | TEVA_MDL_A_01251352 | | | | | | | |
| CE-901 | 01/26/2009 | Medical Information Request Monitoring (C-300) | TEVA_MDL_A_03070586 | TEVA_MDL_A_03070587 | | | | | | | |
| CE-902 | 01/28/2009 | Cephalon 2008 Global Compliance Report (Jan. 28 2009) | TEVA_MDL_A_13583946 | TEVA_MDL_A_13583978 | | | | | | | |
| CE-903 | 00/00/2004 | 2004 Cephalon Code of Conduct | TEVA_MDL_A_09624030 | TEVA_MDL_A_09624698 | | | | | | | |
| CE-904 | 02/13/2009 | inVentiv Health Care Compliance Training Interactions with Health Care Professionals | TEVA_MDL_A_11426483 | TEVA_MDL_A_11426483 | | | | | | | |
| CE-905 | 09/29/2004 | Policy on Providing Reimbursement Information to Customers | TEVA_MDL_A_11892838 | TEVA_MDL_A_11892839 | | | | | | | |
| CE-906 | 09/29/2004 | Policy on Advertising and Promotional Materials and Activities | TEVA_MDL_A_11892858 | TEVA_MDL_A_11892861 | | | | | | | |
| CE-907 | 10/04/2019 | Gifts, Meals and Entertainment for Physicians and Other Healthcare Practitioners | TEVA_MDL_A_11892871 | TEVA_MDL_A_11892874 | | | | | | | |
| CE-908 | 09/29/2004 | Policy Re: Sample Management | TEVA_MDL_A_11892875 | TEVA_MDL_A_11892875 | | | | | | | |
| CE-909 | 09/29/2004 | Policy on Preceptorships | TEVA_MDL_A_11892883 | TEVA_MDL_A_11892886 | | | | | | | |
| CE-910 | 09/29/2004 | Policy on Funding to Support Independent, Third-Party Educational or Scientific Meetings | TEVA_MDL_A_11892887 | TEVA_MDL_A_11892899 | | | | | | | |
| CE-911 | 09/29/2004 | Policy on Grants or Support that are not for Independent Medical Education | TEVA_MDL_A_11892900 | TEVA_MDL_A_11892903 | | | | | | | |
| CE-912 | 09/29/2004 | Policy Re: Employee Reporting of Adverse Events, Product Complaints, Tampering, Adulteration and/or Diversion | TEVA_MDL_A_11892904 | TEVA_MDL_A_11892906 | | | | | | | |
| CE-913 | 06/07/2019 | Policy on Gifts, Meals, and Entertainment for Physicians and Other Healthcare Practitioners | TEVA_MDL_A_00552906 | TEVA_MDL_A_00552909 | | | | | | | |
| CE-914 | 02/26/2009 | Implementation Report | TEVA_MDL_A_00560071 | TEVA_MDL_A_00560071 | | | | | | | |
| CE-915 | 01/22/2008 | Cephalon 2008 Organizational Chart | TEVA_MDL_A_00456349 | TEVA_MDL_A_00456409 | | | | | | | |
| CE-916 | 01/01/2009 | Cephalon 2009 Organizational Chart | TEVA_MDL_A_00456410 | TEVA_MDL_A_00456463 | | | | | | | |
| CE-917 | 01/01/2010 | Cephalon 2010 Organizational Chart | TEVA_MDL_A_00456464 | TEVA_MDL_A_00456516 | | | | | | | |
| CE-918 | 10/01/2006 | Cephalon Policy on Third-Party Funding Requests to Support Independent Medical Education Program, (Oct. 2006). | TEVA_MDL_A_06880639 | TEVA_MDL_A_06880655 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-920 | 08/14/2006 | Grant to American Society of Pain Management Nursing for meeting regarding recent advances in pain management | TEVA_MDL_A_01089865 | TEVA_MDL_A_01089870 | | | | | | | |
| CE-921 | 08/12/2004 | Grant for enhancement of National Pain Foundation's education-oriented website and to help raise funds via NPF's "Triumph Dinner" | TEVA_MDL_A_01171351 | TEVA_MDL_A_01171369 | | | | | | | |
| CE-923 | 07/01/2008 | Cephalon Charitable Contributions Policy, (July 1 2008) | TEVA_MDL_A_00552042 | TEVA_MDL_A_00552044 | | | | | | | |
| CE-924 | 08/14/2009 | Cephalon Charitable Contributions Procedure, (Aug. 14, 2009). | TEVA_MDL_A_00552045 | TEVA_MDL_A_00552047 | | | | | | | |
| CE-925 | 07/01/2008 | Cephalon Company Giving Policy | TEVA_MDL_A_00785338 | TEVA_MDL_A_00785342 | | | | | | | |
| CE-927 | 02/03/2003 | Request for Funding for Educational Activity (payee: MediCom) | TEVA_MDL_A_01850590 | TEVA_MDL_A_01850597 | | | | | | | |
| CE-928 | 09/09/2004 | AAPM Symposium Proposal for Cephalon (payee: Conexus) | TEVA_MDL_A_01851280 | TEVA_MDL_A_01851296 | | | | | | | |
| CE-929 | 11/30/2005 | Educational Grant Draft Request (payee: Fusion) | TEVA_MDL_A_01854921 | TEVA_MDL_A_01854944 | | | | | | | |
| CE-930 | 11/28/2006 | Agreement regarding Chronic Pain Management with Opioids Symposium (payee: Boston U School of Medicine) | TEVA_MDL_A_00837109 | TEVA_MDL_A_00837132 | | | | | | | |
| CE-932 | 01/15/2009 | Independent Educational Program Grant Agreement (payee: MediCom Worldwide) | TEVA_MDL_A_00850584 | TEVA_MDL_A_00850727 | | | | | | | |
| CE-933 | 01/19/2010 | Independent Educational Program Grant Agreement (payee: Albert Einstein College of Medicine) | TEVA_MDL_A_01176915 | TEVA_MDL_A_01176951 | | | | | | | |
| CE-937 | 07/09/2004 | Education Grant Draft Request (American Society of Addiction Medicine) | TEVA_MDL_A_06343520 | TEVA_MDL_A_06343759 | | | | | | | |
| CE-940 | 08/12/2004 | Educational Grant Draft Request (American Pain Foundation) | TEVA_MDL_A_05509299 | TEVA_MDL_A_05509312 | | | | | | | |
| CE-941 | 01/09/2007 | Educational Grant Draft Request (American Pain Foundation) | TEVA_MDL_A_01174115 | TEVA_MDL_A_01174115 | | | | | | | |
| CE-942 | 03/06/2007 | Unrestricted Educational Grant Agreement between Cephalon and American Pain Foundation) | TEVA_MDL_A_03315373 | TEVA_MDL_A_03315375 | | | | | | | |
| CE-943 | 07/17/2008 | Unrestricted Educational Grant Agreement between Cephalon and American Pain Foundation) | TEVA_MDL_A_03315969 | TEVA_MDL_A_03315975 | | | | | | | |
| CE-946 | 11/30/2005 | Educational Grant Draft Request (payee: Tufts) | TEVA_MDL_A_01854945 | TEVA_MDL_A_01854959 | | | | | | | |
| CE-947 | 12/06/2006 | Educational Grant Agreement (payee: SciMed) | TEVA_MDL_A_01164505 | TEVA_MDL_A_01164528 | | | | | | | |
| CE-948 | 12/16/2008 | Educational Grant Agreement (payee: Montefiore) | TEVA_MDL_A_00849962 | TEVA_MDL_A_00850031 | | | | | | | |
| CE-949 | 12/05/2011 | Educational Grant Agreement (payee: MediCom) | TEVA_MDL_A_01176720 | TEVA_MDL_A_01176751 | | | | | | | |
| CE-950 | 11/27/2006 | Educational Grant Agreement (payee: Advanced Strategies in Medicine) | TEVA_MDL_A_00839940 | TEVA_MDL_A_00839996 | | | | | | | |
| CE-962 | 11/20/2006 | IEP Grant Agreement (MediCom Worldwide, Inc.) | TEVA_MDL_A_00503071 | TEVA_MDL_A_00503107 | | | | | | | |
| CE-963 | 12/06/2006 | IEP Grant Agreement (Medical Learning Solutions) | TEVA_MDL_A_03315345 | TEVA_MDL_A_03315372 | | | | | | | |
| CE-964 | 04/05/2007 | IEP Grant Agreement (SciMed) | TEVA_MDL_A_06755520 | TEVA_MDL_A_06755542 | | | | | | | |
| CE-966 | 08/28/2007 | IEP Grant Agreement (FSMB) | TEVA_MDL_A_01088845 | TEVA_MDL_A_01088857 | | | | | | | |
| CE-967 | 06/28/2003 | Consulting Agreement (Dr. Gerald Aronoff) | TEVA_MDL_A_13591816 | TEVA_MDL_A_13591817 | | | | | | | |
| CE-969 | 09/08/2005 | Consulting Agreement (Dr. Gerald Aronoff) | TEVA_MDL_A_13599853 | TEVA_MDL_A_13599854 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-971 | 02/01/2007 | IEP Grant Agreement (Cleveland Clinic Foundation) | TEVA_MDL_A_00843019 | TEVA_MDL_A_00843045 | | | | | | | |
| CE-973 | 05/01/2007 | Managed Care Cephalon Speaker Agreement - Dr. Gerald Aronoff | TEVA_MDL_A_13603675 | TEVA_MDL_A_13603685 | | | | | | | |
| CE-974 | 03/20/2011 | Consulting Agreement with Dr. Gerald Aronoff | TEVA_MDL_A_13745185 | TEVA_MDL_A_13745197 | | | | | | | |
| CE-975 | 09/19/2006 | Consulting Agreement with Dr. Gerald Aronoff | TEVA_MDL_A_06747131 | TEVA_MDL_A_06747144 | | | | | | | |
| CE-977 | 07/24/2006 | Medical Education Agreement (Medscape LLC) | TEVA_MDL_A_00502714 | TEVA_MDL_A_00502715 | | | | | | | |
| CE-981 | 11/25/2008 | IEP Grant Agreement (Medscape) | TEVA_MDL_A_06761210 | TEVA_MDL_A_06761237 | | | | | | | |
| CE-982 | 04/01/2009 | IEP Grant Agreement (Medscape LLC) | TEVA_MDL_A_06794147 | TEVA_MDL_A_06794207 | | | | | | | |
| CE-986 | 11/27/2006 | IEP Grant Agreement (Vital Issues in Medicine) | TEVA_MDL_A_00836297 | TEVA_MDL_A_00836324 | | | | | | | |
| CE-991 | 03/01/2011 | Consulting Agreement - Dr. Perry Fine | TEVA_MDL_A_03314967 | TEVA_MDL_A_03314981 | | | | | | | |
| CE-999 | 10/26/2007 | Grant Agreement (Beth Israel Medical Center) | TEVA_MDL_A_00849375 | TEVA_MDL_A_00849416 | | | | | | | |
| CE-1001 | 01/15/2009 | IEP Grant Agreement (Beth Israel Medical Center) | TEVA_MDL_A_06766836 | TEVA_MDL_A_06766852 | | | | | | | |
| CE-1003 | 09/09/2009 | Advisory Board Agreement Dr. Russell Portenoy | TEVA_MDL_A_09540158 | TEVA_MDL_A_09540159 | | | | | | | |
| CE-1004 | 02/23/2010 | IEP Grant Agreement (Beth Israel Medical Center) | TEVA_MDL_A_00855331 | TEVA_MDL_A_00855339 | | | | | | | |
| CE-1005 | 02/11/2011 | Advisory Board Agreement Dr. Russell Portenoy | TEVA_MDL_A_07249931 | TEVA_MDL_A_07249938 | | | | | | | |
| CE-1006 | 10/18/2011 | IEP Grant Agreement (MediCom Worldwide, Inc.) | TEVA_MDL_A_01176418 | TEVA_MDL_A_01176472 | | | | | | | |
| CE-1007 | 02/24/2006 | Letter re CME Symposium AAPM | TEVA_MDL_A_03314982 | TEVA_MDL_A_03314983 | | | | | | | |
| CE-1008 | 09/13/2006 | Educational Grant Draft Request ACPA | TEVA_MDL_A_01089593 | TEVA_MDL_A_01089596 | | | | | | | |
| CE-1009 | 09/13/2006 | Educational Grant Draft Request APF | TEVA_MDL_A_01089587 | TEVA_MDL_A_01089589 | | | | | | | |
| CE-1010 | 09/13/2006 | Educational Grant Draft Request APF | TEVA_MDL_A_01089590 | TEVA_MDL_A_01089592 | | | | | | | |
| CE-1011 | 12/04/2006 | Educational Grant Draft Request APS | TEVA_MDL_A_00829238 | TEVA_MDL_A_00829239 | | | | | | | |
| CE-1012 | 11/27/2006 | Educational Grant Draft Request ASM | TEVA_MDL_A_01172593 | TEVA_MDL_A_01172621 | | | | | | | |
| CE-1015 | 02/03/2006 | Amendment to 11/19/05 Clinical Trial Protocol Work Order Dr. Donald Taylor | TEVA_MDL_A_13746847 | TEVA_MDL_A_13746847 | | | | | | | |
| CE-1017 | 06/09/2006 | Educational Grant Draft Request FSMB | TEVA_MDL_A_01088810 | TEVA_MDL_A_01088820 | | | | | | | |
| CE-1019 | 11/13/2006 | Educational Grant Draft Request Medicom | TEVA_MDL_A_01172729 | TEVA_MDL_A_01172759 | | | | | | | |
| CE-1020 | 01/26/2009 | Cephalon Speaker Bureau Management | TEVA_MDL_A_00953748 | TEVA_MDL_A_00953754 | | | | | | | |
| CE-1021 | 07/27/2017 | Marketing Speaker Bureau Policy | TEVA_MDL_A_00954145 | TEVA_MDL_A_00954169 | | | | | | | |
| CE-1025 | 10/04/2019 | Promotional Meetings Policy | TEVA_MDL_A_11892876 | TEVA_MDL_A_11892882 | | | | | | | |
| CE-1026 | 04/10/2003 | CME versus Promotional Guidelines | TEVA_MDL_A_05397081 | TEVA_MDL_A_05397081 | | | | | | | |
| CE-1027 | 05/05/2004 | Sales Bulletin - New Process for Educational Grants | TEVA_MDL_A_05484703 | TEVA_MDL_A_05484704 | | | | | | | |
| CE-1028 | 09/29/2006 | CSP Planning System User Manual (2006) | TEVA_MDL_A_00583032 | TEVA_MDL_A_00583069 | | | | | | | |
| CE-1029 | 03/26/2007 | [Standard] Speaker Agreement (March 2007) | TEVA_MDL_A_00633735 | TEVA_MDL_A_00633742 | | | | | | | |
| CE-1030 | 10/12/2010 | Cephalon Pain Franchise Fentora Speaker Training (2010) | TEVA_MDL_A_00666538 | TEVA_MDL_A_00666607 | | | | | | | |
| CE-1031 | 08/12/2006 | Cephalon Pain Franchise Speaker Training (Aug 11 2006) | TEVA_MDL_A_00677115 | TEVA_MDL_A_00677115 | | | | | | | |
| CE-1032 | 04/11/2008 | Abuse, Addiction, and Diversion of Controlled Substances (Apr. 11 2008) | TEVA_MDL_A_00679713 | TEVA_MDL_A_00679713 | | | | | | | |
| CE-1033 | 07/14/2007 | Cephalon Pain Franchise Speaker Training (Jul 14 2007) | TEVA_MDL_A_00681509 | TEVA_MDL_A_00681509 | | | | | | | |
| CE-1035 | 02/25/2004 | 2004 Medical Education Agreement for CME Lecture Series | TEVA_MDL_A_00503141 | TEVA_MDL_A_00503146 | | | | | | | |
| CE-1036 | 01/27/2003 | MediCom Medical Education Agreement for 2002 Medical Education Programs | TEVA_MDL_A_00503257 | TEVA_MDL_A_00503261 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1037 | 01/01/2008 | Cephalon Policy on Third-Party Grant Requests | TEVA_MDL_A_00553027 | TEVA_MDL_A_00553029 | | | | | | | |
| CE-1042 | 08/12/2004 | Medical education grant to support reprinting of “the TARGET Card and TARGET Pain Notebook” and outreach to nonprofit organizations about these materials | TEVA_MDL_A_01166356 | TEVA_MDL_A_01166358 | | | | | | | |
| CE-1043 | 12/15/2006 | Educational Grant Draft Request (APF) - Chronic Pain Management with Opioids | TEVA_MDL_A_01169010 | TEVA_MDL_A_01169032 | | | | | | | |
| CE-1044 | 08/12/2011 | Independent Educational Program Grant Agreement (AAPM) - Changing Landscape of Opioid Therapy | TEVA_MDL_A_01176224 | TEVA_MDL_A_01176245 | | | | | | | |
| CE-1048 | 03/01/2009 | Portenoy Advisory Board Agreement | TEVA_MDL_A_00784866 | TEVA_MDL_A_00784873 | | | | | | | |
| CE-1049 | 01/26/2009 | Independent Medical Education Grants Policy | TEVA_MDL_A_00785735 | TEVA_MDL_A_00785740 | | | | | | | |
| CE-1050 | 12/06/2006 | Educational grant to SciMed for an accredited APS CME Poster Book titled “Updates in Chronic Pain Management” | TEVA_MDL_A_00829261 | TEVA_MDL_A_00829268 | | | | | | | |
| CE-1058 | 01/23/2003 | Grant Request from Medicom Worldwide Inc. for year-long CME lecture series through 2003 | TEVA_MDL_A_02683563 | TEVA_MDL_A_02683563 | | | | | | | |
| CE-1059 | 03/01/2007 | Sales Policy Handbook – Policy on Promotional Meetings (“CPS”), (Mar. 2007) | TEVA_MDL_A_06880674 | TEVA_MDL_A_06880690 | | | | | | | |
| CE-1060 | 05/13/2005 | Actiq Speaker Training (May 13 2005) | TEVA_MDL_A_07079928 | TEVA_MDL_A_07079928 | | | | | | | |
| CE-1061 | 09/10/2004 | Cephalon Speaker Bureau Policy (2004) | TEVA_MDL_A_03206965 | TEVA_MDL_A_03206973 | | | | | | | |
| CE-1066 | 01/23/2004 | Letter from Cephalon to DDMAC re Actiq | TEVA_MDL_A_04784719 | TEVA_MDL_A_04785017 | | | | | | | |
| CE-1068 | 10/12/2004 | American Pain Society Educational Grant Request and Agreement for Commercial Support of CME Activities | TEVA_MDL_A_05510585 | TEVA_MDL_A_05510594 | | | | | | | |
| CE-1072 | 00/00/2007 | Fentora Secure Program (2007) | TEVA_MDL_A_06384952 | TEVA_MDL_A_06384966 | | | | | | | |
| CE-1073 | 10/01/2003 | Actiq Speaker Bureau Training Guidelines (Oct. 1 2003) | TEVA_MDL_A_06560910 | TEVA_MDL_A_06560912 | | | | | | | |
| CE-1074 | 05/12/2006 | Cephalon Speaker Identification and Development | TEVA_MDL_A_06560913 | TEVA_MDL_A_06560915 | | | | | | | |
| CE-1075 | 09/12/2006 | Portenoy Preceptor Agreement | TEVA_MDL_A_06753556 | TEVA_MDL_A_06753563 | | | | | | | |
| CE-1076 | 04/07/2007 | Cephalon Cogenix LLC Speaker Agreement (Apr. 2007) | TEVA_MDL_A_06756402 | TEVA_MDL_A_06756410 | | | | | | | |
| CE-1077 | 05/02/2008 | Cephalon entered into an agreement with Medicom Worldwide and Medical Learning Solutions to support an educational program titled “2008 Emerging Solutions in Pain lecture in Conjunction with AAPM 2008.” | TEVA_MDL_A_06764039 | TEVA_MDL_A_06764083 | | | | | | | |
| CE-1080 | 11/04/1998 | Actiq Label | TEVA_MDL_A_13750961 | TEVA_MDL_A_13750989 | | | | | | | |
| CE-1081 | 00/00/2004 | Actiq Label | TEVA_MDL_A_13745721 | TEVA_MDL_A_13745751 | | | | | | | |
| CE-1082 | 00/00/2005 | Actiq Label | TEVA_MDL_A_13744637 | TEVA_MDL_A_13744667 | | | | | | | |
| CE-1083 | 00/00/2006 | Actiq Label | TEVA_MDL_A_13749671 | TEVA_MDL_A_13749763 | | | | | | | |
| CE-1084 | 00/00/2007 | Actiq Label | TEVA_MDL_A_13745533 | TEVA_MDL_A_13745545 | | | | | | | |
| CE-1085 | 09/01/2009 | Actiq Label | TEVA_MDL_A_13745238 | TEVA_MDL_A_13745252 | | | | | | | |
| CE-1086 | 01/01/2011 | Actiq Label | TEVA_MDL_A_13748903 | TEVA_MDL_A_13748921 | | | | | | | |
| CE-1087 | 12/20/2011 | Actiq Label | TEVA_MDL_A_13744071 | TEVA_MDL_A_13744089 | | | | | | | |
| CE-1088 | 12/01/2016 | Actiq Label | TEVA_MDL_A_13748191 | TEVA_MDL_A_13748216 | | | | | | | |
| CE-1089 | 06/01/2006 | Fentora Label | TEVA_MDL_A_13751010 | TEVA_MDL_A_13751050 | | | | | | | |
| CE-1090 | 12/05/2007 | Fentora Label | TEVA_MDL_A_13748837 | TEVA_MDL_A_13748878 | | | | | | | |
| CE-1091 | 04/01/2009 | Fentora Label | TEVA_MDL_A_13755545 | TEVA_MDL_A_13755573 | | | | | | | |
| CE-1092 | 01/05/2011 | Fentora Label | TEVA_MDL_A_13748710 | TEVA_MDL_A_13748723 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1093 | 07/01/2011 | Fentora Label | TEVA_MDL_A_13743152 | TEVA_MDL_A_13743161 | | | | | | | |
| CE-1094 | 12/20/2011 | Fentora Label | TEVA_MDL_A_11404718 | TEVA_MDL_A_11404855 | | | | | | | |
| CE-1095 | 12/21/2011 | Fentora Label | TEVA_MDL_A_13747680 | TEVA_MDL_A_13747695 | | | | | | | |
| CE-1096 | 03/01/2007 | Cephalon Policy Regarding Medical Information Request Forms (MIRFs) (March 2007) | TEVA_MDL_A_04794310 | TEVA_MDL_A_04794315 | | | | | | | |
| CE-1097 | 02/25/2005 | Cephalon Handling Unsolicited Medical Communications (SOP-0321-D08) (Feb. 2005) | TEVA_MDL_A_11837123 | TEVA_MDL_A_11837129 | | | | | | | |
| CE-1098 | 01/26/2009 | Cephalon Medical Information Request Monitoring (GC-210) | TEVA_MDL_A_00552427 | TEVA_MDL_A_00552428 | | | | | | | |
| CE-1099 | 07/01/2008 | Cephalon Submission of Medical Requests (WMRO-116)(July, 2008) | TEVA_MDL_A_00552687 | TEVA_MDL_A_00552690 | | | | | | | |
| CE-1100 | 05/01/2004 | Cephalon Guide for Discussions with Physicians, May 2004 | TEVA_MDL_A_02678395 | TEVA_MDL_A_02678395 | | | | | | | |
| CE-1101 | 05/06/2008 | Fentora sNDA Briefing Book | TEVA_MDL_A_00193936 | TEVA_MDL_A_00194048 | | | | | | | |
| CE-1102 | 11/12/2008 | Letter from Penny Levin, Cephalon, to Robert Rappaport, FDA, General Correspondence Information Package – Type A Meeting | TEVA_MDL_A_00199116 | TEVA_MDL_A_00199256 | | | | | | | |
| CE-1103 | 11/23/2010 | Letter from Susan Franks, Director, Regulatory Affairs, Cephalon, to Robert Rappaport, FDA | TEVA_MDL_A_00294264 | TEVA_MDL_A_00294266 | | | | | | | |
| CE-1104 | 05/11/2007 | Correspondence discussed in Letter from Penny Levin, Director, Regulatory Affairs, Cephalon, to Robert Rappaport, FDA, with sNDA Briefing Package | TEVA_MDL_A_00758548 | TEVA_MDL_A_00758820 | | | | | | | |
| CE-1105 | 04/08/2008 | Report from FDA Office of Surveillance & Epidemiology Fentora RiskMAP & Postmarketing Review Team to FDA Anesthetic & Life Support Drugs Advisory Committee Members & FDA Drug Safety & Risk Management Advisory Committee Members | TEVA_MDL_A_07864370 | TEVA_MDL_A_07864502 | | | | | | | |
| CE-1106 | 05/03/2005 | Actiq (Oral Transmucosal Fentanyl Citrate, OTFC) Official Correspondence Log | TEVA_MDL_A_08261145 | TEVA_MDL_A_08261145 | | | | | | | |
| CE-1108 | 01/01/2006 | Cephalon – Launch of FBT MESSAGE MASTER & SHOWFLOW, at pp. 7–8 | TEVA_MDL_A_00368662 | TEVA_MDL_A_00368675 | | | | | | | |
| CE-1109 | 04/15/2005 | Letter from Cephalon to FDA acknowledgment of meeting minutes | TEVA_MDL_A_01584973 | TEVA_MDL_A_01584989 | | | | | | | |
| CE-1110 | 01/26/2009 | Cephalon Activity Review & Evaluation (CARE) Process (Jan. 2009) | TEVA_MDL_A_00552037 | TEVA_MDL_A_00552041 | | | | | | | |
| CE-1111 | 01/26/2009 | | TEVA_MDL_A_00552513 | TEVA_MDL_A_00552525 | | | | | | | |
| CE-1112 | 12/16/2008 | Cephalon Promotional Review Process Training (Dec. 2008) | TEVA_MDL_A_08923233 | TEVA_MDL_A_08923298 | | | | | | | |
| CE-1113 | 04/15/2005 | Cephalon's Acknowledgment of DDMAC Meeting Minutes | TEVA_MDL_A_00266190 | TEVA_MDL_A_00266206 | | | | | | | |
| CE-1114 | 10/24/2005 | Cephalon Pharmaceutical Operations Organizational Chart (May 2006) | TEVA_MDL_A_02383517 | TEVA_MDL_A_02383517 | | | | | | | |
| CE-1115 | 01/01/2004 | Cephalon Marketing Department Organizational Chart (Jan. 2004) | TEVA_MDL_A_02383521 | TEVA_MDL_A_02383526 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1116 | Undated | ACTIQ New Hire Kit | TEVA_MDL_A_04561246 | TEVA_MDL_A_04561247 | | | | | | | |
| CE-1117 | Undated | Actiq Breakthrough Pain Learning System | TEVA_MDL_A_05931629 | TEVA_MDL_A_05932241 | | | | | | | |
| CE-1118 | 05/14/1999 | Letter to Thomas Willer (FDA) re: NDA 20-747 (05/14/1999); Letter to John Markow (FDA) re NDA 20-747 (04/16/1999) | TEVA_MDL_A_11104032 | TEVA_MDL_A_11104588 | | | | | | | |
| CE-1120 | 11/16/2000 | Actiq Master Plan (2000) | TEVA_MDL_A_00454747 | TEVA_MDL_A_00454807 | | | | | | | |
| CE-1121 | 01/01/2001 | Actiq Marketing 2001 | TEVA_MDL_A_00454808 | TEVA_MDL_A_00454815 | | | | | | | |
| CE-1122 | 01/01/2002 | Actiq 2002 Marketing Plan | TEVA_MDL_A_00454816 | TEVA_MDL_A_00454871 | | | | | | | |
| CE-1123 | 01/01/2003 | Actiq 2003 Marketing Plan | TEVA_MDL_A_00454872 | TEVA_MDL_A_00454940 | | | | | | | |
| CE-1124 | 01/01/2004 | 2004 Actiq Marketing Plan | TEVA_MDL_A_00454941 | TEVA_MDL_A_00454999 | | | | | | | |
| CE-1125 | 01/01/2005 | 2005 Actiq Marketing Plan | TEVA_MDL_A_00455000 | TEVA_MDL_A_00455083 | | | | | | | |
| CE-1126 | 10/27/2004 | Sales Bulletin – Ensuring Appropriate Targeting and Promotion of Actiq | TEVA_MDL_A_04756549 | TEVA_MDL_A_04756550 | | | | | | | |
| CE-1127 | 04/23/2003 | Product Promotion Guidelines | TEVA_MDL_A_05896296 | TEVA_MDL_A_05896296 | | | | | | | |
| CE-1128 | 03/05/2002 | 2002 Actiq Sales Aid | TEVA_MDL_A_11115315 | TEVA_MDL_A_11115343 | | | | | | | |
| CE-1129 | 04/29/2004 | Sales Bulletin 14 | TEVA_MDL_A_04816393 | TEVA_MDL_A_04816394 | | | | | | | |
| CE-1130 | 02/26/2008 | Cephalon, Sales Operations "Do Not Promote/Do Not Call Documentation Policy" | TEVA_MDL_A_00642507 | TEVA_MDL_A_00642513 | | | | | | | |
| CE-1131 | 01/26/2009 | Cephalon Targeting Assessment and Call Activity Policy, (June 2009) | TEVA_MDL_A_00552706 | TEVA_MDL_A_00552708 | | | | | | | |
| CE-1132 | 03/01/2007 | Cephalon Targeting and “Do Not Detail” Policy (March, 2007) | TEVA_MDL_A_00552880 | TEVA_MDL_A_00552883 | | | | | | | |
| CE-1133 | 02/01/2010 | Cephalon Global Pharm Operations Policies | TEVA_MDL_A_00562311 | TEVA_MDL_A_00562355 | | | | | | | |
| CE-1134 | 06/04/2009 | Email regarding instituting a new Do Not Compensate (DNC) policy for Fentora. | TEVA_MDL_A_00970646 | TEVA_MDL_A_00970648 | | | | | | | |
| CE-1135 | 03/00/2007 | Sales Policy Handbook – Policy on Providing Reimbursement Information to Customers (March 2007) | TEVA_MDL_A_06880691 | TEVA_MDL_A_06880694 | | | | | | | |
| CE-1136 | 10/01/2004 | Cephalon Policy on Identifying Called on Universe of Physicians in Connection with Promotional Activities (Oct. 2004) | TEVA_MDL_A_04794307 | TEVA_MDL_A_04794309 | | | | | | | |
| CE-1137 | 01/26/2005 | OVF Commercial Strategy Meeting (Jan. 2005) | TEVA_MDL_A_00360974 | TEVA_MDL_A_00360974 | | | | | | | |
| CE-1138 | 08/23/2006 | Sales Training on the RiskMAP (2006) | TEVA_MDL_A_00365152 | TEVA_MDL_A_00365152 | | | | | | | |
| CE-1139 | 12/04/2008 | Fentora Pre-module: Introduction to Pain (2008) | TEVA_MDL_A_00390332 | TEVA_MDL_A_00390409 | | | | | | | |
| CE-1140 | 08/21/2006 | FENTORA Launch Agenda (Aug. 2006) | TEVA_MDL_A_00390728 | TEVA_MDL_A_00390728 | | | | | | | |
| CE-1141 | 04/30/2008 | FENTORA 90 Day Plan: “One New Patient per Week,” (Apr. 30, 2008) | TEVA_MDL_A_00398705 | TEVA_MDL_A_00398705 | | | | | | | |
| CE-1142 | 03/23/2011 | Cephalon Sales Training & Development Phase II Training – CVA Workshop Facilitator’s Guide | TEVA_MDL_A_00544344 | TEVA_MDL_A_00544433 | | | | | | | |
| CE-1143 | 03/03/2009 | FENTORA 2009 National Sales Meeting: Q2 2009 90-Day Plan (2009) | TEVA_MDL_A_01095930 | TEVA_MDL_A_01095944 | | | | | | | |
| CE-1144 | 11/11/2008 | Fentora Questions & Answers for Patients | TEVA_MDL_A_00724412 | TEVA_MDL_A_00724429 | | | | | | | |
| CE-1145 | 01/11/2019 | FENTORA Reimbursement Kit | TEVA_MDL_A_00752865 | TEVA_MDL_A_00752866 | | | | | | | |
| CE-1146 | 08/01/2013 | US Specialty Medicines: CNS: Fentora 2014 Annual Operating Plan (Aug. 2013) | TEVA_MDL_A_01253817 | TEVA_MDL_A_01255558 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1147 | 05/18/2006 | FEBT Launch Playbook: Steering Committee Presentation (May 2006) | TEVA_MDL_A_07360899 | TEVA_MDL_A_07360899 | | | | | | | |
| CE-1148 | 01/05/2010 | FENTORA 2011 Brand Plan (Jan. 5 2010)(Draft) | TEVA_MDL_A_00550572 | TEVA_MDL_A_00550593 | | | | | | | |
| CE-1149 | 11/29/2005 | FEBT (Fentanyl Effervescent Buccal Tablet) 2005–2006 Marketing Plan (Jun. 2005) | TEVA_MDL_A_00550595 | TEVA_MDL_A_00550814 | | | | | | | |
| CE-1150 | 08/13/2007 | Fentora 2008 Brand Plan | TEVA_MDL_A_00550836 | TEVA_MDL_A_00550836 | | | | | | | |
| CE-1151 | 07/08/2009 | Fentora 2009 Brand Plan | TEVA_MDL_A_00550838 | TEVA_MDL_A_00550881 | | | | | | | |
| CE-1152 | 01/01/2007 | Fentora Marketing Plan 2007 | TEVA_MDL_A_00550891 | TEVA_MDL_A_00550891 | | | | | | | |
| CE-1153 | 01/01/2010 | Fentora 2010 Brand Plan | TEVA_MDL_A_00550892 | TEVA_MDL_A_00550960 | | | | | | | |
| CE-1154 | 03/05/2015 | FENTORA (fentanyl buccal tablet) US Regional Brand Plan (Mar. 5 2015) | TEVA_MDL_A_08794090 | TEVA_MDL_A_08794106 | | | | | | | |
| CE-1155 | 02/10/2010 | Fentora 2010 National Sales Meeting – Exploring the CVA Workshop Slides | TEVA_MDL_A_00345610 | TEVA_MDL_A_00345644 | | | | | | | |
| CE-1157 | 04/15/2008 | Sales Bulletin WLF Policy Update – Ending Use of Reprints | TEVA_MDL_A_00739357 | TEVA_MDL_A_00739357 | | | | | | | |
| CE-1158 | 09/28/2009 | PCS Fall 2009 POA Training Workshops | TEVA_MDL_A_01220047 | TEVA_MDL_A_01220047 | | | | | | | |
| CE-1159 | 10/08/2019 | Doing What Matters!, Tampa/Phoenix POA | TEVA_MDL_A_01316550 | TEVA_MDL_A_01316636 | | | | | | | |
| CE-1160 | 03/10/2010 | 2010 Field Action Plan | TEVA_MDL_A_01325583 | TEVA_MDL_A_01325583 | | | | | | | |
| CE-1161 | 02/25/2008 | Email from Michael Morreale re National Sales Meeting Follow Up | TEVA_MDL_A_09601972 | TEVA_MDL_A_09601973 | | | | | | | |
| CE-1162 | 07/19/2007 | Sales Bulletin | TEVA_MDL_A_00013847 | TEVA_MDL_A_00013856 | | | | | | | |
| CE-1163 | 05/08/2011 | Cephalon Pain Care Business Overview | TEVA_MDL_A_00010688 | TEVA_MDL_A_00010731 | | | | | | | |
| CE-1164 | 12/18/2007 | Cephalon Reimbursement Process and Procedure Guide | TEVA_MDL_A_00012827 | TEVA_MDL_A_00012868 | | | | | | | |
| CE-1165 | 07/01/2008 | Cephalon Reimbursement Process and Procedure | TEVA_MDL_A_00552538 | TEVA_MDL_A_00552584 | | | | | | | |
| CE-1166 | 01/26/2009 | Cephalon Targeting Assessment and Call Activity (GPO-130)(Jan. 26 2009) | TEVA_MDL_A_00819289 | TEVA_MDL_A_00819292 | | | | | | | |
| CE-1167 | 07/01/2009 | Reimbursement Process and Procedure Guide | TEVA_MDL_A_01188202 | TEVA_MDL_A_01188248 | | | | | | | |
| CE-1168 | 07/16/2004 | Cephalon Sales Department Organizational Chart | TEVA_MDL_A_01373059 | TEVA_MDL_A_01373150 | | | | | | | |
| CE-1169 | 04/00/2005 | Policy on Providing Reimbursement Information to Customers | TEVA_MDL_A_04756907 | TEVA_MDL_A_04756912 | | | | | | | |
| CE-1170 | 12/12/2003 | Memo from Roy Craig to U.S. Sales re “Ensuring Appropriate Targeting And Promotion of ACTIQ,” Dec. 12 2003 | TEVA_MDL_A_05445644 | TEVA_MDL_A_05445712 | | | | | | | |
| CE-1171 | 01/31/2006 | ACTIQ Reimbursement Hotline flyer | TEVA_MDL_A_08857270 | TEVA_MDL_A_08857271 | | | | | | | |
| CE-1172 | 07/01/2008 | Reimbursement Process and Procedure Guide | TEVA_MDL_A_08924132 | TEVA_MDL_A_08924178 | | | | | | | |
| CE-1173 | 01/08/2019 | Standards of Global Business Practices (Cephalon Code of Conduct) | TEVA_MDL_A_00552635 | TEVA_MDL_A_00552681 | | | | | | | |
| CE-1174 | 01/01/2009 | Cephalon US Sales and Marketing Policy (2009) | TEVA_MDL_A_00552730 | TEVA_MDL_A_00552765 | | | | | | | |
| CE-1175 | 06/07/2019 | Marketing Policy Handbook | TEVA_MDL_A_00552840 | TEVA_MDL_A_00552849 | | | | | | | |
| CE-1176 | 06/07/2019 | Marketing Policy on Grants | TEVA_MDL_A_00552919 | TEVA_MDL_A_00552932 | | | | | | | |
| CE-1177 | 06/07/2019 | Interactions Among MSLs, Cephalon Business Personnel (e.g., Marketing) and HCPs | TEVA_MDL_A_00552942 | TEVA_MDL_A_00552944 | | | | | | | |
| CE-1178 | 09/07/2019 | Policy on Providing Reimbursement Information to Customers | TEVA_MDL_A_00553053 | TEVA_MDL_A_00553056 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|----------------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1179 | 10/06/2019 | Policy on Interactions Between MSLs, Cephalon Business Personnel (e.g., Sales, Account Management, and Marketing) and Healthcare Professionals | TEVA_MDL_A_00553057 | TEVA_MDL_A_00553058 | | | | | | | |
| CE-1180 | 02/20/2009 | General and Specific Training | TEVA_MDL_A_00560368 | TEVA_MDL_A_00560370 | | | | | | | |
| CE-1181 | 07/01/2008 | Email from A. Pyfer to PCS Sales Management | TEVA_MDL_A_00971774 | TEVA_MDL_A_00971776 | | | | | | | |
| CE-1182 | 10/06/2019 | Cephalon 2006 Sales Policy Handbook | TEVA_MDL_A_01251767 | TEVA_MDL_A_01251777 | | | | | | | |
| CE-1183 | 03/01/2007 | Cephalon Sales Policy Handbook- Mar. 2007 | TEVA_MDL_A_06880605 | TEVA_MDL_A_06880614 | | | | | | | |
| CE-1184 | 10/03/2001 | Cephalon Review and Approval of Promotional Materials (SOP-0348-R01) | TEVA_MDL_A_04785055 | TEVA_MDL_A_04785062 | | | | | | | |
| CE-1185 | 10/01/2004 | Cephalon Sales Policy Handbook- Oct. 2004 | TEVA_MDL_A_04794285 | TEVA_MDL_A_04794294 | | | | | | | |
| CE-1186 | 04/01/2005 | Exhibit IV Laws and Standards that Affect the Sale and Marketing of Cephalon Products | TEVA_MDL_A_05662727 | TEVA_MDL_A_05662730 | | | | | | | |
| CE-1187 | 06/07/2019 | Marketing Policy on Developing Promotional and Advertising Materials | TEVA_MDL_A_00552902 | TEVA_MDL_A_00552905 | | | | | | | |
| CE-1188 | 03/04/2004 | Compliance Lecture | TEVA_MDL_A_11137773 | TEVA_MDL_A_11137773 | | | | | | | |
| CE-1190 | 11/00/2006 | CME Program Information and Distribution Announcements | TEVA_MDL_A_07838533 | TEVA_MDL_A_07838536 | | | | | | | |
| CE-1191 | 03/00/2008 | Revised PI and HCP Sales Bulletin | TEVA_MDL_A_00402658 | TEVA_MDL_A_00402658 | | | | | | | |
| CE-1192 | 08/00/2007 | Policy on Providing Reimbursement Information Sales Bulletin | TEVA_MDL_A_00701428 | TEVA_MDL_A_00701436 | | | | | | | |
| CE-1193 | 09/00/2007 | Dear HCP Sales Bulletin | TEVA_MDL_A_00390605 | TEVA_MDL_A_00390605 | | | | | | | |
| CE-1194 | 08/00/2007 | Clinical Trial Abstracts Sales Bulletin | TEVA_MDL_A_00739337 | TEVA_MDL_A_00739337 | | | | | | | |
| CE-1195 | 09/00/2006 | FENTORA RiskMAP Sales Bulletin | TEVA_MDL_A_07416850 | TEVA_MDL_A_07416850 | | | | | | | |
| CE-1196 | 12/00/2008 | Medical Educationa lGrant Requests Sales Bulletins | TEVA_MDL_A_02379242 | TEVA_MDL_A_02379244 | | | | | | | |
| CE-1197 | 02/00/2006 | Child Safety Information and Proper Storage & Disposal of Actiq | TEVA_MDL_A_04758223 | TEVA_MDL_A_04758226 | | | | | | | |
| CE-1198 | 07/00/2007 | Frequently Asked Questions from Compliance Sales Meeting | TEVA_MDL_A_07353865 | TEVA_MDL_A_07353874 | | | | | | | |
| CE-1199 | 03/07/2019 | Policy on Dissemination of Certain Off-Label Peer-Reviewed Reprints and Reference Textbooks (WLF Policy) | TEVA_MDL_A_00553033 | TEVA_MDL_A_00553035 | | | | | | | |
| CE-1200 | 07/27/2010 | PCS New Hire Training – Sales Operations Department (July 2010) | TEVA_MDL_A_00681276 | TEVA_MDL_A_00681276 | | | | | | | |
| CE-1201 | 01/01/2004 | Cephalon Incentive Compensation Plan Payment Policies for All Cephalon Field Sales Personnel (Jan 2004) | TEVA_MDL_A_00406531 | TEVA_MDL_A_00406533 | | | | | | | |
| CE-1202 | 01/26/2009 | Cephalon Employee Compensation Policy (January 26, 2009) | TEVA_MDL_A_00552245 | TEVA_MDL_A_00552246 | | | | | | | |
| CE-1203 | 10/04/2012 | Incentive Compensation for Sales Reps - Redline Draft | TEVA_MDL_A_00961784 | TEVA_MDL_A_00961793 | | | | | | | |
| CE-1204 | 00/00/2006 | Cephalon Inc. Minute Book: Management Incentive Compensation Plan | TEVA_MDL_A_09621973 | TEVA_MDL_A_09622326 | | | | | | | |
| CE-1205 | 01/01/2007 | 3rd Quarter 2007 Incentive Compensation Plan | TEVA_MDL_A_00455140 | TEVA_MDL_A_00455141 | | | | | | | |
| CE-1206 | 02/20/2008 | “Dear Healthcare Provider” Letter notifying healthcare provider of completed Fentora labels, (Feb 20 2008) | TEVA_MDL_A_00868502 | TEVA_MDL_A_00868504 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1207 | 09/10/2007 | "Dear Healthcare Provider: Important Safety Information for Fentora" Letter (Sept. 10 2007) | TEVA_MDL_A_01009322 | TEVA_MDL_A_01009325 | | | | | | | |
| CE-1208 | 06/01/2009 | Cephalon - SOP-0013489 | TEVA_MDL_A_01088881 | TEVA_MDL_A_01088884 | | | | | | | |
| CE-1209 | 01/22/2008 | Product Bulletin issued by Cephalon regarding updates to Fentora labels (Jan 22 2008) | TEVA_MDL_A_01211330 | TEVA_MDL_A_01211330 | | | | | | | |
| CE-1210 | 04/28/2004 | E-mail from Andy Pyfer to Stacey Beckhardt (RE: Associated Press Article: "Increase in abuse reported of narcotic lollipops for cancer patients"). | TEVA_MDL_A_04108856 | TEVA_MDL_A_04108858 | | | | | | | |
| CE-1211 | 12/16/2011 | Cephalon RC0351178 12-16-11.pdf | TEVA_MDL_A_01463427 | TEVA_MDL_A_01463428 | | | | | | | |
| CE-1212 | 01/31/2012 | Cephalon_RC0351178_01-30-2012.pdf | TEVA_MDL_A_02806082 | TEVA_MDL_A_02806082 | | | | | | | |
| CE-1213 | 07/01/2008 | Cephalon Reporting of Adverse Events, Product Complaints and Suspected Diversions, (July 1, 2008). | TEVA_MDL_A_00552589 | TEVA_MDL_A_00552591 | | | | | | | |
| CE-1214 | 11/19/2004 | Actiq Risk Management Program | TEVA_MDL_A_00270514 | TEVA_MDL_A_00270535 | | | | | | | |
| CE-1215 | 08/01/2001 | Actiq Risk Management Program | TEVA_MDL_A_00271190 | TEVA_MDL_A_00271221 | | | | | | | |
| CE-1216 | 08/22/2006 | Chronology of FDA-Approved Changes to the Actiq Risk Management Program (Aug 22 2006) | TEVA_MDL_A_00271315 | TEVA_MDL_A_00271493 | | | | | | | |
| CE-1217 | 01/06/2006 | Amendment to S-020 (Jan 6 2006) | TEVA_MDL_A_00275953 | TEVA_MDL_A_00276034 | | | | | | | |
| CE-1218 | 12/22/2006 | Amendment to S-020 and Request for Meeting to Discuss Revisions to Actiq RMP | TEVA_MDL_A_00277891 | TEVA_MDL_A_00277984 | | | | | | | |
| CE-1219 | 09/17/2008 | New Supplement for NDA 20-747: Proposed Risk Evaluation & Mitigation Strategy (REMS) Actiq, (Sept. 16 2008) | TEVA_MDL_A_00285468 | TEVA_MDL_A_00285668 | | | | | | | |
| CE-1220 | 08/06/2010 | Actiq Risk Evaluation & Mitigation Strategy, (Aug 6 2010) | TEVA_MDL_A_00294131 | TEVA_MDL_A_00294258 | | | | | | | |
| CE-1221 | 08/06/2010 | Summary of Changes – Proposed Actiq REMS, (Aug. 6, 2010) | TEVA_MDL_A_00294259 | TEVA_MDL_A_00294260 | | | | | | | |
| CE-1222 | 11/23/2010 | Actiq & Fentora Proposed Risk Evaluation & Mitigation Strategy | TEVA_MDL_A_00294267 | TEVA_MDL_A_00294374 | | | | | | | |
| CE-1223 | 10/13/2007 | Fentora sNDA RiskMAP Tools Review Meeting: Pain Care Franchise Marketing (Oct. 12 2007) | TEVA_MDL_A_00376199 | TEVA_MDL_A_00376199 | | | | | | | |
| CE-1224 | 07/20/2011 | Actiq and Fentora REMS | TEVA_MDL_A_01010424 | TEVA_MDL_A_01010537 | | | | | | | |
| CE-1225 | 12/15/2003 | Carol Marchione, Memorandum on Actions to Respond to Audit Findings Regarding the Actiq Risk Management Program (Quality Assurance Memorandum – 12/02/03), | TEVA_MDL_A_01159549 | TEVA_MDL_A_01159553 | | | | | | | |
| CE-1226 | 11/22/2004 | Actiq Prior Approval Supplement: Revised RMP (Nov. 22 2004) | TEVA_MDL_A_01578534 | TEVA_MDL_A_01578613 | | | | | | | |
| CE-1227 | 01/13/2011 | Charter Agreement of the TIRF REMS Industry Group (Jan 13 2011) | TEVA_MDL_A_06779361 | TEVA_MDL_A_06779384 | | | | | | | |
| CE-1228 | 12/28/2011 | Supplemental Approval for Fentora REMS | TEVA_MDL_A_07679384 | TEVA_MDL_A_07679521 | | | | | | | |
| CE-1229 | 06/30/2010 | Summary of Changes – Actiq REMS (June 30 2010) | TEVA_MDL_A_08510383 | TEVA_MDL_A_08510384 | | | | | | | |
| CE-1230 | 02/11/2005 | SOP-0001053, for Marketing Support of the Actiq Risk Management Program | TEVA_MDL_A_08531805 | TEVA_MDL_A_08531810 | | | | | | | |
| CE-1231 | 11/06/2018 | Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation & Mitigation Strategy (REMS) | TEVA_MDL_A_11087241 | TEVA_MDL_A_11087411 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|--|--|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1232 | 04/01/2007 | Fentora Risk Minimization Actiqon Plan (The Secure Program) Quarterly Report | TEVA_MDL_A_00037913 | TEVA_MDL_A_00037972 | | | | | | | |
| CE-1233 | 09/19/2006 | Letter from Penny S. Levin, M.S., Associate Director, Regulatory Affairs, Cephalon, to Robert Rappaport, M.D., FDA | TEVA_MDL_A_00265075 | TEVA_MDL_A_00265425 | | | | | | | |
| CE-1234 | 06/05/2012 | TIRF REMS Approval Letter | TEVA_MDL_A_00710057 | TEVA_MDL_A_00710205 | | | | | | | |
| CE-1235 | 11/12/1999 | Actiq (oral transmucosal fentanyl citrate, OTFC) Risk Management Program – 1st Quarterly Report | TEVA_MDL_A_11105721 | TEVA_MDL_A_11105733 | | | | | | | |
| CE-1237 | 04/13/2007 | Fentora Risk Management Program 1st - 10th Quarterly Reports | TEVA_MDL_A_10313692 - TEVA_MDL_A_10313708; TEVA_MDL_A_10315736 - TEVA_MDL_A_10315760; TEVA_MDL_A_10316841 - TEVA_MDL_A_10316900; TEVA_MDL_A_10422175 - TEVA_MDL_A_10422232; TEVA_MDL_A_10497915 - TEVA_MDL_A_10498256; TEVA_MDL_A_10502990 - TEVA_MDL_A_10503077; TEVA_MDL_A_10510166 - TEVA_MDL_A_10510333; TEVA_MDL_A_10552587 - TEVA_MDL_A_10552662; TEVA_MDL_A_10552668 - TEVA_MDL_A_10552773; TEVA_MDL_A_10562042 - TEVA_MDL_A_10562090; | TEVA_MDL_A_10313692 - TEVA_MDL_A_10313708; TEVA_MDL_A_10315736 - TEVA_MDL_A_10315760; TEVA_MDL_A_10316841 - TEVA_MDL_A_10316900; TEVA_MDL_A_10422175 - TEVA_MDL_A_10422232; TEVA_MDL_A_10497915 - TEVA_MDL_A_10498256; TEVA_MDL_A_10502990 - TEVA_MDL_A_10503077; TEVA_MDL_A_10510166 - TEVA_MDL_A_10510333; TEVA_MDL_A_10552587 - TEVA_MDL_A_10552662; TEVA_MDL_A_10552668 - TEVA_MDL_A_10552773; TEVA_MDL_A_10562042 - TEVA_MDL_A_10562090; | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---|---|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1240 | 11/12/1999 | Actiq Risk Management Program - 1st - 10th Quarterly Reports | TEVA_MDL_A_11105721 - TEVA_MDL_A_11105733; TEVA_MDL_A_11105746 - TEVA_MDL_A_11105761; TEVA_MDL_A_11107186 - TEVA_MDL_A_11107203; TEVA_MDL_A_11108180 - TEVA_MDL_A_11108198; TEVA_MDL_A_11108258 - TEVA_MDL_A_11108279; TEVA_MDL_A_11108280 - TEVA_MDL_A_11108303; TEVA_MDL_A_11113764 - TEVA_MDL_A_11113802; TEVA_MDL_A_11113967 - TEVA_MDL_A_11113985; TEVA_MDL_A_11114141 - TEVA_MDL_A_11114159 | TEVA_MDL_A_11105721 - TEVA_MDL_A_11105733; TEVA_MDL_A_11105746 - TEVA_MDL_A_11105761; TEVA_MDL_A_11107186 - TEVA_MDL_A_11107203; TEVA_MDL_A_11108180 - TEVA_MDL_A_11108198; TEVA_MDL_A_11108258 - TEVA_MDL_A_11108279; TEVA_MDL_A_11108280 - TEVA_MDL_A_11108303; TEVA_MDL_A_11113764 - TEVA_MDL_A_11113802; TEVA_MDL_A_11113967 - TEVA_MDL_A_11113985; TEVA_MDL_A_11114141 - TEVA_MDL_A_11114159 | | | | | | | |
| CE-1250 | 02/28/2002 | Actiq Risk Mangement Program - 11th - 20th Quarterly Reports | TEVA_MDL_A_08242777 - TEVA_MDL_A_08242797; TEVA_MDL_A_11115637 - TEVA_MDL_A_11115661; TEVA_MDL_A_11117191 - TEVA_MDL_A_11117223; TEVA_MDL_A_11117531 - TEVA_MDL_A_11117555; TEVA_MDL_A_11118999 - TEVA_MDL_A_11119025; TEVA_MDL_A_11120800 - TEVA_MDL_A_11120823; TEVA_MDL_A_11121911 - TEVA_MDL_A_11121940; TEVA_MDL_A_11836580 - TEVA_MDL_A_11836602; TEVA_MDL_A_01574944 - TEVA_MDL_A_01574987; TEVA_MDL_A_01576048 - TEVA_MDL_A_01576070 | TEVA_MDL_A_08242777 - TEVA_MDL_A_08242797; TEVA_MDL_A_11115637 - TEVA_MDL_A_11115661; TEVA_MDL_A_11117191 - TEVA_MDL_A_11117223; TEVA_MDL_A_11117531 - TEVA_MDL_A_11117555; TEVA_MDL_A_11118999 - TEVA_MDL_A_11119025; TEVA_MDL_A_11120800 - TEVA_MDL_A_11120823; TEVA_MDL_A_11121911 - TEVA_MDL_A_11121940; TEVA_MDL_A_11836580 - TEVA_MDL_A_11836602; TEVA_MDL_A_01574944 - TEVA_MDL_A_01574987; TEVA_MDL_A_01576048 - TEVA_MDL_A_01576070 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|--|--|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1260 | 10/05/2004 | Actiq Risk Management Program - 21st - 30th Quarterly Reports | TEVA_MDL_A_08437872 - TEVA_MDL_A_08437899; TEVA_MDL_A_00267755 - TEVA_MDL_A_00267778; TEVA_MDL_A_00268414 - TEVA_MDL_A_00268483; TEVA_MDL_A_00268683 - TEVA_MDL_A_00268720; TEVA_MDL_A_00268778 - TEVA_MDL_A_00268805; TEVA_MDL_A_00276183 - TEVA_MDL_A_00276218; TEVA_MDL_A_00276298 - TEVA_MDL_A_00276327; TEVA_MDL_A_00276352 - TEVA_MDL_A_00276383; TEVA_MDL_A_00276445 - TEVA_MDL_A_00276469 | TEVA_MDL_A_08437872 - TEVA_MDL_A_08437899; TEVA_MDL_A_00267755 - TEVA_MDL_A_00267778; TEVA_MDL_A_00268414 - TEVA_MDL_A_00268483; TEVA_MDL_A_00268683 - TEVA_MDL_A_00268720; TEVA_MDL_A_00268778 - TEVA_MDL_A_00268805; TEVA_MDL_A_00276183 - TEVA_MDL_A_00276218; TEVA_MDL_A_00276298 - TEVA_MDL_A_00276327; TEVA_MDL_A_00276352 - TEVA_MDL_A_00276383; TEVA_MDL_A_00276445 - TEVA_MDL_A_00276469 | | | | | | | |
| CE-1269 | 03/29/2007 | Actiq Risk Management Program - 31st - 39th Quarterly Report | TEVA_MDL_A_00283237 - TEVA_MDL_A_00283264; TEVA_MDL_A_00283269 - TEVA_MDL_A_00283297; TEVA_MDL_A_00283384 - TEVA_MDL_A_00283416; TEVA_MDL_A_00283443 - TEVA_MDL_A_00283488; TEVA_MDL_A_00285282 - TEVA_MDL_A_00285324; TEVA_MDL_A_00285333 - TEVA_MDL_A_00285412; TEVA_MDL_A_00285413 - TEVA_MDL_A_00285467; TEVA_MDL_A_00285713 - TEVA_MDL_A_00285761; TEVA_MDL_A_00292654 - TEVA_MDL_A_00292703 | TEVA_MDL_A_00283264 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---|---|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1278 | 05/28/2009 | Actiq Risk Management Program - 40th - 49th Quarterly Report | TEVA_MDL_A_00292892 - TEVA_MDL_A_00292940; TEVA_MDL_A_00292945 - TEVA_MDL_A_00292996; TEVA_MDL_A_00293428 - TEVA_MDL_A_00293478; TEVA_MDL_A_00295463 - TEVA_MDL_A_00295512; TEVA_MDL_A_00295557 - TEVA_MDL_A_00295611; TEVA_MDL_A_00295780 - TEVA_MDL_A_00295828; TEVA_MDL_A_00295841 - TEVA_MDL_A_00295892; TEVA_MDL_A_00299921 - TEVA_MDL_A_00299960; TEVA_MDL_A_00300050 - TEVA_MDL_A_00300092; TEVA_MDL_A_00300163 - TEVA_MDL_A_00300206 | TEVA_MDL_A_00292892 - TEVA_MDL_A_00292940; TEVA_MDL_A_00292945 - TEVA_MDL_A_00292996; TEVA_MDL_A_00293428 - TEVA_MDL_A_00293478; TEVA_MDL_A_00295463 - TEVA_MDL_A_00295512; TEVA_MDL_A_00295557 - TEVA_MDL_A_00295611; TEVA_MDL_A_00295780 - TEVA_MDL_A_00295828; TEVA_MDL_A_00295841 - TEVA_MDL_A_00295892; TEVA_MDL_A_00299921 - TEVA_MDL_A_00299960; TEVA_MDL_A_00300050 - TEVA_MDL_A_00300092; TEVA_MDL_A_00300163 - TEVA_MDL_A_00300206 | | | | | | | |
| CE-1298 | 10/01/2009 | Fentora Risk Minimization Plan - 11th - 19th Quarterly Report | TEVA_MDL_A_10568672 - TEVA_MDL_A_10568718; TEVA_MDL_A_10598611 - TEVA_MDL_A_10598668; TEVA_MDL_A_00652142 - TEVA_MDL_A_00652200; TEVA_MDL_A_10621200 - TEVA_MDL_A_10621254; TEVA_MDL_A_10635646 - TEVA_MDL_A_10635696; TEVA_MDL_A_10641276 - TEVA_MDL_A_10641328; TEVA_MDL_A_10645019 - TEVA_MDL_A_10645067; TEVA_MDL_A_10657239 - TEVA_MDL_A_10657291; TEVA_MDL_A_10666318 - TEVA_MDL_A_10666370 | TEVA_MDL_A_10568672 - TEVA_MDL_A_10568718; TEVA_MDL_A_10598611 - TEVA_MDL_A_10598668; TEVA_MDL_A_00652142 - TEVA_MDL_A_00652200; TEVA_MDL_A_10621200 - TEVA_MDL_A_10621254; TEVA_MDL_A_10635646 - TEVA_MDL_A_10635696; TEVA_MDL_A_10641276 - TEVA_MDL_A_10641328; TEVA_MDL_A_10645019 - TEVA_MDL_A_10645067; TEVA_MDL_A_10657239 - TEVA_MDL_A_10657291; TEVA_MDL_A_10666318 - TEVA_MDL_A_10666370 | | | | | | | |
| CE-1307 | 01/28/2009 | Cephalon 2008 Global Compliance Report | TEVA_MDL_A_00360420 | TEVA_MDL_A_00360452 | | | | | | | |
| CE-1309 | 06/00/2007 | Marketing Speaker Bureau (CSP) Policy Cephalon Jun-07 | TEVA_MDL_A_00552396 | TEVA_MDL_A_00552420 | | | | | | | |
| CE-1310 | 10/00/2006 | Sales Policy Handbook, with exhibits and Government Employee Certification Form | TEVA_MDL_A_00552850 | TEVA_MDL_A_00552860 | | | | | | | |
| CE-1311 | 03/00/2007 | Promotional Materials and Activities Cephalon Mar-07 | TEVA_MDL_A_00552870 | TEVA_MDL_A_00552879 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1312 | 03/00/2007 | Medical Information Request Forms Cephalon Mar-07 | TEVA_MDL_A_00552884 | TEVA_MDL_A_00552890 | | | | | | | |
| CE-1313 | 06/00/2007 | Preceptorships and exhibits Cephalon Jun-07 | TEVA_MDL_A_00552945 | TEVA_MDL_A_00552958 | | | | | | | |
| CE-1314 | 06/00/2007 | Speaker Bureau (CSP) Cephalon Jun-07 | TEVA_MDL_A_00552970 | TEVA_MDL_A_00552994 | | | | | | | |
| CE-1315 | 03/00/2007 | Promotional Meetings ("CSPs") Cephalon Mar-07 | TEVA_MDL_A_00552995 | TEVA_MDL_A_00553011 | | | | | | | |
| CE-1316 | 01/00/2008 | Third Party Grant Requests Cephalon Jan-08 | TEVA_MDL_A_00553030 | TEVA_MDL_A_00553032 | | | | | | | |
| CE-1317 | 11/04/1998 | Anesta Corporation, and Abbott Laboratories, "Actiq Risk Management Program," November 4, 1998 | TEVA_MDL_A_00564336 | TEVA_MDL_A_00564365 | | | | | | | |
| CE-1318 | 09/10/2007 | Cephalon, Inc., "Important Safety Information for Fentora," September 10, 2007 | TEVA_MDL_A_00970847 | TEVA_MDL_A_00970850 | | | | | | | |
| CE-1319 | 12/28/2011 | Actiq TIRF REMS Documentation | TEVA_MDL_A_00709777 | TEVA_MDL_A_00710056 | | | | | | | |
| CE-1320 | 00/00/2009 | 2009 Global Compliance Incident Details Report | TEVA_MDL_A_00769186 | TEVA_MDL_A_00769186 | | | | | | | |
| CE-1321 | 03/00/2007 | Policy on Promotional Materials and Activities Cephalon Mar-07 | TEVA_MDL_A_01251780 | TEVA_MDL_A_01251789 | | | | | | | |
| CE-1322 | Undated | Understanding FDA Regulations | TEVA_MDL_A_02724063 | TEVA_MDL_A_02724063 | | | | | | | |
| CE-1323 | 11/19/2009 | Report on Independent Review Organization's Engagement | TEVA_MDL_A_02939244 | TEVA_MDL_A_02939340 | | | | | | | |
| CE-1324 | 10/00/2004 | Policy on Advertising and Promotional Materials and Activities | TEVA_MDL_A_04794303 | TEVA_MDL_A_04794306 | | | | | | | |
| CE-1325 | 10/00/2004 | Grants or Support That Are Not For Independent Medical Education | TEVA_MDL_A_04794345 | TEVA_MDL_A_04794348 | | | | | | | |
| CE-1326 | 01/04/2009 | Cephalon Compliance Investigations and Disciplinary Actions Report | TEVA_MDL_A_06616796 | TEVA_MDL_A_06616855 | | | | | | | |
| CE-1327 | 00/00/2005 | Cephalon Newsletter (Summer 2005) | TEVA_MDL_A_08272952 | TEVA_MDL_A_08272957 | | | | | | | |
| CE-1328 | 10/00/2004 | Medical Information Request Forms Cephalon Oct-04 | TEVA_MDL_A_11892865 | TEVA_MDL_A_11892870 | | | | | | | |
| CE-1329 | Undated | Teva Year 4 FENTORA Message Recall Surveys | TEVA_MDL_A_00561498 | TEVA_MDL_A_00561500 | | | | | | | |
| CE-1330 | 1/8/2004 | Actiq Risk Management letters that were sent to doctors | TEVA_MDL_A_11161114 | TEVA_MDL_A_11161115 | | | | | | | |
| CE-1331 | 9/10/2007 | Dear Doctor Letter | TEVA_MDL_A_03400542 | TEVA_MDL_A_03400545 | | | | | | | |
| CE-1332 | 4/9/2009 | Cephlaon Response to 2009 Untitled Letter | TEVA_MDL_A_00600492 | TEVA_MDL_A_00600495 | | | | | | | |
| CE-1333 | 4/27/2009 | Regulatory Telephone Contract Report | TEVA_MDL_A_01089145 | TEVA_MDL_A_01089147 | | | | | | | |
| CE-1334 | 6/16/2008 | RiskMAP supplemental slide deck, Fentora Secure Program | TEVA_MDL_A_06384818 | TEVA_MDL_A_06384847 | | | | | | | |
| CE-1335 | 7/1/2005 | Email from Randy Spokane to William Carnohan | TEVA_MDL_A_00984511 | TEVA_MDL_A_00984512 | | | | | | | |
| CE-1336 | 8/8/2011 | Email from Randy Spokane to Bryan Stefanski and John Harold | TEVA_MDL_A_01114501 | TEVA_MDL_A_01114501 | | | | | | | |
| CE-1337 | 6/10/2003 | Email from William Carnohan to Sales PCS Atlantic Coast | TEVA_MDL_A_05833743 | TEVA_MDL_A_05833743 | | | | | | | |
| CE-1338 | 6/4/2009 | Email from Jim Reilly to Sales PCS All | TEVA_MDL_A_00865675 | TEVA_MDL_A_00865676 | | | | | | | |
| CE-1339 | 12/20/2005 | Email from Randy Spokane to Peter Cooke | TEVA_MDL_A_00985881 | TEVA_MDL_A_00985882 | | | | | | | |
| CE-1340 | 8/17/2007 | Email from Randy Spokane to Sales PCS East | TEVA_MDL_A_01106639 | TEVA_MDL_A_01106639 | | | | | | | |
| CE-1341 | 10/17/2011 | Email from Randy Spokane to Bill Cunningham | TEVA_MDL_A_01115661 | TEVA_MDL_A_01115661 | | | | | | | |
| CE-1342 | 4/8/2011 | Email from Randy Spokane to Sales PCS East Region Managers | TEVA_MDL_A_01325272 | TEVA_MDL_A_01325272 | | | | | | | |
| CE-1343 | 9/7/2007 | Email from Randy Spokane to Sales PCS East Managers and Carol Stewart | TEVA_MDL_A_01326136 | TEVA_MDL_A_01326136 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|----------------|------------|---|--|--|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| CE-1344 | 10/4/2007 | Email from Randy Spokane to Kerri Romagna | TEVA_MDL_A_01326529 | TEVA_MDL_A_01326529 | | | | | | | |
| CE-1345 | 11/16/2007 | Email from Randy Spokane to Sales PCS East Managers and Carol Stewart | TEVA_MDL_A_01977159 | TEVA_MDL_A_01977159 | | | | | | | |
| CE-1346 | 2/1/2005 | Email from Randy Spokane to Sales Pennsylvania West | TEVA_MDL_A_09063736 | TEVA_MDL_A_09063736 | | | | | | | |
| CE-1347 | 7/11/2007 | Email from Randy Spokane to Dean Robinson | TEVA_MDL_A_09072747 | TEVA_MDL_A_09072748 | | | | | | | |
| CE-1348 | 11/4/2003 | Email from Michael Morreale to Sales Ohio Valley | TEVA_MDL_A_09592948 | TEVA_MDL_A_09592949 | | | | | | | |
| CE-1349 | 6/3/2004 | Email from Michael Morreale to Daniel Potenza | TEVA_MDL_A_09594006 | TEVA_MDL_A_09594006 | | | | | | | |
| CE-1350 | 10/27/2004 | Email from Michael Morreale to Sales Ohio Valley | TEVA_MDL_A_09594946 | TEVA_MDL_A_09594946 | | | | | | | |
| CE-1351 | 1/6/2005 | Email from Michael Morreale to Sales Ohio Valley | TEVA_MDL_A_09595359 | TEVA_MDL_A_09595360 | | | | | | | |
| CE-1352 | 1/26/2005 | Email from Michael Morreale to Sales Ohio Valley | TEVA_MDL_A_09595478 | TEVA_MDL_A_09595478 | | | | | | | |
| CE-1353 | 5/19/2009 | Email from Michael Morreale to Timothy Sweeney | TEVA_MDL_A_09607918 | TEVA_MDL_A_09607919 | | | | | | | |
| CE-1354 | | MIRF Data 2006-2018 | TEVA_MDL_A_11772091 | TEVA_MDL_A_11772100 | | | | | | | |
| CE-1355 | | Compliance Incident Summaries (2008-2013) | TEVA_MDL_A_00771366 - TEVA_MDL_A_00771366; TEVA_MDL_A_00783105 - TEVA_MDL_A_00783105; TEVA_MDL_A_01252264- TEVA_MDL_A_01252264; TEVA_MDL_A_01253052- TEVA_MDL_A_01253052; TEVA_MDL_A_04321294 - TEVA_MDL_A_04321294 | TEVA_MDL_A_00771366 - TEVA_MDL_A_00771366; TEVA_MDL_A_00783105 - TEVA_MDL_A_00783105; TEVA_MDL_A_01252264- TEVA_MDL_A_01252264; TEVA_MDL_A_01253052- TEVA_MDL_A_01253052; TEVA_MDL_A_04321294 - TEVA_MDL_A_04321294 | | | | | | | |
| CE-1356 | | Cephalon Inc. Compliance Investigations and Disciplinary Actions Report (2004-2008) | TEVA_MDL_A_01251300 | TEVA_MDL_A_01251301 | | | | | | | |
| CE-1357 | 00/00/2008 | Incident Log Summary 01/08 - 07/08 | TEVA_MDL_A_11882894 | TEVA_MDL_A_11882894 | | | | | | | |
| CE-1358 | 00/00/2010 | Compliance Logs 2010 | TEVA_MDL_A_00633795 - TEVA_MDL_A_00633795; TEVA_MDL_A_00633805 - TEVA_MDL_A_00633805; TEVA_MDL_A_00775204 - TEVA_MDL_A_00775204; TEVA_MDL_A_00775561 - TEVA_MDL_A_00775561; TEVA_MDL_A_00775562; TEVA_MDL_A_00775739 - TEVA_MDL_A_00775742 | TEVA_MDL_A_00633795 - TEVA_MDL_A_00633795; TEVA_MDL_A_00633805 - TEVA_MDL_A_00633805; TEVA_MDL_A_00775204 - TEVA_MDL_A_00775204; TEVA_MDL_A_00775561 - TEVA_MDL_A_00775561; TEVA_MDL_A_00775562; TEVA_MDL_A_00775739 - TEVA_MDL_A_00775742 | | | | | | | |
| CE-1359 | 1/23/2005 | Email from Roy Craig to Ryan Barnes, Alan Beckman, William Carnohan, Bill Cunningham, Joeseeph Datin, Charles DeWildt, Gregory S. Martin, Dan Scott, David Shimokawa, and Michael Theim | TEVA_MDL_A_00573011 | TEVA_MDL_A_00573013 | | | | | | | |
| TE-1 | 11/05/2016 | Actiq and Fentora Clinical Study Reports | TEVA_MDL_A_04213348 | TEVA_MDL_A_04213356 | | | | | | | Actiq & F |
| TE-2 | Undated | Actiq and Fentora Clinical Study Reports | TEVA_MDL_A_04250791 | TEVA_MDL_A_04250857 | | | | | | | |
| TE-3 | Undated | Actiq and Fentora Clinical Study Reports | TEVA_MDL_A_04250858 | TEVA_MDL_A_04250891 | | | | | | | |
| TE-4 | 09/30/2014 | Actiq and Fentora Clinical Study Reports | TEVA_MDL_A_04250892 | TEVA_MDL_A_04250932 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-5 | 03/14/2018 | Actiq and Fentora Clinical Study Reports | TEVA_MDL_A_04250933 | TEVA_MDL_A_04251049 | | | | | | | |
| TE-6 | 07/31/2015 | Actiq and Fentora Clinical Study Reports | TEVA_MDL_A_04251064 | TEVA_MDL_A_04251070 | | | | | | | |
| TE-7 | 12/12/2014 | Distribution and Supply Agreement Between Purdue Pharma L.P. and Teva Pharmaceuticals USA, Inc. | TEVA_MDL_A_01459814 | TEVA_MDL_A_01459866 | | | | | | | |
| TE-8 | 11/01/1997 | Generic Wholesale Service Agreement Between Cardinal Health and Teva Pharmaceuticals USA | TEVA_MDL_A_02837166 | TEVA_MDL_A_02837187 | | | | | | | |
| TE-9 | 08/02/2016 | Quality Agreement Between Allergan PLC and Teva Pharmaceuticals Industries Ltd. | TEVA_MDL_A_03066252 | TEVA_MDL_A_03066307 | | | | | | | |
| TE-10 | 01/17/2012 | Risk Evaluation and Mitigation Strategies Amendment Between Cephalon, Inc. and Miami-Luken, Inc. | TEVA_MDL_A_03443993 | TEVA_MDL_A_03443998 | | | | | | | |
| TE-11 | 01/01/2012 | Master Distribution Services Agreement Between AmerisourceBergen and Teva Pharmaceuticals USA, Inc. | TEVA_MDL_A_03447808 | TEVA_MDL_A_03447847 | | | | | | | |
| TE-12 | 09/01/2012 | Amendment No. 1 to Distribution Services Agreement Between Teva Pharmaceuticals USA, Inc. and Miami-Luken, Inc. | TEVA_MDL_A_03448911 | TEVA_MDL_A_03448921 | | | | | | | |
| TE-13 | 04/03/2015 | Distribution Services Agreement Between Teva Pharmaceuticals USA, Inc. and Anda, Inc. | TEVA_MDL_A_03451410 | TEVA_MDL_A_03451456 | | | | | | | |
| TE-14 | 01/01/2015 | Master Distribution Services Agreement Between AmerisourceBergen and Teva Pharmaceuticals USA, Inc. | TEVA_MDL_A_03451519 | TEVA_MDL_A_03451565 | | | | | | | |
| TE-15 | 05/01/2015 | National Redistribution Center Agreement Between Teva Pharmaceuticals USA, Inc. and McKesson Corporation | TEVA_MDL_A_03462063 | TEVA_MDL_A_03462079 | | | | | | | |
| TE-16 | 12/15/2017 | Generic Wholesale Service Agreement Between Cardinal Health and Teva Pharmaceuticals USA, Inc. | TEVA_MDL_A_03464455 | TEVA_MDL_A_03464484 | | | | | | | |
| TE-17 | 02/01/2017 | Master Distribution Services Agreement Between AmerisourceBergen and Teva Pharmaceuticals USA, Inc. | TEVA_MDL_A_03464712 | TEVA_MDL_A_03464770 | | | | | | | |
| TE-18 | 12/13/2016 | Quality Agreement Between Purdue Pharma L.P. and Teva Pharmaceuticals USA, Inc. | TEVA_MDL_A_04346745 | TEVA_MDL_A_04346766 | | | | | | | |
| TE-19 | 12/18/2014 | Distribution and Supply Agreement By and Between Purdue Pharma L.P. and Teva Pharmaceuticals USA, INC. | TEVA_MDL_A_03434545 | TEVA_MDL_A_03434611 | | | | | | | |
| TE-20 | 08/02/2016 | Teva Pharmaceutical Industries Ltd and Allergan PLC, Supply Agreement (Teva to Allergan) | TEVA_MDL_A_03504309 | TEVA_MDL_A_03504368 | | | | | | | |
| TE-32 | 04/19/2012 | RTL-Actiq Conversions | TEVA_MDL_A_01156009 | TEVA_MDL_A_01156011 | | | | | | | |
| TE-33 | Undated | Actiq (Fentanyl Citrate) Oral Transmucosal Lozenge, CII Standard Response Letters Index | TEVA_MDL_A_00705826 | TEVA_MDL_A_00705826 | | | | | | | |
| TE-34 | Undated | ACT001 – General Information | TEVA_MDL_A_01086138 | TEVA_MDL_A_01086149 | | | | | | | |
| TE-35 | Undated | ACT002 – Relative Analgesic Potency | TEVA_MDL_A_01086013 | TEVA_MDL_A_01086015 | | | | | | | |
| TE-36 | Undated | ACT003 – Analgesic Effects Compared with Other Opioids | TEVA_MDL_A_01086154 | TEVA_MDL_A_01086158 | | | | | | | |
| TE-37 | Undated | ACT004 – Onset and Duration of Analgesia | TEVA_MDL_A_01086159 | TEVA_MDL_A_01086161 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|--------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-38 | Undated | ACT006 – Differences Between ACTIQ and Fentanyl Oralet | TEVA_MDL_A_01086052 | TEVA_MDL_A_01086052 | | | | | | | |
| TE-39 | Undated | ACT007 – Occurrence of Dental Caries | TEVA_MDL_A_01086162 | TEVA_MDL_A_01086164 | | | | | | | |
| TE-40 | Undated | ACT008 – Use as Pre-Med or for Acute, Postoperative Pain | TEVA_MDL_A_00705126 | TEVA_MDL_A_00705128 | | | | | | | |
| TE-41 | Undated | ACT009 – Use in Pediatric Patients | TEVA_MDL_A_01086165 | TEVA_MDL_A_01086167 | | | | | | | |
| TE-42 | Undated | ACT010 – Occurrence of Mucositis/Stomatitis | TEVA_MDL_A_01085860 | TEVA_MDL_A_01085864 | | | | | | | |
| TE-44 | Undated | ACT012 – Differences in the Amount of Fentanyl in ACTIQ vs. Transdermal Formulation (Duragesic) | TEVA_MDL_A_01085869 | TEVA_MDL_A_01085871 | | | | | | | |
| TE-45 | Undated | ACT013 – Potential for Drug Abuse, Addiction and Diversion | TEVA_MDL_A_00705196 | TEVA_MDL_A_00705200 | | | | | | | |
| TE-46 | Undated | ACT015 – Effect on Respiratory Function | TEVA_MDL_A_01086172 | TEVA_MDL_A_01086176 | | | | | | | |
| TE-47 | Undated | ACT016 – Adverse Effect on Oral Mucosa | TEVA_MDL_A_01085872 | TEVA_MDL_A_01085875 | | | | | | | |
| TE-48 | Undated | ACT018 – Drug Interaction Profile | TEVA_MDL_A_01086177 | TEVA_MDL_A_01086180 | | | | | | | |
| TE-49 | Undated | ACT020 – Pharmacokinetic Profile of ACTIQ | TEVA_MDL_A_01086181 | TEVA_MDL_A_01086186 | | | | | | | |
| TE-50 | Undated | ACT022 – Dosing and Administration | TEVA_MDL_A_01086187 | TEVA_MDL_A_01086195 | | | | | | | |
| TE-51 | Undated | ACT023 – Overall Safety Profile | TEVA_MDL_A_01086196 | TEVA_MDL_A_01086205 | | | | | | | |
| TE-52 | Undated | ACT026 – Use in the Treatment of Migraine Headache | TEVA_MDL_A_00705228 | TEVA_MDL_A_00705229 | | | | | | | |
| TE-53 | Undated | ACT032 – Occurrence of Death | TEVA_MDL_A_00705240 | TEVA_MDL_A_00705242 | | | | | | | |
| TE-54 | Undated | ACT033 – Occurrence of Accidental Exposure in Children | TEVA_MDL_A_01086211 | TEVA_MDL_A_01086214 | | | | | | | |
| TE-55 | Undated | ACT039 – Efficacy Profile | TEVA_MDL_A_01086215 | TEVA_MDL_A_01086221 | | | | | | | |
| TE-56 | Undated | ACT040 – Risk Evaluation and Mitigation Strategy (REMS) | TEVA_MDL_A_01086018 | TEVA_MDL_A_01086019 | | | | | | | |
| TE-66 | 11/04/2015 | ACT-40017 Oral Transmucosal Fentanyl Citrate (OTFC) - Trade Journal Product Announcement Email (v1.0) | TEVA_MDL_A_01130659 | TEVA_MDL_A_01130660 | | | | | | | |
| TE-67 | 11/04/2015 | ACT-40016 Oral Transmucosal Fentanyl Citrate - Homepage and New Teva Generic pages (v1.0) | TEVA_MDL_A_01130652 | TEVA_MDL_A_01130658 | | | | | | | |
| TE-68 | 11/04/2015 | ACT-40015 Oral Transmucosal Fentanyl Citrate (OTFC) - Trade Pricing Email (v1.0) | TEVA_MDL_A_01130651 | TEVA_MDL_A_01130651 | | | | | | | |
| TE-69 | 11/04/2015 | ACT-40014 Oral Transmucosal Fentanyl Citrate (OTFC) - Teva Dose Email (v1.0) | TEVA_MDL_A_01130649 | TEVA_MDL_A_01130650 | | | | | | | |
| TE-70 | 11/04/2015 | ACT-40013 Oral Transmucosal Fentanyl Citrate (OTFC) - Pharmacist Corner Email (v1.0) | TEVA_MDL_A_01130647 | TEVA_MDL_A_01130648 | | | | | | | |
| TE-71 | 11/04/2015 | ACT-40012 Oral Transmucosal Fentanyl Citrate (OTFC) - Trade Customer Email (v1.0) | TEVA_MDL_A_01130646 | TEVA_MDL_A_01130646 | | | | | | | |
| TE-72 | 11/04/2015 | ACT-40011 Oral Transmucosal Fentanyl Citrate (OTFC) - Consumer Email (v1.0) | TEVA_MDL_A_01130641 | TEVA_MDL_A_01130645 | | | | | | | |
| TE-83 | 11/01/2011 | FENTORA REMS On-Demand Webcast Audio Recording | TEVA_MDL_A_01154987 | TEVA_MDL_A_01155042 | | | | | | | |
| TE-91 | 11/20/2011 | FENTORA Prescribing Information PHASE II Workshop Handouts | TEVA_MDL_A_01155240 | TEVA_MDL_A_01155268 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-95 | 11/20/2011 | Certification Exam: Pain Physiology, Assessment, and Management | TEVA_MDL_A_01155292 | TEVA_MDL_A_01155301 | | | | | | | |
| TE-98 | 11/29/2011 | Fentora Annotated PI Certification Exam | TEVA_MDL_A_01155310 | TEVA_MDL_A_01155320 | | | | | | | |
| TE-99 | 12/08/2011 | CVA Update | TEVA_MDL_A_01155321 | TEVA_MDL_A_01155334 | | | | | | | |
| TE-101 | 12/19/2011 | REMS PPAF Mgrs Meeting/Jan 2012 POA Facilitator Guide and Workshop | TEVA_MDL_A_01155343 | TEVA_MDL_A_01155368 | | | | | | | |
| TE-102 | 12/19/2011 | "Creating Balance" - Promotional and REMS Activities - Managers Meeting/Jan 2012 POA FENTORA Facilitator Guide and Workshop | TEVA_MDL_A_01155369 | TEVA_MDL_A_01155406 | | | | | | | |
| TE-103 | 12/19/2011 | REMS Enrollement Mgrs Meeting/JAN 2012 POA Facilitator Guide and Workshop | TEVA_MDL_A_01155407 | TEVA_MDL_A_01155422 | | | | | | | |
| TE-105 | 01/05/2012 | PPAF Leave Behind | TEVA_MDL_A_01155449 | TEVA_MDL_A_01155454 | | | | | | | |
| TE-109 | 01/08/2012 | Creating Balance Workshop Worksheets | TEVA_MDL_A_01155465 | TEVA_MDL_A_01155466 | | | | | | | |
| TE-110 | 01/12/2012 | "Creating Balance" – Promotional and REMS Activities - JAN 2012 POA FENTORA Powerpoint slides | TEVA_MDL_A_01155467 | TEVA_MDL_A_01155504 | | | | | | | |
| TE-126 | 02/09/2012 | ACTIQ and FENTORA Combined TIRF ISI | TEVA_MDL_A_01155672 | TEVA_MDL_A_01155675 | | | | | | | |
| TE-127 | 02/13/2012 | FENTORA NFM Facilitator Guide | TEVA_MDL_A_01155676 | TEVA_MDL_A_01155696 | | | | | | | |
| TE-137 | 02/23/2012 | BTP Speaker Program Invite Update | TEVA_MDL_A_01155729 | TEVA_MDL_A_01155731 | | | | | | | |
| TE-138 | 02/23/2012 | REMS Speaker Program Invite Update | TEVA_MDL_A_01155732 | TEVA_MDL_A_01155734 | | | | | | | |
| TE-140 | 02/28/2012 | Efficacy Leave Behind Update | TEVA_MDL_A_01155766 | TEVA_MDL_A_01155769 | | | | | | | |
| TE-141 | 02/28/2012 | Dosing Leave Behind | TEVA_MDL_A_01155770 | TEVA_MDL_A_01155771 | | | | | | | |
| TE-142 | 03/01/2012 | Absolute and Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate Training Guide | TEVA_MDL_A_01155781 | TEVA_MDL_A_01155783 | | | | | | | |
| TE-143 | 03/01/2012 | FENTORA FAQ and Responses | TEVA_MDL_A_01155784 | TEVA_MDL_A_01155795 | | | | | | | |
| TE-149 | 03/27/2012 | Efficacy Leave Behind Training Guide | TEVA_MDL_A_01155843 | TEVA_MDL_A_01155845 | | | | | | | |
| TE-150 | 03/27/2012 | Touch Screen Panels | TEVA_MDL_A_01155874 | TEVA_MDL_A_01155891 | | | | | | | |
| TE-152 | 03/29/2012 | Fentora Q&A | TEVA_MDL_A_01155904 | TEVA_MDL_A_01155910 | | | | | | | |
| TE-157 | 04/06/2012 | FENTORA Annotated CVA | TEVA_MDL_A_01155930 | TEVA_MDL_A_01155961 | | | | | | | |
| TE-158 | 04/09/2012 | Fentora ISI Panel | TEVA_MDL_A_01155964 | TEVA_MDL_A_01155964 | | | | | | | |
| TE-164 | 04/23/2012 | PCS ITC Pre-Exam | TEVA_MDL_A_01156012 | TEVA_MDL_A_01156026 | | | | | | | |
| TE-167 | 04/24/2012 | Case-Based Promotional Slide Deck | TEVA_MDL_A_01156090 | TEVA_MDL_A_01156152 | | | | | | | |
| TE-171 | 04/27/2012 | Fentora Dosing DSA (July Pilot) | TEVA_MDL_A_01156302 | TEVA_MDL_A_01156338 | | | | | | | |
| TE-172 | 05/07/2012 | PI Workshop for ITC | TEVA_MDL_A_01156339 | TEVA_MDL_A_01156383 | | | | | | | |
| TE-174 | 05/07/2012 | FENTORA PI ITC Workshop - Master Activity Worksheet | TEVA_MDL_A_01156387 | TEVA_MDL_A_01156417 | | | | | | | |
| TE-190 | 07/16/2012 | Fentora October DSA | TEVA_MDL_A_01156704 | TEVA_MDL_A_01156788 | | | | | | | |
| TE-192 | 08/13/2012 | CVA Update | TEVA_MDL_A_01156828 | TEVA_MDL_A_01156844 | | | | | | | |
| TE-193 | 08/13/2012 | Slim Jim Update | TEVA_MDL_A_01156845 | TEVA_MDL_A_01156870 | | | | | | | |
| TE-194 | 08/13/2012 | Efficacy Leave Behind Update | TEVA_MDL_A_01156871 | TEVA_MDL_A_01156872 | | | | | | | |
| TE-195 | 08/13/2012 | Dosing Leave Behind Update | TEVA_MDL_A_01156873 | TEVA_MDL_A_01156874 | | | | | | | |
| TE-204 | 08/29/2012 | Rep Triggered Email Weinstein | TEVA_MDL_A_01157001 | TEVA_MDL_A_01157001 | | | | | | | |
| TE-205 | 08/29/2012 | Rep Triggered Email Portenoy | TEVA_MDL_A_01157002 | TEVA_MDL_A_01157002 | | | | | | | |
| TE-208 | 09/26/2012 | BTP Speaker Program Invite Template Refresh | TEVA_MDL_A_01157071 | TEVA_MDL_A_01157072 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-213 | 10/02/2012 | PPLS Update: Disease State | TEVA_MDL_A_01157159 | TEVA_MDL_A_01157238 | | | | | | | |
| TE-214 | 10/16/2012 | FENTORA abbreviated case-based promotional slide deck | TEVA_MDL_A_01157247 | TEVA_MDL_A_01157289 | | | | | | | |
| TE-218 | 11/14/2012 | Initial Training Class PCS Dosing Workshop | TEVA_MDL_A_01157342 | TEVA_MDL_A_01157367 | | | | | | | |
| TE-221 | 11/26/2012 | Pain Physiology, Assessment and Management Workshop | TEVA_MDL_A_01157370 | TEVA_MDL_A_01157393 | | | | | | | |
| TE-222 | 12/11/2012 | Table Top Panels Refresh | TEVA_MDL_A_01157471 | TEVA_MDL_A_01157474 | | | | | | | |
| TE-228 | 01/08/2013 | Clinical Data RTM | TEVA_MDL_A_01157582 | TEVA_MDL_A_01157584 | | | | | | | |
| TE-231 | 01/11/2013 | Convention ISI Panel | TEVA_MDL_A_01157697 | TEVA_MDL_A_01157697 | | | | | | | |
| TE-238 | 05/03/2013 | FEN-40043 FAQ and Responses (v1.0) | TEVA_MDL_A_01131144 | TEVA_MDL_A_01131156 | | | | | | | |
| TE-239 | 09/27/2013 | FEN-40084 Fentora eNewsletter 3 (v1.0) | TEVA_MDL_A_01131520 | TEVA_MDL_A_01131524 | | | | | | | |
| TE-241 | 03/12/2015 | FEN-40264 2015 FENTORA Convention Touchscreen Plasma Panel (v1.0) | TEVA_MDL_A_01133682 | TEVA_MDL_A_01133746 | | | | | | | |
| TE-243 | 01/01/2013 | FENTORA Prescription Savings Card Brochure (2013) | TEVA_MDL_A_01131171 | TEVA_MDL_A_01131188 | | | | | | | |
| TE-244 | Undated | Fentora (Fentanyl Buccal Tablet) Standard Response Letter Index | TEVA_MDL_A_00706096 | TEVA_MDL_A_00706097 | | | | | | | |
| TE-245 | Undated | FEN002 – General Information | TEVA_MDL_A_01085242 | TEVA_MDL_A_01085255 | | | | | | | |
| TE-246 | Undated | FEN003 – Pharmacokinetic (PK) Profile of Fentanyl | TEVA_MDL_A_00704432 | TEVA_MDL_A_00704439 | | | | | | | |
| TE-247 | Undated | FEN004 – Clinical Data Comparing FENTORA to OTFC | TEVA_MDL_A_00704440 | TEVA_MDL_A_00704445 | | | | | | | |
| TE-248 | Undated | FEN006 – Analgesic Potency Relative to that of Other Opioid Medications | TEVA_MDL_A_00704446 | TEVA_MDL_A_00704450 | | | | | | | |
| TE-251 | 02/04/2014 | FEN010 – Drug Interaction Profile | TEVA_MDL_A_00704475 | TEVA_MDL_A_00704477 | | | | | | | |
| TE-252 | 02/04/2014 | FEN011 – Dosing and Administration | TEVA_MDL_A_00704713 | TEVA_MDL_A_00704718 | | | | | | | |
| TE-253 | 08/22/2011 | FEN012 – Potential for Drug Abuse, Addiction and Diversion | TEVA_MDL_A_00705427 | TEVA_MDL_A_00705432 | | | | | | | |
| TE-254 | 02/04/2014 | FEN013 – Use in Patients with Mucositis (Stomatitis) | TEVA_MDL_A_01085314 | TEVA_MDL_A_01085316 | | | | | | | |
| TE-255 | 02/04/2014 | FEN014 – Use for Management of BTP in Opioid-Tolerant Patients with Chronic Noncancer Pain conditions | TEVA_MDL_A_00704493 | TEVA_MDL_A_00704501 | | | | | | | |
| TE-256 | 02/04/2014 | FEN016 – Use in Pediatric Patients | TEVA_MDL_A_00704727 | TEVA_MDL_A_00704728 | | | | | | | |
| TE-257 | 02/04/2014 | FEN019 – Use in Elderly Patients | TEVA_MDL_A_00704729 | TEVA_MDL_A_00704730 | | | | | | | |
| TE-258 | 02/04/2014 | FEN021 – Effect on Respiratory Function | TEVA_MDL_A_00704519 | TEVA_MDL_A_00704522 | | | | | | | |
| TE-259 | 08/22/2011 | FEN022 – Use as a Premedication or for the Management of Acute or Postoperative Pain in Adults | TEVA_MDL_A_00705460 | TEVA_MDL_A_00705461 | | | | | | | |
| TE-260 | 02/04/2014 | FEN025 – Application Site Reactions in the Oral Mucosa | TEVA_MDL_A_00704735 | TEVA_MDL_A_00704737 | | | | | | | |
| TE-261 | 09/06/2011 | FEN027 – Use for the Management of BTP in Opioid-Tolerant Patients with Chronic Lower Back Pain | TEVA_MDL_A_00705556 | TEVA_MDL_A_00705563 | | | | | | | |
| TE-262 | 09/06/2011 | FEN028 – Use for the Management of BTP in Opioid-Tolerant Patients with Chronic Neuropathic Pain | TEVA_MDL_A_00705657 | TEVA_MDL_A_00705664 | | | | | | | |
| TE-263 | 11/04/2010 | FEN029 – Occurrence of Death | TEVA_MDL_A_00705681 | TEVA_MDL_A_00705683 | | | | | | | |
| TE-264 | 02/04/2014 | FEN033 – Risk Evaluation and Mitigation Strategy (REMS) | TEVA_MDL_A_00704757 | TEVA_MDL_A_00704758 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-265 | 02/06/2014 | FEN035 – Analgesic Effects Compared to Other Opioids for the Management of Breakthrough Pain in Opioid Tolerant Patients | TEVA_MDL_A_00704560 | TEVA_MDL_A_00704569 | | | | | | | |
| TE-266 | 02/06/2014 | FEN0036 – Occurrence of Dental Disorders Coincident with Use of FENTORA | TEVA_MDL_A_00704581 | TEVA_MDL_A_00704583 | | | | | | | |
| TE-271 | 05/26/2017 | FEN-40537 - Fentora Pain Product Learning System - Marketplace Module (v1.0) | TEVA_MDL_A_01136028 | TEVA_MDL_A_01136092 | | | | | | | |
| TE-272 | 05/18/2017 | FEN-40536 - Fentora PLS Disease State Certification Exam (v1.0) | TEVA_MDL_A_01136020 | TEVA_MDL_A_01136027 | | | | | | | |
| TE-273 | 05/18/2017 | FEN-40535 - Fentora PLS Disease State Module (v1.0) | TEVA_MDL_A_01135946 | TEVA_MDL_A_01136019 | | | | | | | |
| TE-275 | 04/24/2017 | FEN-40522 FENTORA 2017 Patient Brochure (Print) (v1.0) | TEVA_MDL_A_01135921 | TEVA_MDL_A_01135930 | | | | | | | |
| TE-280 | 04/07/2017 | FEN-40514 FENTORA Taking Your Medication Brochure Update (v1.0) | TEVA_MDL_A_01135855 | TEVA_MDL_A_01135862 | | | | | | | |
| TE-281 | 04/24/2017 | FEN-40512 FENTORA Patient Brochure Holder Update (v1.0) | TEVA_MDL_A_01135840 | TEVA_MDL_A_01135843 | | | | | | | |
| TE-283 | 03/06/2017 | FEN-40505 Managing Breakthrough Pain in Patients with Cancer (v1.0) | TEVA_MDL_A_01135783 | TEVA_MDL_A_01135838 | | | | | | | |
| TE-285 | 03/06/2017 | FEN-40498 FENTORA Downloadable Patient Materials (v1.0) | TEVA_MDL_A_01135743 | TEVA_MDL_A_01135780 | | | | | | | |
| TE-288 | 03/30/2017 | FEN-40481 FENTORA Sublingual Leave Behind (v1.0) | TEVA_MDL_A_01135675 | TEVA_MDL_A_01135677 | | | | | | | |
| TE-289 | 03/28/2017 | FEN-40480 Fentora Dosing Leave Behind (v1.0) | TEVA_MDL_A_01135672 | TEVA_MDL_A_01135674 | | | | | | | |
| TE-290 | 03/30/2017 | FEN-40479 FENTORA Patient Profile Detail Piece / Leave Behind (v1.0) | TEVA_MDL_A_01135667 | TEVA_MDL_A_01135671 | | | | | | | |
| TE-294 | 03/21/2017 | FEN-40472 FENTORA Clinical Trial Rep Triggered Letter Update (v1.0) | TEVA_MDL_A_01135655 | TEVA_MDL_A_01135658 | | | | | | | |
| TE-300 | 01/12/2017 | FEN-40465 FENTORA Indication and ISI - Professional (v2.0) | TEVA_MDL_A_01135611 | TEVA_MDL_A_01135613 | | | | | | | |
| TE-311 | 10/21/2016 | FEN-40442 FENTORA Dosing and Administration Rep Triggered Letter (v1.0) | TEVA_MDL_A_01135276 | TEVA_MDL_A_01135278 | | | | | | | |
| TE-312 | 10/21/2016 | FEN-40441 FENTORA Clinical Trial Rep Triggered Letter (v1.0) | TEVA_MDL_A_01135272 | TEVA_MDL_A_01135275 | | | | | | | |
| TE-313 | 10/17/2016 | FEN-40440 FENTORA Direct Mail Newsletter 5 (v1.0) | TEVA_MDL_A_01135270 | TEVA_MDL_A_01135271 | | | | | | | |
| TE-322 | 07/28/2016 | FEN-40425 FENTORA Patient Profile 2 Direct Mailer (v1.0) | TEVA_MDL_A_01135226 | TEVA_MDL_A_01135229 | | | | | | | |
| TE-329 | 07/08/2016 | FEN-40414 FENTORA Direct Mail Newsletter 2 (v1.0) | TEVA_MDL_A_01135201 | TEVA_MDL_A_01135202 | | | | | | | |
| TE-331 | 06/03/2016 | FEN-40409 - FENTORA Access Advisor Web PDF (v1.0) | TEVA_MDL_A_01135176 | TEVA_MDL_A_01135195 | | | | | | | |
| TE-341 | 05/31/2016 | FEN-40392 FENTORA Clinical Trials Rep Triggered Email (Desktop and Mobile) (v1.0) | TEVA_MDL_A_01135038 | TEVA_MDL_A_01135042 | | | | | | | |
| TE-343 | 05/31/2016 | FEN-40390 FENTORA Administration & Dosing Rep Triggered Email (Desktop and Mobile) (v1.0) | TEVA_MDL_A_01135028 | TEVA_MDL_A_01135032 | | | | | | | |
| TE-344 | 04/25/2016 | FEN-40389 FENTORA Direct Mail Newsletter 1 (v1.0) | TEVA_MDL_A_01135024 | TEVA_MDL_A_01135027 | | | | | | | |
| TE-352 | 03/04/2016 | FEN-40374 FENTORA Resource Guide (v1.0) | TEVA_MDL_A_01134894 | TEVA_MDL_A_01134903 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-360 | 09/08/2016 | FEN-40360 Web-based On-demand FENTORA promotional presentation (v2.0) | TEVA_MDL_A_01134682 | TEVA_MDL_A_01134704 | | | | | | | |
| TE-369 | 12/22/2015 | FEN-40346 Guide to FENTORA Messaging (v1.0) | TEVA_MDL_A_01134573 | TEVA_MDL_A_01134582 | | | | | | | |
| TE-384 | 06/28/2016 | FEN-40324 FENTORA Managing Breakthrough Cancer Pain (v1.0) | TEVA_MDL_A_01134259 | TEVA_MDL_A_01134266 | | | | | | | |
| TE-391 | 10/15/2015 | FEN-40314 FENTORA Perspectives in Palliative Care Live Program Guidebook (v1.0) | TEVA_MDL_A_01134185 | TEVA_MDL_A_01134236 | | | | | | | |
| TE-392 | 10/15/2015 | FEN-40313 FENTORA Oncology Live Program Guidebook (v1.0) | TEVA_MDL_A_01134133 | TEVA_MDL_A_01134184 | | | | | | | |
| TE-396 | 09/03/2015 | FEN-40308 My Daily Breakthrough Cancer Pain Journal (v1.0) | TEVA_MDL_A_01134087 | TEVA_MDL_A_01134104 | | | | | | | |
| TE-398 | 09/03/2015 | FEN-40306 FENTORA Patient Starter Kit Housing Unit (v1.0) | TEVA_MDL_A_01134073 | TEVA_MDL_A_01134084 | | | | | | | |
| TE-401 | 08/07/2015 | FEN-40302 2015 FENTORA Speaker Program Invitation (Palliative Care) (v1.0) | TEVA_MDL_A_01134055 | TEVA_MDL_A_01134069 | | | | | | | |
| TE-402 | 08/07/2015 | FEN-40301 2015 FENTORA Speaker Program Invitation (ONC) (v1.0) | TEVA_MDL_A_01134040 | TEVA_MDL_A_01134054 | | | | | | | |
| TE-403 | 08/07/2015 | FEN-40300 2015 FENTORA Speaker Program Invitation (BTP) (v1.0) | TEVA_MDL_A_01134025 | TEVA_MDL_A_01134039 | | | | | | | |
| TE-421 | 07/13/2015 | FEN-40274 eNewsletter 1 Direct Mail (v1.0) | TEVA_MDL_A_01133755 | TEVA_MDL_A_01133756 | | | | | | | |
| TE-428 | 04/27/2015 | FEN-40255 FENTORA eDetail (v1.0) | TEVA_MDL_A_01133616 | TEVA_MDL_A_01133670 | | | | | | | |
| TE-432 | 04/20/2015 | FEN-40250 ITC Workshop: Marketplace (v1.0) | TEVA_MDL_A_01133568 | TEVA_MDL_A_01133597 | | | | | | | |
| TE-433 | 04/17/2015 | FEN-40247 Fentora ITC Workshop: Messaging Resources (v1.0) | TEVA_MDL_A_01133501 | TEVA_MDL_A_01133567 | | | | | | | |
| TE-434 | 02/03/2015 | FEN-40246 FENTORA Speaker Program Follow-up RTL (v1.0) | TEVA_MDL_A_01133498 | TEVA_MDL_A_01133500 | | | | | | | |
| TE-441 | 12/03/2014 | FEN-40238 Managing Breakthrough Pain in Patients with Cancer (revision) (v2.0) | TEVA_MDL_A_01133311 | TEVA_MDL_A_01133362 | | | | | | | |
| TE-442 | 12/11/2014 | FEN-40235 Managing Breakthrough Pain in Patients with Cancer - Live Program Guidebook (v2.0) | TEVA_MDL_A_01133258 | TEVA_MDL_A_01133305 | | | | | | | |
| TE-443 | 01/13/2015 | FEN-40234 Fentora DSA Update (v1.0) | TEVA_MDL_A_01133190 | TEVA_MDL_A_01133257 | | | | | | | |
| TE-444 | 10/21/2014 | FEN-40233 Fentora Product Theater Invitation for the Palliative Care in Oncology Symposium (v1.0) | TEVA_MDL_A_01133186 | TEVA_MDL_A_01133189 | | | | | | | |
| TE-452 | 09/04/2014 | FEN-40222 FENTORA PAINWeek Product Presentation (v1.0) | TEVA_MDL_A_01132925 | TEVA_MDL_A_01132975 | | | | | | | |
| TE-453 | 09/12/2014 | FEN-40212 Perspectives in Palliative Care: Managing BTP (Live Program Workbook) (v1.0) | TEVA_MDL_A_01132870 | TEVA_MDL_A_01132921 | | | | | | | |
| TE-460 | 11/07/2014 | FEN-40203_FENTORA Rx Peer Insights Email 1 (v1.0) | TEVA_MDL_A_01132851 | TEVA_MDL_A_01132851 | | | | | | | |
| TE-463 | 09/25/2014 | FEN-40199 Perspectives in Palliative Care: Managing Breakthrough Pain (Faculty Guide) (v1.0) | TEVA_MDL_A_01132759 | TEVA_MDL_A_01132794 | | | | | | | |
| TE-464 | 09/19/2014 | FEN-40198 Perspectives in Palliative Care: Managing Breakthrough Pain (Participant Guide) (v1.0) | TEVA_MDL_A_01132723 | TEVA_MDL_A_01132758 | | | | | | | |
| TE-475 | 04/30/2014 | FEN-40175 Sublingual Leave-Behind (v1.0) | TEVA_MDL_A_01132499 | TEVA_MDL_A_01132500 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-476 | 04/15/2014 | FEN-40173 PPLS Disease State Certification Exam (v1.0) | TEVA_MDL_A_01132486 | TEVA_MDL_A_01132493 | | | | | | | |
| TE-478 | 04/10/2014 | FEN-40171 Fentora Annotated PI Certification Exam (v1.0) | TEVA_MDL_A_01132467 | TEVA_MDL_A_01132477 | | | | | | | |
| TE-479 | 04/10/2014 | FEN-40164 ITC Disease State Workshop (v1.0) | TEVA_MDL_A_01132430 | TEVA_MDL_A_01132453 | | | | | | | |
| TE-480 | 03/18/2014 | FEN-40163 ITC Exam (v1.0) | TEVA_MDL_A_01132419 | TEVA_MDL_A_01132429 | | | | | | | |
| TE-481 | 04/23/2014 | FEN-40160 Patient Brochure (v1.0) | TEVA_MDL_A_01132399 | TEVA_MDL_A_01132418 | | | | | | | |
| TE-482 | 04/04/2014 | FEN-40159 PPLS Disease State Module (v1.0) | TEVA_MDL_A_01132325 | TEVA_MDL_A_01132398 | | | | | | | |
| TE-487 | 04/02/2014 | FEN-40150 FENTORA Dosing Leave Behind (v1.0) | TEVA_MDL_A_01132234 | TEVA_MDL_A_01132235 | | | | | | | |
| TE-488 | 02/14/2014 | FEN-40149 Fentora Annotated DSA (v1.0) | TEVA_MDL_A_01132215 | TEVA_MDL_A_01132233 | | | | | | | |
| TE-496 | 02/13/2014 | FEN-40133 Fentora Managed Care Leave-Behind (v1.0) | TEVA_MDL_A_01132030 | TEVA_MDL_A_01132031 | | | | | | | |
| TE-498 | 01/31/2014 | FEN-40129 Clinical Trials RTL (v1.0) | TEVA_MDL_A_01132023 | TEVA_MDL_A_01132026 | | | | | | | |
| TE-499 | 04/23/2014 | FEN-40128 Administration and Dosing RTL (v1.0) | TEVA_MDL_A_01132020 | TEVA_MDL_A_01132022 | | | | | | | |
| TE-509 | 12/04/2013 | FEN-40111 FENTORA Pain Program Guidebook (v1.0) | TEVA_MDL_A_01131884 | TEVA_MDL_A_01131931 | | | | | | | |
| TE-510 | 12/04/2013 | FEN-40110 FENTORA Oncology Program Guidebook (v1.0) | TEVA_MDL_A_01131840 | TEVA_MDL_A_01131883 | | | | | | | |
| TE-511 | 10/28/2013 | FEN-40104 REAPPROVAL Disease State Module (FEN-2512) (v1.0) | TEVA_MDL_A_01131758 | TEVA_MDL_A_01131837 | | | | | | | |
| TE-512 | 02/18/2014 | FEN-40103 FENTORA DSA (v1.0) | TEVA_MDL_A_01131696 | TEVA_MDL_A_01131757 | | | | | | | |
| TE-518 | 10/02/2013 | FEN-40095 REAPPROVAL Fentora Slim Jim (v1.0) | TEVA_MDL_A_01131636 | TEVA_MDL_A_01131661 | | | | | | | |
| TE-520 | 10/09/2013 | FEN-40092 FENTORA Digital Sales Aid Workshop (DSA) (v1.0) | TEVA_MDL_A_01131561 | TEVA_MDL_A_01131602 | | | | | | | |
| TE-523 | 09/27/2013 | FEN-40082 New Hire Dosing Workshop (v1.0) | TEVA_MDL_A_01131494 | TEVA_MDL_A_01131519 | | | | | | | |
| TE-526 | 09/06/2013 | FEN-40074 Perspectives in Oncology: Managing Breakthrough Pain (Participant Guide) (v1.0) | TEVA_MDL_A_01131428 | TEVA_MDL_A_01131462 | | | | | | | |
| TE-527 | 10/04/2013 | FEN-40073 Perspectives in Oncology: Managing Breakthrough Pain (Faculty Guide) (v1.0) | TEVA_MDL_A_01131393 | TEVA_MDL_A_01131427 | | | | | | | |
| TE-529 | 08/23/2013 | FEN-40057 Oncology Speaker Program Invite (v1.0) | TEVA_MDL_A_01131362 | TEVA_MDL_A_01131364 | | | | | | | |
| TE-530 | 01/13/2014 | FEN-40055 Fentora.com HCP Website (v1.0) | TEVA_MDL_A_01131337 | TEVA_MDL_A_01131358 | | | | | | | |
| TE-531 | 01/13/2014 | FEN-40054 Fentora.com Patient Website (v1.0) | TEVA_MDL_A_01131325 | TEVA_MDL_A_01131336 | | | | | | | |
| TE-532 | 08/23/2013 | FEN-40051 Managing Breakthrough Pain in Patients With Cancer Slide Deck (v1.0) | TEVA_MDL_A_01131283 | TEVA_MDL_A_01131324 | | | | | | | |
| TE-533 | 07/19/2013 | FEN-40050 Managing Breakthrough Pain In The Oncology Setting: An Interdisciplinary Approach (v1.0) | TEVA_MDL_A_01131244 | TEVA_MDL_A_01131282 | | | | | | | |
| TE-534 | 05/29/2013 | FEN-40049 FENTORA Annotated PI (v2.0) | TEVA_MDL_A_01131189 | TEVA_MDL_A_01131243 | | | | | | | |
| TE-543 | 10/18/2013 | FEN-40029 Fentora eDetail (v1.0) | TEVA_MDL_A_01131076 | TEVA_MDL_A_01131125 | | | | | | | |
| TE-552 | 04/19/2013 | FEN-40012 Fentora Sublingual Administration Introductory Letter (v1.0) | TEVA_MDL_A_01130981 | TEVA_MDL_A_01130983 | | | | | | | |
| TE-556 | 05/13/2013 | FEN-40005 Fentora iRep DSA (v1.0) | TEVA_MDL_A_01130789 | TEVA_MDL_A_01130869 | | | | | | | |
| TE-557 | 04/02/2013 | FEN-40003 Fentora Med Guide (v1.0) | TEVA_MDL_A_01130785 | TEVA_MDL_A_01130788 | | | | | | | |
| TE-561 | 10/05/2016 | TIRF-40017 TIRF REMS Rep Triggered Letter (v1.0) | TEVA_MDL_A_01140787 | TEVA_MDL_A_01140790 | | | | | | | |
| TE-566 | 03/25/2014 | TIRF-40011 PPAF Patient Education Leave Behind (v1.0) | TEVA_MDL_A_01140768 | TEVA_MDL_A_01140779 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-570 | 12/18/2013 | TIRF-40007 RE-APPROVAL PPAF Patient Brochure (zinc # TIRF-0018) (v1.0) | TEVA_MDL_A_01140700 | TEVA_MDL_A_01140711 | | | | | | | |
| TE-571 | 12/20/2013 | TIRF-40006 RE-APPROVAL - TIRF REMS Enrollment Kit (old zinc # TIRF-0017) (v1.0) | TEVA_MDL_A_01140698 | TEVA_MDL_A_01140699 | | | | | | | |
| TE-573 | 10/23/2013 | TIRF-40003 RTL TIRF Re-enrollment (v1.0) | TEVA_MDL_A_01140693 | TEVA_MDL_A_01140696 | | | | | | | |
| TE-577 | 01/17/2012 | TIRF REMS FAQ | TEVA_MDL_A_01155637 | TEVA_MDL_A_01155649 | | | | | | | |
| TE-579 | 02/24/2012 | TIRF REMS Access Leave Behind | TEVA_MDL_A_01155735 | TEVA_MDL_A_01155740 | | | | | | | |
| TE-580 | 02/28/2012 | TIRF REMS Access HCP Letter | TEVA_MDL_A_01155772 | TEVA_MDL_A_01155775 | | | | | | | |
| TE-581 | 02/28/2012 | TIRF PPAF Cover Letter | TEVA_MDL_A_01155776 | TEVA_MDL_A_01155779 | | | | | | | |
| TE-582 | 03/06/2012 | Triage Matrix | TEVA_MDL_A_01155796 | TEVA_MDL_A_01155796 | | | | | | | |
| TE-583 | 03/06/2012 | Call Center FAQ | TEVA_MDL_A_01155797 | TEVA_MDL_A_01155807 | | | | | | | |
| TE-584 | 03/06/2012 | Call Center Verbiage- HCP (Post TIRF REMS) | TEVA_MDL_A_01155808 | TEVA_MDL_A_01155809 | | | | | | | |
| TE-586 | 03/07/2012 | PPAF Rep Triggered Mailer | TEVA_MDL_A_01155813 | TEVA_MDL_A_01155816 | | | | | | | |
| TE-587 | 03/20/2012 | PPAF Patient Education Leave Behind | TEVA_MDL_A_01155826 | TEVA_MDL_A_01155837 | | | | | | | |
| TE-588 | 03/27/2012 | TIRF REMS Access Leave Behind Training Guide | TEVA_MDL_A_01155842 | TEVA_MDL_A_01155842 | | | | | | | |
| TE-590 | 03/27/2012 | LAZANDA Product Bulletin | TEVA_MDL_A_01155857 | TEVA_MDL_A_01155867 | | | | | | | |
| TE-604 | 10/01/2012 | Pain Care Proactive Talking Points | TEVA_MDL_A_01157082 | TEVA_MDL_A_01157084 | | | | | | | |
| TE-605 | 11/08/2012 | Breakthrough Pain Animation | TEVA_MDL_A_01157325 | TEVA_MDL_A_01157329 | | | | | | | |
| TE-607 | 12/11/2012 | PPAF Patient Education Leave Behind | TEVA_MDL_A_01157477 | TEVA_MDL_A_01157488 | | | | | | | |
| TE-614 | | Chargeback Data for Actiq and Fentora 2011 through April 2018. | TEVA_MDL_A_02401118 | TEVA_MDL_A_02401118 | | | | | | | |
| TE-615 | | Actiq and Fentora AR Transactional Data (All Invoices and Credits Issued) for April 2012 through April 2018. | TEVA_MDL_A_02419961 | TEVA_MDL_A_02419961 | | | | | | | |
| TE-616 | | Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2016 | TEVA_MDL_A_02419964 | TEVA_MDL_A_02419964 | | | | | | | |
| TE-617 | | Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for June 2017-2018 | TEVA_MDL_A_02419965 | TEVA_MDL_A_02419965 | | | | | | | |
| TE-618 | | Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2008-2010 | TEVA_MDL_A_02419966 | TEVA_MDL_A_02419966 | | | | | | | |
| TE-619 | | Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2011-2013 | TEVA_MDL_A_02419967 | TEVA_MDL_A_02419967 | | | | | | | |
| TE-620 | | Accounts Receivable Transactional Data (Invoices and Credit Memos) for Generic Opioids for 2014-2015 | TEVA_MDL_A_02419968 | TEVA_MDL_A_02419968 | | | | | | | |
| TE-621 | | Direct Sales data 1/2006-7/2018 | TEVA_MDL_A_02416192 | TEVA_MDL_A_02416192 | | | | | | | |
| TE-622 | | Indirect Sales data 5.1.18-7.29.18 | TEVA_MDL_A_02416193 | TEVA_MDL_A_02416193 | | | | | | | |
| TE-623 | | Indirect Sales data 2011 | TEVA_MDL_A_02416194 | TEVA_MDL_A_02416194 | | | | | | | |
| TE-624 | | Indirect Sales data 2012 | TEVA_MDL_A_02416195 | TEVA_MDL_A_02416195 | | | | | | | |
| TE-625 | | Indirect Sales data 2013 | TEVA_MDL_A_02416196 | TEVA_MDL_A_02416196 | | | | | | | |
| TE-626 | | Indirect Sales data 2014 | TEVA_MDL_A_02416197 | TEVA_MDL_A_02416197 | | | | | | | |
| TE-627 | | Indirect Sales data 2015 | TEVA_MDL_A_02416198 | TEVA_MDL_A_02416198 | | | | | | | |
| TE-628 | | Indirect Sales data 2016 | TEVA_MDL_A_02416199 | TEVA_MDL_A_02416199 | | | | | | | |
| TE-629 | | Indirect Sales data 1.1.17-3.31.17 | TEVA_MDL_A_02416200 | TEVA_MDL_A_02416200 | | | | | | | |
| TE-630 | | Indirect Sales data 4.1.17-6.30.17 | TEVA_MDL_A_02416201 | TEVA_MDL_A_02416201 | | | | | | | |
| TE-631 | | Indirect Sales data 7.1.17-9.30.17 | TEVA_MDL_A_02416202 | TEVA_MDL_A_02416202 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-632 | | Indirect Sales data 10.1.17-12.31.17 | TEVA_MDL_A_02416203 | TEVA_MDL_A_02416203 | | | | | | | |
| TE-633 | | Indirect Sales data 1.1.18-4.30.18 | TEVA_MDL_A_02416204 | TEVA_MDL_A_02416204 | | | | | | | |
| TE-634 | 07/01/2012 | Reporting and Investigations of Misconduct US Policy - 400 | TEVA_MDL_A_00553150 | TEVA_MDL_A_00553152 | | | | | | | |
| TE-635 | 01/01/2012 | Teva Employee Conduct Policy | TEVA_MDL_A_00553159 | TEVA_MDL_A_00553160 | | | | | | | |
| TE-636 | 02/27/2006 | Teva Code of Business Conduct | TEVA_MDL_A_00553166 | TEVA_MDL_A_00553192 | | | | | | | |
| TE-637 | 11/15/2016 | Handling Safety Information on Company Products | TEVA_MDL_A_04243438 | TEVA_MDL_A_04243445 | | | | | | | |
| TE-638 | 07/01/2012 | Teva Incident Management (Compliance Procedure-100), (Jul. 2012) | TEVA_MDL_A_00553116 | TEVA_MDL_A_00553120 | | | | | | | |
| TE-639 | 03/22/2017 | Onboarding Toolkit COE iMCM Advisor | TEVA_MDL_A_01078522 | TEVA_MDL_A_01078522 | | | | | | | |
| TE-640 | 09/24/2013 | September 24, 2013 Government & Public Policy PPT | TEVA_MDL_A_01088049 | TEVA_MDL_A_01088074 | | | | | | | |
| TE-641 | 07/20/2017 | Government Affairs and Public Policy at Teva | TEVA_MDL_A_01088358 | TEVA_MDL_A_01088358 | | | | | | | |
| TE-642 | 02/28/2013 | Exit Meeting Presentation for OIG – “OIG Site Visit – February 28, 2013 – Compliance Program Overview | TEVA_MDL_A_00774868 | TEVA_MDL_A_00774913 | | | | | | | |
| TE-643 | 08/03/2017 | Consultants and Consulting Services Spreadsheet | TEVA_MDL_A_13253980 | TEVA_MDL_A_13253988 | | | | | | | |
| TE-644 | 07/10/2013 | Integrity In Focus: Products and Promotion | TEVA_MDL_A_00772936 | TEVA_MDL_A_00773149 | | | | | | | |
| TE-645 | 08/10/2015 | Teva U.S. Specialty Medicines Compliance Policy Manual | TEVA_MDL_A_00787206 | TEVA_MDL_A_00787332 | | | | | | | |
| TE-646 | 01/01/2015 | Teva 2015 Organizational Chart | TEVA_MDL_A_00537729 | TEVA_MDL_A_00538894 | | | | | | | |
| TE-647 | 02/26/2018 | Example of Letter of Independence | TEVA_MDL_A_01090282 | TEVA_MDL_A_01090286 | | | | | | | |
| TE-648 | 09/07/2015 | Teva SOP on US Medical Education Grants | TEVA_MDL_A_01090293 | TEVA_MDL_A_01090303 | | | | | | | |
| TE-649 | 08/04/2015 | Grant Review Check List | TEVA_MDL_A_01090304 | TEVA_MDL_A_01090307 | | | | | | | |
| TE-650 | 08/01/2013 | US Policy-205 – Independent Medical Education Grants | TEVA_MDL_A_01090487 | TEVA_MDL_A_01090492 | | | | | | | |
| TE-651 | 10/27/2014 | Template Letter of Agreement - Educational Programs | TEVA_MDL_A_01178682 | TEVA_MDL_A_01178683 | | | | | | | |
| TE-652 | 02/27/2015 | Educational grant to support a live program for clinicians about the needs of patients with common pain disorders titled “2015 Essential Tools for Treating the Patient in Pain.” | TEVA_MDL_A_01529685 | TEVA_MDL_A_01529685 | | | | | | | |
| TE-653 | 12/01/2016 | Fentora Label | TEVA_MDL_A_13747313 | TEVA_MDL_A_13747335 | | | | | | | |
| TE-654 | 12/01/2016 | Fentanyl Buccal Tablets Label | TEVA_MDL_A_13746820 | TEVA_MDL_A_13746846 | | | | | | | |
| TE-655 | 07/01/2012 | Teva Medical Science Liaison Policy (US Policy-210), (Jul. 2012) | TEVA_MDL_A_00553127 | TEVA_MDL_A_00553131 | | | | | | | |
| TE-656 | 07/01/2012 | Teva Medical Information Request Monitoring (Compliance Procedure-300)(Jul. 2012) | TEVA_MDL_A_00553125 | TEVA_MDL_A_00553126 | | | | | | | |
| TE-657 | 07/01/2012 | Submission of Medical Requests US Policy - 215 | TEVA_MDL_A_00553161 | TEVA_MDL_A_00553162 | | | | | | | |
| TE-658 | 12/20/2011 | Regulatory Affairs Project Update | TEVA_MDL_A_00990906 | TEVA_MDL_A_00990912 | | | | | | | |
| TE-659 | 11/13/2018 | Transcript of FDA Commissioner Scott Gottlieb’s speech on November 13, 2018 | TEVA_MDL_A_13743890 | TEVA_MDL_A_13743897 | | | | | | | |
| TE-661 | 05/16/2017 | Postoperative Opioid Prescribing and the Pain Scores on Hospital Consumer Assessment of Healthcare Providers and Systems Survey, JAMA | TEVA_MDL_A_13763517 | TEVA_MDL_A_13763519 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-662 | 02/10/2015 | Letter from Grant Erdel to the Honorable Joseph Crisco and the Honorable Robert Megna re: support for SB 21, An Act concerning health insurance coverage of abuse-deterrent opioid analgesics | TEVA_MDL_A_00694928 | TEVA_MDL_A_00694929 | | | | | | | |
| TE-663 | 07/28/2011 | Discussion with the Office of the Vice President of the United States | TEVA_MDL_A_01086959 | TEVA_MDL_A_01086988 | | | | | | | |
| TE-664 | 05/08/2017 | US Government Affairs Strategic Plan | TEVA_MDL_A_01087400 | TEVA_MDL_A_01087400 | | | | | | | |
| TE-665 | 07/04/2013 | Rx Drug Abuse: Teva Alliance with Cardinal Health and CVS Caremark | TEVA_MDL_A_01088104 | TEVA_MDL_A_01088106 | | | | | | | |
| TE-666 | 02/24/2015 | NTE [New Therapeutic Entities] Interview with Ed Silverman | TEVA_MDL_A_01088126 | TEVA_MDL_A_01088127 | | | | | | | |
| TE-667 | 02/06/2014 | Issue Brief: Rx Abuse | TEVA_MDL_A_01088297 | TEVA_MDL_A_01088303 | | | | | | | |
| TE-668 | 07/09/2013 | Introduction to the "Alliance" (Members: CVS-Caremark, Cardinal Health, Teva, AMA, NCPA) | TEVA_MDL_A_01088400 | TEVA_MDL_A_01088400 | | | | | | | |
| TE-669 | 04/02/2014 | Prescription Drug Abuse: Public Health Approach to Addressing the Epidemic and Preserving Access to Treatment for Chronic Pain | TEVA_MDL_A_01088419 | TEVA_MDL_A_01088420 | | | | | | | |
| TE-670 | 03/11/2013 | Position Statement: Abuse Deterrence and Generic Market Entry | TEVA_MDL_A_01088574 | TEVA_MDL_A_01088574 | | | | | | | |
| TE-671 | 03/15/2013 | Letter from Penny Levin re: Draft guidance for industry on "abuse deterrent opioids - evaluation and labeling" | TEVA_MDL_A_01088619 | TEVA_MDL_A_01088622 | | | | | | | |
| TE-672 | 10/15/2015 | Statement for the Record Submitted by Teva Pharmaceuticals: Senate Finance Subcommittee on Health Care Field Hearing: Examining Heroin and Opiate Abuse in Southwestern Pennsylvania | TEVA_MDL_A_01088623 | TEVA_MDL_A_01088625 | | | | | | | |
| TE-673 | 12/06/2015 | What Is Teva Doing to Help Address the Opioid Abuse Epidemic in the U.S.? (draft) | TEVA_MDL_A_01088696 | TEVA_MDL_A_01088697 | | | | | | | |
| TE-674 | 09/13/2018 | Legal HCP Opioids Commercial_2007 to 2017_All values.xlsx | TEVA_MDL_A_03413816 | TEVA_MDL_A_03413816 | | | | | | | |
| TE-675 | 02/26/2019 | Statement from FDA Commissioner Scott Gottlieb, M.D. on the Agencys 2019.pdf | TEVA_MDL_A_13745160 | TEVA_MDL_A_13745169 | | | | | | | |
| TE-676 | 07/29/2019 | Deposition by Written Questions of Valli Baldassano | | | | | | | | | |
| TE-677 | 05/17/2007 | Board of Directors Meeting | TEVA_MDL_A_06654815 | TEVA_MDL_A_06655042 | | | | | | | |
| TE-678 | 09/00/2012 | PCS Home Study Training Guide | TEVA_MDL_A_02396899 | TEVA_MDL_A_02396919 | | | | | | | |
| TE-679 | 04/29/2008 | email from M. Morreale | TEVA_MDL_A_07244892 | TEVA_MDL_A_07244893 | | | | | | | |
| TE-680 | Undated | IQVIA data | TEVA_MDL_A_02416209 | TEVA_MDL_A_02416209 | | | | | | | |
| TE-681 | Undated | IQVIA data | TEVA_MDL_A_03413818 | TEVA_MDL_A_03413818 | | | | | | | |
| TE-682 | Undated | IQVIA data | TEVA_MDL_A_08677335 | TEVA_MDL_A_08677335 | | | | | | | |
| TE-683 | 00/00/2006 | Drug Enforcement Administration 2006 Practitioner's Manual | TEVA_MDL_A_13749277 | TEVA_MDL_A_13749338 | | | | | | | |
| TE-684 | 10/06/2010 | Role of Authorized Agents in Communicating Controlled Substance Prescriptions to Pharmacies | TEVA_MDL_A_13754779 | TEVA_MDL_A_13754783 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---|---|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-685 | Undated | Lisa Kohler Deposition Exhibit 5: PowerPoint Slides Entitled "Forensic Medicine and the Community, What is Forensic Medicine and How Does it Enhance our Community" | | | | | | | | | |
| TE-686 | 09/01/2014 | Cynthia Weiskittle Deposition Exhibit 7: September 2014 white paper published by Child Welfare Opiate Engagement Project | | | | | | | | | |
| TE-688 | 04/17/2014 | April 17, 2014 report "Ohio's Prescription Drug Overdose Epidemic: Epidemiology, Contributing Factors and Ongoing Prevention efforts" | CUYAH_001547662 | CUYAH_001547725 | | | | | | | |
| TE-694 | 00/00/2014 | OARRS Training | BOP_MDL072649 | BOP_MDL072714 | | | | | | | |
| TE-695 | 10/30/2012 | Email from M. Pallo to E. Griffin | BOP_MDL103450 | BOP_MDL103450 | | | | | | | |
| TE-696 | 10/29/2012 | Email from C. Reed to E. Griffin | BOP_MDL103451 | BOP_MDL103451 | | | | | | | |
| TE-697 | 10/01/2016 | Order of the Ohio State Board of Pharmacy | BOP_MDL113537 | BOP_MDL113551 | | | | | | | |
| TE-698 | 02/15/2012 | Order of the Ohio State Board of Pharmacy | BOP_MDL209035 | BOP_MDL209043 | | | | | | | |
| TE-699 | 08/06/2013 | Minutes of the August 6, 2013 Ohio State Board of Pharmacy | BOP_MDL212264 | BOP_MDL212275 | | | | | | | |
| TE-700 | 01/29/2018 | OHBOP DEA 106 Forms Jan. 2017-Dec 2017 | BOP_MDL417771 | BOP_MDL417771 | | | | | | | |
| TE-701 | 05/08/2013 | Minutes of the May 6-8, 2013 Ohio State Board of Pharmacy | BOP_MDL470388 | BOP_MDL470426 | | | | | | | |
| TE-702 | 10/18/2012 | Pharmacy Board Insider newsletter | BOP_MDL643725 | BOP_MDL643730 | | | | | | | |
| TE-704 | | Cuyahoga County Medical Examiner Data | CUYAH_000134580 | CUYAH_016502694 | | | | | | | |
| TE-705 | | Ohio Board of Pharmacy Data | BOP_MDL 1st Production_000001 BOP_MDL_ 2nd Production_000001 BOP_MDL 5th Production_000001 BOP_MDL000001 OBPM_MDL_000000001 Ohio BOP 00000001 OhioPharmMins_0000001 | BOP_MDL_ 1st Production_012552 BOP_MDL 2nd Production_012954 BOP_MDL 5th Production_000044 BOP_MDL999749 OBPM_MDL_000000199 Ohio BOP 00012557 OhioPharmMins_0000199 | | | | | | | |
| TE-706 | | Ohio State Medical Board Data | Ohio_State_Medical_Board_00000001 | Ohio_State_Medical_Board_00100791 | | | | | | | |
| TE-707 | | Summit County Medical Examiner Data | SUMMIT_000016567 | SUMMIT_002103713 | | | | | | | |
| TE-708 | 06/10/2014 | Ohio State Board of Pharmacy Settlement Agreement | Ohio BOP 00005186 | Ohio BOP 00005188 | | | | | | | |
| TE-709 | 03/15/2018 | Ohio State Board of Pharmacy Order | Ohio BOP 00005576 | Ohio BOP 00005581 | | | | | | | |
| TE-710 | 10/24/2017 | Order of the Ohio State Board of Pharmacy | Ohio BOP 00009811 | Ohio BOP 00009815 | | | | | | | |
| TE-711 | 09/17/2009 | Order of the Ohio State Board of Pharmacy | Ohio BOP 00010295 | Ohio BOP 00010299 | | | | | | | |
| TE-712 | 10/06/2014 | Ohio Board of Pharmacy Meeting Minutes, October 2014 | BOP_MDL098390 | BOP_MDL098432 | | | | | | | |
| TE-713 | 03/02/2015 | Pharmacy Board meeting minutes, 2015 | BOP_MDL177101 | BOP_MDL177135 | | | | | | | |
| TE-714 | 03/02/2015 | Pharmacy Board meeting minutes, 2015 | BOP_MDL178752 | BOP_MDL178785 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|-----------------------------|---|-----------------------------------|-----------------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-715 | 10/19/2012 | Pharmacy Board order finding M. Mastramico, intern, stole drugs from his employer for personal use | BOP_MDL208345 | BOP_MDL208351 | | | | | | | |
| TE-716 | 09/10/2012 | Pharmacy Board Meeting Minutes, 2012 | BOP_MDL208353 | BOP_MDL208392 | | | | | | | |
| TE-717 | 10/05/2012 | Draft pharmacy board meeting minutes, 2012 | BOP_MDL208405 | BOP_MDL208442 | | | | | | | |
| TE-718 | 09/10/2012 | Pharmacy Board meeting minutes, 2012 | BOP_MDL208443 | BOP_MDL208476 | | | | | | | |
| TE-719 | 09/10/2012 | OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse | BOP_MDL208707 | BOP_MDL208737 | | | | | | | |
| TE-720 | 01/08/2013 | OHBOP order re pharmacist H. Fletcher, drug trafficking | BOP_MDL208873 | BOP_MDL208886 | | | | | | | |
| TE-721 | 09/10/2012 | OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse | BOP_MDL208943 | BOP_MDL208978 | | | | | | | |
| TE-722 | 09/10/2012 | OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse | BOP_MDL211299 | BOP_MDL211304 | | | | | | | |
| TE-723 | 09/10/2012 | OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse | BOP_MDL212128 | BOP_MDL212161 | | | | | | | |
| TE-724 | 09/10/2012 | OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse | BOP_MDL212162 | BOP_MDL212195 | | | | | | | |
| TE-726 | 03/02/2015 | OHBOP orders re various pharmacists for diversion and drug abuse | BOP_MDL450035 | BOP_MDL450068 | | | | | | | |
| TE-727 | 07/11/2012 | OHBOP packet re various pharmacists, drug abuse and diversion | BOP_MDL465725 | BOP_MDL465790 | | | | | | | |
| TE-728 | 03/03/2008 | OHBOP order re pharmacist R. Colosimo, diversion and drug abuse | BOP_MDL466034 | BOP_MDL466070 | | | | | | | |
| TE-729 | 05/24/2012 | OHBOP orders re various pharmacists for diversion and drug abuse | BOP_MDL466266 | BOP_MDL466298 | | | | | | | |
| TE-730 | Not specified; January 2014 | Consent Agreement Ohio Board of Nursing | OBN_MDL 1st Production 040844 | OBN_MDL 1st Production 043085 | | | | | | | |
| TE-733 | 12/01/2017 | Letter from Ohio State Board of Pharmacy to Amy Wildermuth Re: summary suspension order/notice of opportunity for hearing | Ohio BOP 00003054 | Ohio BOP 00003057 | | | | | | | |
| TE-734 | 07/09/2008 | State Medical Board of Ohio Meeting Agenda | Ohio_State_Medical_Board_00007729 | Ohio_State_Medical_Board_00009059 | | | | | | | |
| TE-735 | 12/14/2011 | State Medical Board of Ohio Meeting Agendas and Minutes | Ohio_State_Medical_Board_00053026 | Ohio_State_Medical_Board_00053913 | | | | | | | |
| TE-736 | 07/10/2013 | State Medical Board of Ohio Meeting Agendas and Minutes | Ohio_State_Medical_Board_00064842 | Ohio_State_Medical_Board_00065318 | | | | | | | |
| TE-737 | 01/08/2014 | State Medical Board of Ohio; Agenda; Assigned Committees | Ohio_State_Medical_Board_00067975 | Ohio_State_Medical_Board_00068510 | | | | | | | |
| TE-738 | 08/13/2014 | State Medical Board of Ohio; Agenda; Assigned Committees | Ohio_State_Medical_Board_00071371 | Ohio_State_Medical_Board_00072096 | | | | | | | |
| TE-739 | 11/09/2016 | State Medical Board of Ohio meeting packet, Assigned Committees | Ohio_State_Medical_Board_00083377 | Ohio_State_Medical_Board_00083740 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|-----------------------------------|-----------------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-740 | 01/11/2017 | State Medical Board of Ohio meeting packet, Assigned Committees | Ohio_State_Medical_Board_00084019 | Ohio_State_Medical_Board_00084508 | | | | | | | |
| TE-741 | 02/10/2010 | State Pharmacy Board order | BOP_MDL122386 | BOP_MDL122394 | | | | | | | |
| TE-742 | 07/06/1998 | OHBOP orders re various pharmacists for diversion and drug abuse | BOP_MDL211669 | BOP_MDL212072 | | | | | | | |
| TE-743 | 12/06/2004 | OHBOP order re pharmacist D. Hart, diversion and drug abuse | BOP_MDL212377 | BOP_MDL212400 | | | | | | | |
| TE-744 | 03/05/2001 | OHBOP orders re various pharmacists for diversion and drug abuse | BOP_MDL465897 | BOP_MDL465935 | | | | | | | |
| TE-745 | 04/08/2002 | OHBOP orders re various pharmacists for diversion and drug abuse | BOP_MDL465936 | BOP_MDL465962 | | | | | | | |
| TE-746 | 08/02/2010 | Minutes of the August 2-3, 2010 Ohio State Board of Pharmacy and announcement of settlement agreements re diversion | BOP_MDL466071 | BOP_MDL466103 | | | | | | | |
| TE-747 | 03/08/1999 | OHBOP orders re various pharmacists for diversion and drug abuse | BOP_MDL466151 | BOP_MDL466181 | | | | | | | |
| TE-748 | 07/11/2012 | OHBOP Order re pharmacist H. Ridgeway pertaining to prescription drug abuse and diversion | BOP_MDL467172 | BOP_MDL467181 | | | | | | | |
| TE-749 | 04/19/2012 | OH Board of pharmacy Summary Suspension Order | BOP_MDL470482 | BOP_MDL470490 | | | | | | | |
| TE-750 | Undated | Ohio State Dental Board Disciplinary Action | OSDB_MDL 1st Production_004395 | OSDB_MDL 1st Production_004398 | | | | | | | |
| TE-751 | 02/05/2013 | Teva Promotion and Ad Review Process SOP BM-RA-102 (Feb. 5 2013) | TEVA_MDL_A_00553140 | TEVA_MDL_A_00553149 | | | | | | | |
| TE-752 | 07/02/2012 | Teva Policies and Codes of Conduct | TEVA_MDL_A_00560852 | TEVA_MDL_A_00561167 | | | | | | | |
| TE-753 | 05/16/2018 | Summit County Initial Responses to Manufacturer Defendants First Set of Request for Productions | | | | | | | | | |
| TE-754 | 05/16/2018 | Cuyahoga County Initial Responses to Manufacturer Defendants First Set of Request for Productions | | | | | | | | | |
| TE-755 | 05/16/2018 | Cleveland Initial Responses to Manufacturer Defendants First Set of Request for Productions | | | | | | | | | |
| TE-760 | 06/12/2018 | Cuyahoga 1st Amended Responses to Manufacturer Defendant 1st Set of Interrogatories | | | | | | | | | |
| TE-766 | 08/02/2018 | Cleveland Responses to Manufactuer Defendants 2nd Set of Request for Productions | | | | | | | | | |
| TE-767 | 08/02/2018 | Summit_Akron Responses to Manufactuer Defendants 2nd Set of Request for Productions | | | | | | | | | |
| TE-771 | 08/21/2018 | Cleveland Responses to Manufactuer Defendants Amended 2nd Set of Request for Productions | | | | | | | | | |
| TE-773 | 11/02/2018 | Cleveland Rogs updated with SM Cohens Discovery Ruling No_ 5 | | | | | | | | | |
| TE-779 | 11/28/2018 | Cleveland and Cuyahoga Amended Response to Manufacturer Defendant Rog. No. 27 | | | | | | | | | |
| TE-780 | 11/30/2018 | Cuyahoga Written Response to Rule 30b6 Topic No. 36 | | | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-787 | 01/07/2018 | Cleveland Written Response to Defendant Rule 30b6 No 7 & 8 | | | | | | | | | |
| TE-789 | 01/18/2018 | Plaintiffs Supplement Response to Manufacturer Defendants 1st Set of Interrogatories | | | | | | | | | |
| TE-790 | 01/25/2019 | Plaintiffs Amended Response to Discovery Ruling No 12 | | | | | | | | | |
| TE-793 | 03/04/2019 | Plaintiffs Response to Manufacturer Defendants 4th Set of Interrogatories | | | | | | | | | |
| TE-802 | 05/29/2019 | Plaintiffs Written Responses to Defendants Rule 30b6 Rule - Topics 4_5_6_19 | | | | | | | | | |
| TE-809 | 10.31.2019 | Cuyahoga Responses Retail Pharma to 1st Set of Rog and Distributor Defendant to 4th Set of Rogs | | | | | | | | | |
| TE-810 | 10.31.2018 | Cuyahoga Amended Responses to Retail Pharma 1st Set of Rog and Distributor Defendants 4th Set of Rog | | | | | | | | | |
| TE-820 | 12.17.2018 | Akron Supplemental Responses to Distributor Defendants Interrogatories No. 24-27 | | | | | | | | | |
| TE-822 | 12.14.2018 | Plaintiffs Supplemental Response to Distributor Defendants Rog. Nos. 24-27 | | | | | | | | | |
| TE-829 | 10.31.2018 | Cuyahoga Amended Responses to Retail Pharma 1st Set of Rog and Distributor Defendants 4th Set of Rog | | | | | | | | | |
| TE-830 | 10.31.2018 | Cuyahoga Responses Retail Pharma to 1st Set of Rog and Distributor Defendant to 4th Set of Rogs | | | | | | | | | |
| TE-839 | 08.13.2018 | Cuyahoga 1st Amended Responses Distributor Defendants 3rd Set of Interrogatories | | | | | | | | | |
| TE-841 | 08.10.2018 | Clevelands Amended Responses and Objections to Distributor Defendants Request for Production No. 13-17 and 19-22 | | | | | | | | | |
| TE-844 | 07.24.2018 | Summit_Akron Responses to Distributor Defendants Second Set of Request for Production | | | | | | | | | |
| TE-846 | 07.23.2018 | Cleveland Response to Distributor Defendants 3rd Set of Interrogatories | | | | | | | | | |
| TE-852 | 06.18.2018 | Cleveland 1st Amended Response to Distributor Defendants 1st Set of Interrogatories | | | | | | | | | |
| TE-861 | 03/04/2019 | Distributor Defendants Report in Support of Partial Objection to Discovery Ruling No. 17 Regarding SACWIS DATA | | | | | | | | | |
| TE-862 | 10/27/2005 | ACTIQ 2006 Marketing Plan | TEVA_MDL_A_03235020 | TEVA_MDL_A_03235128 | | | | | | | |
| TE-863 | 05/19/2014 | Teva DNC Exemption Process (5/19/2014) | TEVA_MDL_A_00977184 | TEVA_MDL_A_00977186 | | | | | | | |
| TE-864 | 04/15/2014 | Teva Do Not Call (DNC) Form Pain Care | TEVA_MDL_A_01086432 | TEVA_MDL_A_01086433 | | | | | | | |
| TE-865 | 07/01/2012 | Targeting Assessment and Call Activity US Policy - 165 | TEVA_MDL_A_00553163 | TEVA_MDL_A_00553165 | | | | | | | |
| TE-866 | 01/16/2014 | Email removing prescriber | TEVA_MDL_A_00977857 | TEVA_MDL_A_00977859 | | | | | | | |
| TE-867 | 05/01/2012 | FENTORA Brand Review (May, 2012) | TEVA_MDL_A_02970485 | TEVA_MDL_A_02970485 | | | | | | | |
| TE-868 | 01/01/2013 | Fast Start Meeting (Jan. 2013). | TEVA_MDL_A_00978659 | TEVA_MDL_A_00978659 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-869 | 01/19/2012 | A Brand New Day: TEVA Pain Care 180-Day Plan, January – June 2012 | TEVA_MDL_A_01108365 | TEVA_MDL_A_01108365 | | | | | | | |
| TE-870 | 00/00/2012 | 2012 FENTORA Brand Plan | TEVA_MDL_A_02767253 | TEVA_MDL_A_02767266 | | | | | | | |
| TE-871 | 02/22/2008 | 2008 National Sales Meeting Presentation | TEVA_MDL_A_03222359 | TEVA_MDL_A_03222408 | | | | | | | |
| TE-872 | 01/08/2007 | PCS Sales Leadership Kick-Off Meeting (Jan 2007) | TEVA_MDL_A_03228476 | TEVA_MDL_A_03228566 | | | | | | | |
| TE-873 | 09/12/2019 | Facilitator Guide - Fentora Finishing the Call Workshop | TEVA_MDL_A_01156937 | TEVA_MDL_A_01156961 | | | | | | | |
| TE-874 | 03/17/2014 | FENTORA (fentanyl buccal tablet) CII Regional Brand Plan | TEVA_MDL_A_08680767 | TEVA_MDL_A_08680785 | | | | | | | |
| TE-875 | 07/01/2012 | Integrity Principles Policy US Policy - 100 | TEVA_MDL_A_00553193 | TEVA_MDL_A_00553217 | | | | | | | |
| TE-876 | | Teva 2014 North America Specialty Medicines President's Club Awards (2014) | TEVA_MDL_A_01086541 | TEVA_MDL_A_01086768 | | | | | | | |
| TE-878 | 02/07/2007 | DEA Letter to all entities re controlled substance distribution. | TEVA_MDL_A_01039159 | TEVA_MDL_A_01039162 | | | | | | | |
| TE-879 | 09/27/2006 | DEA Letter to All Entities re Responsibilities of Controlled Substance Distribution (Sept. 27, 2006) | TEVA_MDL_A_01039163 | TEVA_MDL_A_01039166 | | | | | | | |
| TE-880 | 12/27/2007 | DEA Letter to All Entities re Responsibilities of Controlled Substance Distribution (December 27, 2007) | TEVA_MDL_A_01039167 | TEVA_MDL_A_01039168 | | | | | | | |
| TE-881 | 03/05/2013 | SORDS Summary | TEVA_MDL_A_01042796 | TEVA_MDL_A_01042796 | | | | | | | |
| TE-882 | 02/19/2013 | Teva SOM Policy Statement | TEVA_MDL_A_01042821 | TEVA_MDL_A_01042821 | | | | | | | |
| TE-883 | 01/23/2013 | SORDS - Orders on DEA Hold (screen shots of system) | TEVA_MDL_A_01042832 | TEVA_MDL_A_01042844 | | | | | | | |
| TE-884 | 01/01/2014 | Teva - SOM - SORDS PowerPoint 2014 | TEVA_MDL_A_01042847 | TEVA_MDL_A_01042847 | | | | | | | |
| TE-885 | 01/16/2018 | 2018-01-16 RDC Rochester Suspicious Order Report.docx | TEVA_MDL_A_01057584 | TEVA_MDL_A_01057585 | | | | | | | |
| TE-886 | 11/04/2013 | Teva SOM - Data Tables/Forms to Be Created with Algorithms in SORDS III | TEVA_MDL_A_01060887 | TEVA_MDL_A_01060887 | | | | | | | |
| TE-887 | 01/27/2014 | Teva SOM - SORDS III Option 1 Flow Chart | TEVA_MDL_A_01060888 | TEVA_MDL_A_01060891 | | | | | | | |
| TE-888 | 11/04/2013 | Teva SOM - SORDS III Proposed Flow Chart | TEVA_MDL_A_01060892 | TEVA_MDL_A_01060894 | | | | | | | |
| TE-889 | 05/09/2014 | Controlled Substance SOM SORDS III User Requirements | TEVA_MDL_A_01060897 | TEVA_MDL_A_01060914 | | | | | | | |
| TE-890 | 08/01/2014 | TEVA SOP 8278 -(Do Not Ship List) (Aug. 01, 2014), | TEVA_MDL_A_01061094 | TEVA_MDL_A_01061098 | | | | | | | |
| TE-891 | 08/08/2014 | TEVA SOP-8277 (DEA Order Holds) (Aug 8 2014) | TEVA_MDL_A_01061099 | TEVA_MDL_A_01061106 | | | | | | | |
| TE-892 | 08/01/2014 | TEVA SOP-8279 (Customer Due Diligence)(Aug. 1 2014) | TEVA_MDL_A_01061107 | TEVA_MDL_A_01061113 | | | | | | | |
| TE-893 | 08/01/2014 | TEVA SOP-8280 -(Customer Site Visits) (Aug. 01, 2014), | TEVA_MDL_A_01061114 | TEVA_MDL_A_01061119 | | | | | | | |
| TE-894 | 06/18/2018 | TEVA SOP-8277 (DEA Order Holds) (Jun 18 2018) | TEVA_MDL_A_01158453 | TEVA_MDL_A_01158462 | | | | | | | |
| TE-895 | 06/18/2018 | TEVA SOP 8278 (Do Not Ship List) (June 18, 2018). | TEVA_MDL_A_01158463 | TEVA_MDL_A_01158469 | | | | | | | |
| TE-896 | 06/18/2018 | TEVA SOP 8279 (Customer Due Diligence (Jun. 18 2018) | TEVA_MDL_A_01158470 | TEVA_MDL_A_01158478 | | | | | | | |
| TE-897 | 06/18/2018 | TEVA SOP-8280 -(Customer Site Visits) (June 18, 2018). | TEVA_MDL_A_01158479 | TEVA_MDL_A_01158490 | | | | | | | |
| TE-898 | 06/18/2018 | TEVA SOP-8489 (Jun 18 2018) | TEVA_MDL_A_01158491 | TEVA_MDL_A_01158495 | | | | | | | |
| TE-899 | 03/21/2013 | 2011 Quota Req and DEA Response Pac 1.pdf | TEVA_MDL_A_01087583 | TEVA_MDL_A_01087637 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-900 | 03/21/2013 | 2011 Quota Req and DEA Response Pac 2.pdf | TEVA_MDL_A_01087638 | TEVA_MDL_A_01087683 | | | | | | | |
| TE-901 | 03/21/2013 | 2012 Quota Req and DEA Response Pac 1.pdf | TEVA_MDL_A_01087684 | TEVA_MDL_A_01087741 | | | | | | | |
| TE-902 | 12/23/2011 | Barr Laboratories RB0234005 12-22-2011.pdf | TEVA_MDL_A_02541088 | TEVA_MDL_A_02541089 | | | | | | | |
| TE-903 | 01/09/2012 | 2012 SV Quota Approval Methylphen 22Dec2011.pdf | TEVA_MDL_A_07219437 | TEVA_MDL_A_07219438 | | | | | | | |
| TE-904 | 03/20/2012 | 2012 SV Quota Approval Codeine 19Mar2012.pdf | TEVA_MDL_A_07219534 | TEVA_MDL_A_07219535 | | | | | | | |
| TE-905 | 12/14/2012 | 2012 VA Quota Approval D L Amphet 09Oct2012.pdf | TEVA_MDL_A_07219822 | TEVA_MDL_A_07219823 | | | | | | | |
| TE-906 | 12/19/2012 | 2012 VA Quota Denial D Amphet 09Oct2012.pdf | TEVA_MDL_A_07219886 | TEVA_MDL_A_07219887 | | | | | | | |
| TE-907 | 02/08/2013 | 2012 VA Quota App Morphine 19Sept2012, 113470.pdf | TEVA_MDL_A_07220078 | TEVA_MDL_A_07220085 | | | | | | | |
| TE-908 | 06/26/2013 | 2012 PO Quota Approval Amphet 13Jan2012.pdf | TEVA_MDL_A_07220343 | TEVA_MDL_A_07220344 | | | | | | | |
| TE-909 | 11/15/2013 | 2011 Quota Req and DEA Response Pac 1.pdf | TEVA_MDL_A_07228652 | TEVA_MDL_A_07228706 | | | | | | | |
| TE-910 | 11/15/2013 | 2011 Quota Req and DEA Response Pac 2.pdf | TEVA_MDL_A_07228762 | TEVA_MDL_A_07228807 | | | | | | | |
| TE-911 | 11/15/2013 | 2012 Quota Req and DEA Response Pac 1.pdf | TEVA_MDL_A_07228854 | TEVA_MDL_A_07228911 | | | | | | | |
| TE-912 | 11/15/2013 | 2012 Quota Req and DEA Response Pac 2.pdf | TEVA_MDL_A_07228970 | TEVA_MDL_A_07229022 | | | | | | | |
| TE-913 | 08/16/2011 | TEVA Pharmaceuticals USA RL0146274 08-12-11.PDF | TEVA_MDL_A_13734192 | TEVA_MDL_A_13734192 | | | | | | | |
| TE-914 | 12/15/2011 | Barr Labs RB0234005 12-15-11.pdf | TEVA_MDL_A_13734200 | TEVA_MDL_A_13734200 | | | | | | | |
| TE-915 | 12/23/2011 | Barr Laboratories RB0234005 12-22-2011.pdf | TEVA_MDL_A_13734211 | TEVA_MDL_A_13734212 | | | | | | | |
| TE-916 | 12/23/2011 | Teva RL0146274 PQ 12-22-11.PDF | TEVA_MDL_A_13734216 | TEVA_MDL_A_13734217 | | | | | | | |
| TE-917 | 03/20/2012 | TEVA Pharmaceuticals USA RL0146274 - 03-19-12.PDF | TEVA_MDL_A_13734232 | TEVA_MDL_A_13734233 | | | | | | | |
| TE-918 | 04/18/2012 | Teva Pharmaceuticals_RL0146274_04-17-2012.pdf | TEVA_MDL_A_13734254 | TEVA_MDL_A_13734255 | | | | | | | |
| TE-919 | 09/13/2012 | Barr Laboratories RB0234005 09-12-2012.pdf | TEVA_MDL_A_13734273 | TEVA_MDL_A_13734273 | | | | | | | |
| TE-920 | 07/13/2012 | Cima Laboratories Inc RC0243256 - 07-12-12.PDF | TEVA_MDL_A_13734460 | TEVA_MDL_A_13734460 | | | | | | | |
| TE-921 | 08/16/2012 | Cima Labs RC0243256 08-16-2012.pdf | TEVA_MDL_A_13734497 | TEVA_MDL_A_13734497 | | | | | | | |
| TE-922 | 06/19/2018 | 2018 Releases Second Check.xlsx | TEVA_MDL_A_13253974 | TEVA_MDL_A_13253974 | | | | | | | |
| TE-923 | 06/07/2018 | Holds by Ship To.xlsx | TEVA_MDL_A_13253975 | TEVA_MDL_A_13253975 | | | | | | | |
| TE-924 | 06/07/2018 | Holds Over Time.xlsx | TEVA_MDL_A_13253976 | TEVA_MDL_A_13253976 | | | | | | | |
| TE-925 | 06/19/2018 | 2017 Releases Second Check.xlsx | TEVA_MDL_A_13253977 | TEVA_MDL_A_13253977 | | | | | | | |
| TE-926 | 12/14/2018 | SORDS Pended Orders | TEVA_MDL_A_13583538 | TEVA_MDL_A_13583538 | | | | | | | |
| TE-927 | 12/12/2018 | SOM Customer Risk Evaluation Database.xlsx | TEVA_MDL_A_13253978 | TEVA_MDL_A_13253978 | | | | | | | |
| TE-928 | 12/12/2018 | 2018-12-12 OM DEA Suspicious Order Monitoring.xlsx | TEVA_MDL_A_13253979 | TEVA_MDL_A_13253979 | | | | | | | |
| TE-929 | 02/13/2013 | 2018-12-13 OM DEA Suspicious Order Monitoring.xlsx | TEVA_MDL_A_13583539 | TEVA_MDL_A_13583539 | | | | | | | |
| TE-930 | 05/08/2017 | Suspicious Order Report Re: Capital Wholesale | TEVA_MDL_A_01463918 | TEVA_MDL_A_01463918 | | | | | | | |
| TE-931 | 05/08/2017 | Suspicious Order Report | TEVA_MDL_A_01056166 | TEVA_MDL_A_01056171 | | | | | | | |
| TE-932 | 05/08/2017 | 2015-04-18 Osborn Suspicious Order Report.docx | TEVA_MDL_A_01056173 | TEVA_MDL_A_01056173 | | | | | | | |
| TE-933 | 04/16/2018 | 2015-07-31 Osborn Suspicious Order Report.docx | TEVA_MDL_A_01056175 | TEVA_MDL_A_01056175 | | | | | | | |
| TE-934 | 04/16/2018 | 2018-01-16 RDC Fairfield Suspicious Order Report.docx | TEVA_MDL_A_01057586 | TEVA_MDL_A_01057587 | | | | | | | |
| TE-935 | 04/16/2018 | 2018-01-17 RDC Fairfield Suspicious Order Report.docx | TEVA_MDL_A_01057590 | TEVA_MDL_A_01057591 | | | | | | | |
| TE-936 | 04/16/2018 | 2018-01-18 RDC Rochester Suspicious Order Report.docx | TEVA_MDL_A_01057593 | TEVA_MDL_A_01057594 | | | | | | | |
| TE-937 | 04/16/2018 | 2018-01-23 RDC Fairfield Suspicious Order Report.docx | TEVA_MDL_A_01057596 | TEVA_MDL_A_01057597 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-938 | 04/16/2018 | 2018-01-23 RDC Rochester Suspicious Order Report.docx | TEVA_MDL_A_01057598 | TEVA_MDL_A_01057599 | | | | | | | |
| TE-939 | 04/16/2018 | 2018-02-06 RDC Fairfield Suspicious Order Report.docx | TEVA_MDL_A_01057601 | TEVA_MDL_A_01057601 | | | | | | | |
| TE-940 | 04/16/2018 | 2018-02-06 RDC Rochester Suspicious Order Report.docx | TEVA_MDL_A_01057602 | TEVA_MDL_A_01057602 | | | | | | | |
| TE-941 | 04/16/2018 | 2018-02-07 RDC Rochester Suspicious Order Report.docx | TEVA_MDL_A_01057604 | TEVA_MDL_A_01057604 | | | | | | | |
| TE-942 | 04/16/2018 | 2018-02-13 RDC Rochester Suspicious Order Report.docx | TEVA_MDL_A_01057606 | TEVA_MDL_A_01057606 | | | | | | | |
| TE-943 | 04/16/2018 | 2018-02-15 RDC Rochester Suspicious Order Report.docx | TEVA_MDL_A_01057608 | TEVA_MDL_A_01057608 | | | | | | | |
| TE-944 | 01/16/2018 | 2018-03-30 RDC Fairfield Suspicious Order Report.docx | TEVA_MDL_A_01057612 | TEVA_MDL_A_01057612 | | | | | | | |
| TE-945 | 01/17/2018 | 2018-01-16 RDC Rochester Suspicious Order Report.docx | TEVA_MDL_A_01058103 | TEVA_MDL_A_01058104 | | | | | | | |
| TE-946 | 02/14/2013 | 2018-04-18 R&S Philadelphia Suspicious Order Report.docx | TEVA_MDL_A_01061044 | TEVA_MDL_A_01061045 | | | | | | | |
| TE-947 | 12/01/2014 | DEA Notification Form.doc | TEVA_MDL_A_02331377 | TEVA_MDL_A_02331377 | | | | | | | |
| TE-948 | 08/10/2017 | 2014-12-01 Richie Suspicious Order Report.docx | TEVA_MDL_A_02345901 | TEVA_MDL_A_02345901 | | | | | | | |
| TE-949 | 01/22/2016 | Letter from Joseph Tomkiewicz to Richie Pharmacal | TEVA_MDL_A_01046053 | TEVA_MDL_A_01046053 | | | | | | | |
| TE-950 | 11/21/2014 | Internal Memorandum from Joseph Tomkiewicz to Colleen McGinn | TEVA_MDL_A_02063682 | TEVA_MDL_A_02063685 | | | | | | | |
| TE-951 | 06/25/2015 | Letter from Joseph Tomkiewicz to Drug Enforcement Agency | TEVA_MDL_A_02063701 | TEVA_MDL_A_02063701 | | | | | | | |
| TE-952 | 12/01/2014 | 2014-12-01 Richie Suspicious Order Report.docx | TEVA_MDL_A_02342525 | TEVA_MDL_A_02342525 | | | | | | | |
| TE-953 | 06/04/2015 | TEVA SOP - 8489 | TEVA_MDL_A_03160173 | TEVA_MDL_A_03160175 | | | | | | | |
| TE-954 | 07/08/2014 | Teva Pharmaceuticals North America, Order Management, DEF OPS Enhancements, Functional Design Specification | TEVA_MDL_A_03479111 | TEVA_MDL_A_03479127 | | | | | | | |
| TE-955 | 10/15/2015 | Due diligence documents re: Publix | TEVA_MDL_A_01056233 | TEVA_MDL_A_01056407 | | | | | | | |
| TE-956 | Undated | Due diligence documents re: Publix | TEVA_MDL_A_01056802 | TEVA_MDL_A_01057182 | | | | | | | |
| TE-957 | Undated | SORDS Database Configuration | TEVA_MDL_A_01060884 | TEVA_MDL_A_01060886 | | | | | | | |
| TE-958 | 04/19/2017 | EMED Suspicious Order Report.docx | TEVA_MDL_A_01061035 | TEVA_MDL_A_01061035 | | | | | | | |
| TE-959 | 12/13/2017 | R&S Suspicious Order Report.docx | TEVA_MDL_A_01061036 | TEVA_MDL_A_01061037 | | | | | | | |
| TE-960 | 01/16/2018 | R&S Suspicious Order Report.docx | TEVA_MDL_A_01061038 | TEVA_MDL_A_01061038 | | | | | | | |
| TE-961 | 01/16/2018 | RDC Fairfield Suspicious Order Report.docx | TEVA_MDL_A_01061039 | TEVA_MDL_A_01061040 | | | | | | | |
| TE-962 | 01/16/2018 | RDC Rochester Suspicious Order Report.docx | TEVA_MDL_A_01061041 | TEVA_MDL_A_01061042 | | | | | | | |
| TE-963 | 01/18/2018 | RDC Rochester Suspicious Order Report.docx | TEVA_MDL_A_04205782 | TEVA_MDL_A_04205783 | | | | | | | |
| TE-964 | 03/30/2018 | RDC Fairfield Suspicious Order Report.docx | TEVA_MDL_A_01061043 | TEVA_MDL_A_01061043 | | | | | | | |
| TE-966 | 01/16/2018 | RDC Rochester State Suspicious Order Report.docx | TEVA_MDL_A_01061046 | TEVA_MDL_A_01061047 | | | | | | | |
| TE-967 | 01/18/2018 | RDC Rochester State Suspicious Order Report.docx | TEVA_MDL_A_04205784 | TEVA_MDL_A_04205785 | | | | | | | |
| TE-968 | 10/07/2010 | Timeline of Events Leading Up to the REMS Requirement for Opioid Analgesics, | TEVA_MDL_A_00349300 | TEVA_MDL_A_00349301 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|----------------|------------|--|---------------------------|---------------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-969 | 06/02/2015 | REMS Operations Global Pharmacovigilance & Regulatory Slide Deck | TEVA_MDL_A_01066698 | TEVA_MDL_A_01066698 | | | | | | | |
| TE-970 | 08/03/2018 | TIRF REMS Advisory Committee Briefing Document | TEVA_MDL_A_01089148 | TEVA_MDL_A_01089248 | | | | | | | |
| TE-971 | 01/15/2012 | Teva REMS – Regulatory Affairs Lunch & Learn (Jan 15 2012) | TEVA_MDL_A_03498285 | TEVA_MDL_A_03498285 | | | | | | | |
| TE-972 | Undated | Distributor enrollment form | TEVA_MDL_A_13748755 | TEVA_MDL_A_13748758 | | | | | | | |
| TE-973 | Undated | TIRF REMS Access Education Program for Prescribers and Pharmacists | TEVA_MDL_A_13747107 | TEVA_MDL_A_13747121 | | | | | | | |
| TE-974 | Undated | TIRF REMS Prescriber Enrollment Form | TEVA_MDL_A_13743867 | TEVA_MDL_A_13743869 | | | | | | | |
| TE-975 | Undated | TIRF REMS Patient-Prescriber Agreement Form | TEVA_MDL_A_13750620 | TEVA_MDL_A_13750622 | | | | | | | |
| TE-976 | Undated | TIRF FREMS Corporate Pharmacy Enrollment Form | TEVA_MDL_A_13751497 | TEVA_MDL_A_13751501 | | | | | | | |
| TE-977 | Undated | TIRF REMS Prescriber Enrollees | TEVA_MDL_A_13755784 | TEVA_MDL_A_13755784 | | | | | | | |
| TE-978 | Undated | TIRF REMS Pharmacy Enrollees | TEVA_MDL_A_13748759 | TEVA_MDL_A_13748759 | | | | | | | |
| TE-979 | Undated | TIRF REMS Patient Enrollees | TEVA_MDL_A_13744290 | TEVA_MDL_A_13744290 | | | | | | | |
| TE-980 | Undated | TIRF REMS Prescriptions | TEVA_MDL_A_13751051 | TEVA_MDL_A_13751051 | | | | | | | |
| TE-982 | | TRIG Database of TIRF REMS Access Program Enrollment Forms, Agreements, and Prescription Data | TRIGMDL00000001 | TRIGMDL00355214 | | | | | | | |
| TE-988 | | TIRF REMS Reporting | TEVA_MDL_A_00446500 | TEVA_MDL_A_00446569 | | | | | | | |
| TE-992 | | TIRF REMS Reporting | TEVA_MDL_A_00447807 | TEVA_MDL_A_00448395 | | | | | | | |
| TE-993 | | 24-month REMS Assessment Report | PAR_OPIOID_MDL_0001217772 | PAR_OPIOID_MDL_0001218742 | | | | | | | |
| TE-994 | | TIRF REMS Reporting | INSYS-MDL-015176326 | INSYS-MDL-015176327 | | | | | | | |
| TE-995 | | IMS Xponent | ALLERGAN_MDL_02485011 | ALLERGAN_MDL_02485011 | | | | | | | |
| TE-996 | | IMS Xponent | ALLERGAN_MDL_03281086 | ALLERGAN_MDL_03281086 | | | | | | | |
| TE-998 | 04/01/2018 | 21 C.F.R. § 202.1 | TEVA_MDL_A_13743915 | TEVA_MDL_A_13743925 | | | | | | | |
| TE-999 | 04/01/2018 | 21 C.F.R. § 312.2 | TEVA_MDL_A_13754803 | TEVA_MDL_A_13754805 | | | | | | | |
| TE-1000 | 05/01/2019 | Akinboro, Oladimeji Akinola, Stanley Nwabudike, Camille Edwards, Diana Cirstea, Nana Oduraa Addo-Tabiri, Michael Voisine, . . . Adetola A. Kassim. “Opioid Use Is NOT Associated with in-Hospital Mortality Among Patients with Sickle CELL Disease in the United States: Findings from the National Inpatient Sample.” <i>Blood</i> Vol. 132, Supplement 1: 315 (2018). | TEVA_MDL_A_13745797 | TEVA_MDL_A_13745802 | | | | | | | |
| TE-1001 | 04/11/2018 | Bennett, Daniel S., “Breakthrough Pain: Treatment Rationale With Opioids,” https://www.medscape.org/viewarticle/461612 , accessed April 11, 2018. | TEVA_MDL_A_13745223 | TEVA_MDL_A_13745237 | | | | | | | |
| TE-1003 | 05/00/2011 | Burton, Beth and Giovambattista Zeppetella. “Assessing the impact of breakthrough cancer pain.” <i>British Journal of Nursing</i> Vol. 20, Supplement 5 (2011): pp. S14-S19. | TEVA_MDL_A_13745528 | TEVA_MDL_A_13745532 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1004 | 12/00/2011 | Cephalon, Inc., <i>Special Report: An Integrated Risk Evaluation and Mitigation Strategy for Fentanyl Buccal Tablet (Fentora) and Oral Transmucosal Fentanyl Citrate (Actiq)</i> , 2011. | TEVA_MDL_A_13747854 | TEVA_MDL_A_13747865 | | | | | | | |
| TE-1005 | 12/00/2015 | CMS, <i>Pharmacy Self-Auditing</i> , December 2015. | TEVA_MDL_A_13755688 | TEVA_MDL_A_13755703 | | | | | | | |
| TE-1006 | 00/00/2001 | Collett, B. J. "Chronic opioid therapy for non-cancer pain." <i>British Journal of Anaesthesia</i> Vol. 87, No. 1 (2001): pp. 133-43. | TEVA_MDL_A_13751579 | TEVA_MDL_A_13751589 | | | | | | | |
| TE-1007 | 00/00/2005 | FDA CDER, <i>MAPP 6700.1: Risk Management Activities in OND and ODS, Manual of Policies and Procedures</i> . | TEVA_MDL_A_13747336 | TEVA_MDL_A_13747343 | | | | | | | |
| TE-1008 | 07/12/2018 | FDA, "'Off-Label' and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices - Information Sheet," July 12, 2018, http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm , accessed April 23, 2019. | TEVA_MDL_A_13747677 | TEVA_MDL_A_13747679 | | | | | | | |
| TE-1009 | 04/04/2019 | FDA, "A Guide to Safe Use of Pain Medicine," https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm095673.htm , accessed April 4, 2019. | TEVA_MDL_A_13749339 | TEVA_MDL_A_13749343 | | | | | | | |
| TE-1010 | 09/07/2017 | FDA, "Approved Risk Evaluation and Mitigation Strategies," September 7, 2017, https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm?event=RemisDetails.page&REMS=60 , accessed February 14, 2019. | TEVA_MDL_A_13747044 | TEVA_MDL_A_13747045 | | | | | | | |
| TE-1012 | 02/19/2019 | FDA, "FDA Approved Drug Products, Fentora," https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021947 , accessed February 19, 2019. | TEVA_MDL_A_13743383 | TEVA_MDL_A_13743387 | | | | | | | |
| TE-1013 | 02/13/2019 | FDA, "FDA's Role in Managing Medication Risks," https://www.fda.gov/Drugs/DrugSafety/REMS/ucm592672.htm , accessed February 13, 2019. | TEVA_MDL_A_13744625 | TEVA_MDL_A_13744628 | | | | | | | |
| TE-1014 | 01/13/2009 | FDA, "Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices," January 13, 2009, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-reprint-practices-distribution-medical-journal-articles-and-medical-or-scientific-reference , accessed February 14, 2019. | TEVA_MDL_A_13755642 | TEVA_MDL_A_13755647 | | | | | | | |
| TE-1015 | 00/00/2014 | FDA, "Standardizing and Evaluating Risk Evaluation and Mitigation Strategies," 2014. | TEVA_MDL_A_13745803 | TEVA_MDL_A_13745832 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1016 | 08/03/2018 | FDA, <i>Addendum to the FDA briefing information to summarize TIRF REMS issues relevant to the August 3, 2018 meeting</i> , July 25, 2018. | TEVA_MDL_A_13751607 | TEVA_MDL_A_13751630 | | | | | | | |
| TE-1017 | 00/00/2006 | FDA, <i>An Introduction to the Improved FDA Prescription Drug Labeling</i> , 2006. | TEVA_MDL_A_13747563 | TEVA_MDL_A_13747630 | | | | | | | |
| TE-1018 | 03/00/2005 | FDA, <i>Guidance for Industry, Development and Use of Risk Minimization Action Plans</i> , March 2005. https://www.fda.gov/downloads/drugs/guidancecompliance/regulatoryinformation/guidances/ucm071616.pdf . | TEVA_MDL_A_13744094 | TEVA_MDL_A_13744120 | | | | | | | |
| TE-1019 | 05/00/1999 | FDA, <i>Managing the Risks From Medical Product Use Creating a Risk Management Framework</i> , May 1999. https://hdl.handle.net/2027/umn.31951d016951490 . | TEVA_MDL_A_13743162 | TEVA_MDL_A_13743325 | | | | | | | |
| TE-1020 | 06/00/2018 | FDA, <i>Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers; Guidance for Industry</i> , June 2018. https://www.fda.gov/downloads/drugs/guidancecompliance/regulatoryinformation/guidances/ucm537130.pdf . | TEVA_MDL_A_13743944 | TEVA_MDL_A_13743966 | | | | | | | |
| TE-1021 | 04/00/1982 | FDA. “Use of Approved Drugs for Unlabeled Indications.” <i>FDA Drug Bulletin</i> Vol. 12, No. 1 (April, 1982). | TEVA_MDL_A_13749846 | TEVA_MDL_A_13749851 | | | | | | | |
| TE-1022 | 00/00/2008 | Fine, Perry G., Christine Miaskowski, and Michael Brennan, <i>SELECT (Stratify, Examine, Listen, Evaluate, Control, Tailor): Opioid-Based Management of Persistent and Breakthrough Pain</i> , 2008. | TEVA_MDL_A_13744263 | TEVA_MDL_A_13744274 | | | | | | | |
| TE-1023 | 00/00/2006 | Furlan, Andrea D., Juan A. Sandoval, Angela Mailis-Gagnon, and Eldon Tunks. “Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects.” <i>CMAJ</i> Vol. 174, No. 11 (2006): pp. 1589-94. | TEVA_MDL_A_13744411 | TEVA_MDL_A_13744416 | | | | | | | |
| TE-1024 | 06/27/2018 | Gottlieb, Scott., <i>Remarks by Dr. Gottlieb at the FDA Online Opioid Summit</i> , June 27, 2018. https://www.fda.gov/NewsEvents/Speeches/ucm611945.htm . | TEVA_MDL_A_13744139 | TEVA_MDL_A_13744144 | | | | | | | |
| TE-1025 | 03/03/1998 | Haythornthwaite, Jennifer A., Lynette A. Menefee, Amy L. Quatrano-Piacentini, and Marco Pappagallo. “Outcome of Chronic Opioid Therapy for Non-Cancer Pain.” <i>Journal of Pain and Symptom Management</i> Vol. 15, No. 3 (1998): pp. 185-94. | TEVA_MDL_A_13743842 | TEVA_MDL_A_13743851 | | | | | | | |
| TE-1026 | 09/00/2010 | Jamison, Robert N., Edgar L. Ross, Edward Michna, Li Q. Chen, Caroline Holcomb, and Ajay D. Wasan. “Substance Misuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy: A Randomized Trial.” <i>Pain</i> Vol. 150, No. 3 (2010): pp. 390-400. | TEVA_MDL_A_13744668 | TEVA_MDL_A_13744690 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1027 | 07/29/2011 | Jamison, Robert N., Juliana Serrailier, and Edward Michna. "Assessment and Treatment of Abuse Risk in Opioid Prescribing for Chronic Pain." <i>Pain Research and Treatment</i> Vol. 2011 (2011): pp. 1-12. | TEVA_MDL_A_13748244 | TEVA_MDL_A_13748255 | | | | | | | |
| TE-1028 | 09/14/2004 | Kalso, Eija, Jayne E. Edwards, R. Andrew Moore, and Henry J. McQuay. "Opioids in chronic non-cancer pain: systematic review of efficacy and safety." <i>Pain</i> Vol. 112, No. 3 (2004): pp. 372-80. | TEVA_MDL_A_13755623 | TEVA_MDL_A_13755631 | | | | | | | |
| TE-1029 | 09/00/2015 | Levy, Benjamin, Leonard Paulozzi, Karin A. Mack, and Christopher M. Jones. "Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007-2012." <i>American Journal of Preventive Medicine</i> Vol. 49, No. 3 (2015): pp. 409-13. | TEVA_MDL_A_13747135 | TEVA_MDL_A_13747142 | | | | | | | |
| TE-1030 | 09/00/2004 | Michna, Edward, Edgar L. Ross, Wilfred L. Hynes, Srdjan S. Nedeljkovic, Sharonah Soumekh, David Janfaza, . . . Robert N. Jamison. "Predicting Aberrant Drug Behavior in Patients Treated for Chronic Pain: Importance of Abuse History." <i>Journal of Pain and Symptom Management</i> Vol. 28, No. 3 (2004): pp. 250-58. | TEVA_MDL_A_13750110 | TEVA_MDL_A_13750118 | | | | | | | |
| TE-1031 | 10/00/2013 | Nalamachu, Srinivas, David Charles, Kelly Erola, Laura Knobel, Christina Mayville, Wesley Mizutani, . . . Robert Twillman, <i>Prescription Pain Medication: Preserving Patient Access While Curbing Abuse</i> , 2013. | TEVA_MDL_A_13748760 | TEVA_MDL_A_13748767 | | | | | | | |
| TE-1032 | 01/06/2011 | Nalamachu, Srinivas, David Hassman, Mark S Wallace, Sam Dumble, Rob Derrick, and Julian Howell. "Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain." <i>Current Medical Research and Opinion</i> Vol. 27, No. 3 (2011): pp. 519-30. | TEVA_MDL_A_13754790 | TEVA_MDL_A_13754802 | | | | | | | |
| TE-1033 | 00/00/2010 | Noble, Meredith et al. "Long-term opioid management for chronic noncancer pain." <i>The Cochrane Database of Systematic Reviews</i> Vol. 1 (2010): pp. 1-69. | TEVA_MDL_A_13745457 | TEVA_MDL_A_13745527 | | | | | | | |
| TE-1034 | 00/00/2007 | Passik, S. D., and K. L. Kirsh. "Weighing in on the off-label use of Actiq for noncancer-related pain: a recipe for success or a recipe for disaster?" <i>Pain Medicine</i> Vol. 8, No. 2 (2007): pp. 130-3. | TEVA_MDL_A_13748335 | TEVA_MDL_A_13748338 | | | | | | | |
| TE-1035 | 00/00/2011 | Passik, Steven D., John Messina, Anthony Golsorkhi, and Fang Xie. "Aberrant Drug-Related Behavior Observed During Clinical Studies Involving Patients Taking Chronic Opioid Therapy for Persistent Pain and Fentanyl Buccal Tablet for Breakthrough Pain." <i>Journal of Pain and Symptom Management</i> Vol. 41, No. 1 (2011): pp. 116-25. | TEVA_MDL_A_13750557 | TEVA_MDL_A_13750566 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1036 | 10/00/1997 | Simpson, Richard K., Everton A. Edmondson, Charles F. Constant, and Connie Collier. "Transdermal fentanyl as treatment for chronic low back pain." <i>Journal of Pain and Symptom Management</i> Vol. 14, No. 4 (1997): pp. 218-24. | TEVA_MDL_A_13750632 | TEVA_MDL_A_13750638 | | | | | | | |
| TE-1037 | 03/06/2019 | Substance Abuse and Mental Health Services Administration (SAMHSA), "The CBHSQ Report: How People Obtain the Prescription Pain Relievers they Misuse," 2017. https://www.samhsa.gov/data/sites/default/files/report_2686/ShortReport-2686.html , accessed March 6, 2019. | TEVA_MDL_A_13748396 | TEVA_MDL_A_13748401 | | | | | | | |
| TE-1039 | 00/00/2007 | Taylor, Donald R., Lynn R. Webster, Steven Y. Chun, Jeffrey Reinking, Mary Stegman, Steven Shoemaker, and Barry V. Fortner. "Impact of Breakthrough Pain on Quality of Life in Patients with Chronic, Noncancer Pain: Patient Perceptions and Effect of Treatment with Oral Transmucosal Fentanyl Citrate (OTFC, ACTIQ)." <i>Pain Medicine</i> Vol. 8, No. 3 (2007): pp. 281-88. | TEVA_MDL_A_13743713 | TEVA_MDL_A_13743720 | | | | | | | |
| TE-1042 | 04/24/2019 | U.S. Drug Enforcement Administration, "Practitioner's Manual - Section V - Valid Prescription Requirements," https://www.deadiversion.usdoj.gov/pubs/manuals/pract/section5.htm , accessed April 24, 2019. | TEVA_MDL_A_13751201 | TEVA_MDL_A_13751203 | | | | | | | |
| TE-1045 | 10/10/2017 | Webster, Lynn R. and M. Beth Dove, "Optimizing Opioid Treatment for Breakthrough Pain," 2007. www.medscape.org/viewarticle/563417 , accessed October 10, 2017. | TEVA_MDL_A_13746391 | TEVA_MDL_A_13746403 | | | | | | | |
| TE-1046 | 00/00/2013 | Webster, Lynn R., Kieran A. Slevin, Arvind Narayana, Craig Q. Earl, and Ronghua Yang. "Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes." <i>Pain Medicine</i> Vol. 14, No. 9 (2013): pp. 1332-45. | TEVA_MDL_A_13743349 | TEVA_MDL_A_13743362 | | | | | | | |
| TE-1047 | 09/15/2008 | Misdemeanor Guilty Plea, US v. Cephalon, Inc., United States District Court for the Eastern District of Pennsylvania, September 15, 2008, available at https://www.justice.gov/civil/file/892071/download . | TEVA_MDL_A_13744417 | TEVA_MDL_A_13744429 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1048 | 00/00/2003 | Office of Inspector General, "Compliance Program Guidance for Pharmaceutical Manufacturers," ("OIG Guidance"), 2003, https://oig.hhs.gov/fraud/docs/complianceguidance/042803pharmacymfgnonfr.pdf . | TEVA_MDL_A_13744480 | TEVA_MDL_A_13744535 | | | | | | | |
| TE-1049 | 10/00/2017 | "Neurontin (Gabapentin) Label," 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf . | TEVA_MDL_A_13751052 | TEVA_MDL_A_13751088 | | | | | | | |
| TE-1051 | 04/00/2017 | "Fentora Label, April 2017," 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021947s019lbl.pdf . | TEVA_MDL_A_13746757 | TEVA_MDL_A_13746783 | | | | | | | |
| TE-1053 | 09/00/2018 | "Hysingla ER Label, September 2018," 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf . | TEVA_MDL_A_13747155 | TEVA_MDL_A_13747191 | | | | | | | |
| TE-1055 | 06/00/2017 | "Trazodone Label," 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/071196s062lbl.pdf . | TEVA_MDL_A_13743870 | TEVA_MDL_A_13743884 | | | | | | | |
| TE-1057 | 00/00/2018 | American Chronic Pain Association, "ACPA Resource Guide to Chronic Pain Management: An Integrated Guide to Medical, Interventional, Behavioral, Pharmacologic and Rehabilitation Therapies," 2018. https://www.theacpa.org/wp-content/uploads/2018/03/ACPA_Resource_Guide_2018-Final-v2.pdf . | TEVA_MDL_A_13744691 | TEVA_MDL_A_13744842 | | | | | | | |
| TE-1058 | 00/00/2013 | American Psychiatric Association. "Opioid Use Disorder." <i>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)</i> , 304.00, 2013. | TEVA_MDL_A_13745602 | TEVA_MDL_A_13745610 | | | | | | | |
| TE-1060 | 04/12/2011 | American Society of Addiction Medicine, "Definitions Related to the Use of Opioids for the Treatment of Pain: Consensus Statement of the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine," 2001. https://www.asam.org/docs/default-source/public-policy-statements/1opiod-definitions-consensus-2-011.pdf . | TEVA_MDL_A_13744372 | TEVA_MDL_A_13744385 | | | | | | | |
| TE-1063 | 04/24/2019 | Centers for Disease Control and Prevention, "CDC Advises Against Misapplication of the Guideline for Prescribing Opioids for Chronic Pain," 2019. https://www.cdc.gov/media/releases/2019/s0424-advises-misapplication-guideline-prescribing-opioids.html , accessed April 26, 2019. | TEVA_MDL_A_13750131 | TEVA_MDL_A_13750137 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1067 | 02/11/2014 | Cheatle, Martin D., Thomas Wasser, Carolyn Foster, Akintomi Olugbodi, and Jessica Bryan. "Prevalence of suicidal ideation in patients with chronic non-cancer pain referred to a behaviorally based pain program." <i>Pain Physician</i> Vol. 17, No. 3 (2014): pp. E359-67. | TEVA_MDL_A_13750138 | TEVA_MDL_A_13750147 | | | | | | | |
| TE-1068 | 03/18/2016 | Dowell, Deborah, Tamara Haegerich, and Roger Chou. "CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016." <i>Morbidity and Mortality Weekly Report</i> Vol. 65, No. 1 (2016): pp. 1-49. | TEVA_MDL_A_13749764 | TEVA_MDL_A_13749815 | | | | | | | |
| TE-1069 | 04/25/2019 | Dowell, Deborah, Tamara Haegerich, and Roger Chou. "No Shortcuts to Safer Opioid Prescribing." <i>New England Journal of Medicine</i> (2019): Online at https://www.nejm.org/doi/full/10.1056/NEJMp1904190 . | TEVA_MDL_A_13743434 | TEVA_MDL_A_13743436 | | | | | | | |
| TE-1070 | 09/00/2016 | Dueñas, María, Begona Ojeda, Alejandro Salazar, Juan Antonio Mico, and Inmaculada Failde. "A review of chronic pain impact on patients, their social environment and the health care system." <i>Journal of Pain Research</i> Vol. 9 (2016): pp. 457-61. | TEVA_MDL_A_13749852 | TEVA_MDL_A_13749862 | | | | | | | |
| TE-1073 | 04/00/2019 | FDA, "REMS: FDA's Application of Statutory Factors in Determining When a REMS Is Necessary, Guidance for Industry," April 2019. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM521504.pdf . | TEVA_MDL_A_13743930 | TEVA_MDL_A_13743942 | | | | | | | |
| TE-1074 | 08/00/2017 | FDA, "Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS)," August 2017. https://www.accessdata.fda.gov/drugsatfda_docs/remts/TIRF_2017-09-07_Full.pdf . | TEVA_MDL_A_13750094 | TEVA_MDL_A_13750109 | | | | | | | |
| TE-1075 | 04/00/2017 | Federation of State Medical Boards, "Guidelines for the Chronic Use of Opioid Analgesics," April 2017. http://www.fsmb.org/siteassets/advocacy/policies/opioid_guidelines_as_adopted_april-2017_final.pdf . | TEVA_MDL_A_13755648 | TEVA_MDL_A_13755669 | | | | | | | |
| TE-1080 | 01/00/2016 | Governor's Cabinet Opiate Action Team, "Ohio Guideline for the Management of Acute Pain Outside of Emergency Departments," 2016. https://mha.ohio.gov/Portals/0/assets/Initiatives/GCOAT/Guidelines-Acute-Pain-20160119.pdf , accessed May 1, 2019. | TEVA_MDL_A_13744137 | TEVA_MDL_A_13744138 | | | | | | | |
| TE-1086 | 05/00/2011 | Ling, Walter, Larissa Mooney, and Maureen Hillhouse. "Prescription opioid abuse, pain and addiction: clinical issues and implications." <i>Drug and Alcohol Review</i> Vol. 30, No. 3 (2011): pp. 300-05. | TEVA_MDL_A_13748181 | TEVA_MDL_A_13748190 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1088 | 05/00/2012 | Margarit, Cesar, Joaquim Juliá, Rafael López, Antonio Anton, Yolanda Escobar, Ana Casas, . . . Francisco Zaragoza. "Breakthrough cancer pain—still a challenge." <i>Journal of Pain Research</i> Vol. 5 (2012): p. 559. | TEVA_MDL_A_13755109 | TEVA_MDL_A_13755116 | | | | | | | |
| TE-1092 | 07/20/2018 | Mercadante, Sebastiano, Claudio Adile, Francesco Masedu, Paolo Marchetti, Andrea Costanzi, and Federica Aielli. "Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study." <i>European Journal of Pain</i> Vol. 23, No. 4 (2018): pp. 719-26. | TEVA_MDL_A_13743368 | TEVA_MDL_A_13743375 | | | | | | | |
| TE-1093 | 01/15/2014 | Mistry, Chetna, Monica Bawor, Dipika Desai, David C. Marsh, and Zainab Samaan. "Genetics of opioid dependence: a review of the genetic contribution to opioid dependence." <i>Current Psychiatry Reviews</i> Vol. 10, No. 2 (2014): pp. 156-67. | TEVA_MDL_A_13744275 | TEVA_MDL_A_13744286 | | | | | | | |
| TE-1095 | 04/26/2019 | Multiple Chronic Conditions Resource Center, "Chronic Pain Guidelines," https://www.multiplechronicconditions.org/chronic-pain-guidelines . | TEVA_MDL_A_13743437 | TEVA_MDL_A_13743439 | | | | | | | |
| TE-1100 | 01/00/2019 | National Institute on Drug Abuse, "Treating Opioid Use Disorder during Pregnancy," 2017. https://www.drugabuse.gov/publications/treating-opioid-use-disorder-during-pregnancy/treating-opioid-use-disorder-during-pregnancy . | TEVA_MDL_A_13746807 | TEVA_MDL_A_13746808 | | | | | | | |
| TE-1104 | 10/00/2011 | Passik, Steven D., Kenneth L. Kirsh, and Lynn Webster. "Pseudoaddiction revisited: a commentary on clinical and historical considerations." <i>Pain Management</i> Vol. 1, No. 3 (2011): pp. 239-48. | TEVA_MDL_A_13745971 | TEVA_MDL_A_13745980 | | | | | | | |
| TE-1110 | 05/08/2006 | Radley, David C., Stan N. Finkelstein, and Randall S. Stafford. "Off-label prescribing among office-based physicians." <i>Archives of Internal Medicine</i> Vol. 166, No. 9 (2006): pp. 1021-26. | TEVA_MDL_A_13747143 | TEVA_MDL_A_13747148 | | | | | | | |
| TE-1111 | 09/25/2006 | Rappaport, Bob, "FDA Approval Letter for Fentora," September 25, 2006. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021947s000ltr.pdf . | TEVA_MDL_A_13746325 | TEVA_MDL_A_13746329 | | | | | | | |
| TE-1116 | 02/07/2017 | Simeone, Ronald. "Doctor Shopping Behavior and the Diversion of Prescription Opioids." <i>Substance Abuse: Research and Treatment</i> Vol. 11 (2017): pp. 1-10. | TEVA_MDL_A_13755070 | TEVA_MDL_A_13755079 | | | | | | | |
| TE-1121 | 00/00/2013 | Substance Abuse and Mental Health Services Administration (SAMHSA), "Treatment Improvement Protocol 63," https://www.ncbi.nlm.nih.gov/books/NBK535268/pdf/Bookshelf_NBK535268.pdf . | TEVA_MDL_A_13750639 | TEVA_MDL_A_13750960 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1130 | 09/25/2018 | Weissman, David E. and J. David Haddox. "Opioid pseudoaddiction—an iatrogenic syndrome." <i>Pain</i> Vol. 36, No. 3 (1989): pp. 363-66. | TEVA_MDL_A_13750459 | TEVA_MDL_A_13750463 | | | | | | | |
| TE-1131 | 00/00/2014 | World Health Organization, "Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy," 2014. https://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/ . | TEVA_MDL_A_13749870 | TEVA_MDL_A_13750093 | | | | | | | |
| TE-1132 | 11/00/1998 | "Actiq Label, November 1998," 1998. https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/207471bl.pdf . | TEVA_MDL_A_13743487 | TEVA_MDL_A_13743515 | | | | | | | |
| TE-1133 | 09/00/2006 | "Fentora Label, September 2006," 2006. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/0219471bl.pdf . | TEVA_MDL_A_13747278 | TEVA_MDL_A_13747303 | | | | | | | |
| TE-1134 | 05/00/2008 | Abernethy, Amy P., Jane L. Wheeler, and Barry V. Fortner. "A health economic model of breakthrough pain." <i>American Journal of Managed Care</i> Vol. 14, No. 5 Supplement 1 (2008): pp. S129-40. | TEVA_MDL_A_13747195 | TEVA_MDL_A_13747206 | | | | | | | |
| TE-1135 | 00/00/2005 | American Pain Foundation, "Treatment Options: A Guide for People Living with Pain." | TEVA_MDL_A_13745882 | TEVA_MDL_A_13745965 | | | | | | | |
| TE-1136 | 03/00/2011 | Ashburn, Michael A., Kieran A. Slevin, John Messina, and Fang Xie. "The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain." <i>Anesthesia & Analgesia</i> Vol. 112, No. 3 (2011): pp. 693-702. | TEVA_MDL_A_13745872 | TEVA_MDL_A_13745881 | | | | | | | |
| TE-1137 | 02/24/2003 | Brennan, Michael J., Steven D. Passik, and Kenneth L. Kirsh, "Pharmacologic Management of Breakthrough or Incident Pain," 2003. https://www.medscape.org/viewarticle/449803_print , accessed April 11, 2019. | TEVA_MDL_A_13745981 | TEVA_MDL_A_13745988 | | | | | | | |
| TE-1138 | 03/00/2013 | Caraceni, Augusto, Andrew Davies, Philippe Poulain, Hernán Cortés-Funes, Sunil J. Panchal, and Guido Fanelli. "Guidelines for the management of breakthrough pain in patients with cancer." <i>Journal of the National Comprehensive Cancer Network</i> Vol. 11, Supplement 1(2013): pp. S-29-S-36. | TEVA_MDL_A_13747661 | TEVA_MDL_A_13747668 | | | | | | | |
| TE-1139 | 03/30/2001 | Cephalon, Inc., Form 10-K405, filed March 30, 2001. | TEVA_MDL_A_13745253 | TEVA_MDL_A_13745456 | | | | | | | |
| TE-1140 | 00/00/2010 | Cephalon, Inc., <i>Opioid Medications and REMS: A Patient's Guide</i> , 2010. | TEVA_MDL_A_13743721 | TEVA_MDL_A_13743729 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1141 | 09/00/2015 | Chang, Andrew, Eric J. Roeland, Rabia S. Atayee, Carolyn Revta, and Joseph D. Ma. "Transmucosal immediate-release fentanyl for breakthrough cancer pain: opportunities and challenges for use in palliative care." <i>Journal of Pain & Palliative Care Pharmacotherapy</i> Vol. 29, No. 3 (2015): pp. 247-60. | TEVA_MDL_A_13750464 | TEVA_MDL_A_13750479 | | | | | | | |
| TE-1142 | 02/00/2009 | Chou, Roger, Gilbert J. Fanciullo, Perry G. Fine, Jeremy A. Adler, Jane C. Ballantyne, Pamela Davies, . . . Jeffrey Fudin. "Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain." <i>The Journal of Pain</i> Vol. 10, No. 2 (2009): pp. 113-30. e22. | TEVA_MDL_A_13745120 | TEVA_MDL_A_13745159 | | | | | | | |
| TE-1143 | 01/00/2001 | Coluzzi, Paul H., Lee Schwartzberg, John D. Conroy Jr., Steve Charapata, Mason Gay, Michael A. Busch, . . . Maureen McCracken. "Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)." <i>Pain</i> Vol. 91, No. 1-2 (2001): pp. 123-30. | TEVA_MDL_A_13745755 | TEVA_MDL_A_13745762 | | | | | | | |
| TE-1144 | 11/00/2010 | Fine, Perry G., John Messina, Fang Xie, and James Rathmell. "Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study." <i>Journal of Pain and Symptom Management</i> Vol. 40, No. 5 (2010): pp. 747-60. | TEVA_MDL_A_13755704 | TEVA_MDL_A_13755717 | | | | | | | |
| TE-1146 | 00/00/2007 | Fishman, Scott M. <i>Responsible Opioid Prescribing: A Physician's Guide</i> . Washington, DC: Waterford Life Sciences, 2007. | TEVA_MDL_A_13743746 | TEVA_MDL_A_13743819 | | | | | | | |
| TE-1147 | 02/00/2002 | Fortner, Barry V., Theodore A. Okon, and Russell K. Portenoy. "A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain." <i>The Journal of Pain</i> Vol. 3, No. 1 (2002): pp. 38-44. | TEVA_MDL_A_13751502 | TEVA_MDL_A_13751508 | | | | | | | |
| TE-1148 | 09/20/2012 | Kesselheim, Aaron S., Christopher T. Robertson, Jessica A. Myers, Susannah L. Rose, Victoria Gillet, Kathryn M. Ross, . . . Jerry Avorn. "A Randomized Study of How Physicians Interpret Research Funding Disclosures." <i>New England Journal of Medicine</i> Vol. 367, No. 12 (2012): pp. 1119-27. | TEVA_MDL_A_13745551 | TEVA_MDL_A_13745559 | | | | | | | |
| TE-1149 | 01/00/2011 | Lacasse, Jeffrey R. and Jonathan Leo. "Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research." <i>BMC Research Notes</i> Vol. 4, No. 27 (2011): pp. 1-6. | TEVA_MDL_A_13745624 | TEVA_MDL_A_13745630 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1150 | 07/11/2001 | Mercadante, Sebastiano, Lukas Radbruch, Augusto Caraceni, Nathan Cherny, Stein Kaasa, Friedemann Nauck, . . . Steering Committee of the European Association for Palliative Care Research Network. "Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care." <i>Cancer</i> Vol. 94, No. 3 (2002): pp. 832-39. | TEVA_MDL_A_13745833 | TEVA_MDL_A_13745840 | | | | | | | |
| TE-1151 | 12/07/2015 | Minkowitz, Harold, Janet Bull, R. Charles Brownlow, Neha Parikh, and Richard Rauck. "Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain." <i>Supportive Care in Cancer</i> Vol. 24, No. 6 (2016): pp. 2669-75. | TEVA_MDL_A_13744914 | TEVA_MDL_A_13744920 | | | | | | | |
| TE-1152 | 00/00/2017 | Payne, Richard. "Recognition and diagnosis of breakthrough pain." <i>Pain Medicine</i> Vol. 8, Supplement 1 (2007): pp. S3-S7. | TEVA_MDL_A_13747558 | TEVA_MDL_A_13747562 | | | | | | | |
| TE-1153 | 01/31/2010 | Portenoy, Russell K., Daniel Bruns, Bonnie Shoemaker, and Steven A. Shoemaker. "Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics." <i>Journal of Opioid Management</i> Vol. 6, No. 2 (2010): pp. 97-108. | TEVA_MDL_A_13755673 | TEVA_MDL_A_13755684 | | | | | | | |
| TE-1154 | 08/00/2006 | Portenoy, Russell K., Daniel S. Bennett, Richard Rauck, Steven Simon, Donald Taylor, Michael Brennan, and Steven A. Shoemaker. "Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain." <i>The Journal of Pain</i> Vol. 7, No. 8 (2006): pp. 583-91. | TEVA_MDL_A_13744430 | TEVA_MDL_A_13744438 | | | | | | | |
| TE-1155 | 00/00/2012 | Rudowska, Joanna. "Management of breakthrough pain due to cancer." <i>Contemporary Oncology</i> Vol. 16, No. 6 (2012): pp. 498-501. | TEVA_MDL_A_13750154 | TEVA_MDL_A_13750157 | | | | | | | |
| TE-1156 | 07/28/2016 | Schuckit, Marc A. "Treatment of opioid-use disorders." <i>New England Journal of Medicine</i> Vol. 375, No. 4 (2016): pp. 357-68. | TEVA_MDL_A_13743898 | TEVA_MDL_A_13743909 | | | | | | | |
| TE-1157 | 11/06/2014 | Shimoyama, N., I. Gomyo, O. Teramoto, K. Kojima, H. Higuchi, N. Yukitoshi, . . . M. Shimoyama. "Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain." <i>Japanese Journal of Clinical Oncology</i> Vol. 45, No. 2 (2014): pp. 189-96. | TEVA_MDL_A_13748256 | TEVA_MDL_A_13748263 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1158 | 03/31/2008 | Slatkin, Neal E. and Michele I. Rhiner, "Breakthrough Pain: Improving Recognition and Management to Enhance Quality of Life," 2008. www.medscape.org/viewarticle/572129 , accessed October 10, 2017. | TEVA_MDL_A_13748354 | TEVA_MDL_A_13748366 | | | | | | | |
| TE-1159 | 00/00/2012 | Smith, Howard. "A comprehensive review of rapid-onset opioids for breakthrough pain." <i>CNS Drugs</i> Vol. 26, No. 6 (2012): pp. 509-35. | TEVA_MDL_A_13748217 | TEVA_MDL_A_13748243 | | | | | | | |
| TE-1163 | 04/00/2015 | Vowles, Kevin E., Mindy L. McEntee, Peter Siyahhan Julnes, Tessa Frohe, John P. Ney, and David N. van der Goes. "Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis." <i>Pain</i> Vol. 156, No. 4 (2015): pp. 569-76. | TEVA_MDL_A_13745767 | TEVA_MDL_A_13745774 | | | | | | | |
| TE-1165 | 08/00/2000 | "National Incident-Based Reporting System Volume 1: Data Collection Guidelines," United States Department of Justice and Federal Bureau of Investigation, 2000 | TEVA_MDL_A_13746848 | TEVA_MDL_A_13746975 | | | | | | | |
| TE-1167 | 01/03/2018 | "Questions for the Record from Senator Charles E. Grassley To President and CEO of Healthcare Distribution Alliance, U.S. Senate Committee on the Judiciary – Oversight on the Ensuring Patient Access and Drug Enforcement Act," answered on January 3, 2018 | TEVA_MDL_A_13754784 | TEVA_MDL_A_13754789 | | | | | | | |
| TE-1169 | 06/00/2018 | "Using International Classification of Diseases (ICD) Codes to Assess Opioid-Related Overdose Deaths," Substance Abuse and Mental Health Services Administration, available at https://mnprc.org/wp-content/uploads/2019/01/using-icd-10-codes-to-assess-opioid-related-overdose-deaths.pdf | TEVA_MDL_A_13744463 | TEVA_MDL_A_13744467 | | | | | | | |
| TE-1173 | 11/00/2011 | Ajay Kalra et al., "Understanding Responses to Contradictory Information About Products," <i>Marketing Science</i> , 30(6) (2011) | TEVA_MDL_A_13745572 | TEVA_MDL_A_13745589 | | | | | | | |
| TE-1183 | 06/28/2010 | Center for Disease Control and Prevention, "United States Life Table, 2006," National Vital Statistics Report 58 (June 28, 2010) | TEVA_MDL_A_13745989 | TEVA_MDL_A_13746028 | | | | | | | |
| TE-1184 | 09/28/2011 | Center for Disease Control and Prevention, "United States Life Table, 2007," National Vital Statistics Report 59 (September 28, 2011) | TEVA_MDL_A_13751643 | TEVA_MDL_A_13751703 | | | | | | | |
| TE-1185 | 09/24/2012 | Center for Disease Control and Prevention, "United States Life Table, 2008," National Vital Statistics Report 61 (September 24, 2012) | TEVA_MDL_A_13746227 | TEVA_MDL_A_13746290 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1186 | 01/06/2014 | Center for Disease Control and Prevention, "United States Life Table, 2009," National Vital Statistics Report 62 (January 6, 2014) | TEVA_MDL_A_13751511 | TEVA_MDL_A_13751573 | | | | | | | |
| TE-1187 | 11/06/2014 | Center for Disease Control and Prevention, "United States Life Table, 2010," National Vital Statistics Report 63 (November 6, 2014) | TEVA_MDL_A_13748768 | TEVA_MDL_A_13748830 | | | | | | | |
| TE-1188 | 11/22/2015 | Center for Disease Control and Prevention, "United States Life Table, 2011," National Vital Statistics Report 64 (November 22, 2015) | TEVA_MDL_A_13751121 | TEVA_MDL_A_13751183 | | | | | | | |
| TE-1189 | 11/28/2016 | Center for Disease Control and Prevention, "United States Life Table, 2012," National Vital Statistics Report 65 (November 28, 2016) | TEVA_MDL_A_13743644 | TEVA_MDL_A_13743711 | | | | | | | |
| TE-1190 | 04/11/2017 | Center for Disease Control and Prevention, "United States Life Table, 2013," National Vital Statistics Report 66 (April 11, 2017) | TEVA_MDL_A_13744555 | TEVA_MDL_A_13744618 | | | | | | | |
| TE-1191 | 08/14/2017 | Center for Disease Control and Prevention, "United States Life Table, 2014," National Vital Statistics Report 66 (August 14, 2017) | TEVA_MDL_A_13755718 | TEVA_MDL_A_13755781 | | | | | | | |
| TE-1192 | 11/13/2018 | Center for Disease Control and Prevention, "United States Life Table, 2015," National Vital Statistics Report 67 (November 13, 2018) | TEVA_MDL_A_13744308 | TEVA_MDL_A_13744371 | | | | | | | |
| TE-1194 | 01/13/2012 | Centers for Disease Control and Prevention, "CDC Grand Rounds: Prescription Drug Overdoses – a U.S. Epidemic," Mortality and Morbidity Weekly Report, available at https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6101a3.htm (January 13, 2012) | TEVA_MDL_A_13747669 | TEVA_MDL_A_13747676 | | | | | | | |
| TE-1195 | 02/22/2019 | Centers for Disease Control and Prevention, "Multiple Cause of Death 1999 – 2017," available at https://wonder.cdc.gov/wonder/help/mcd.html | TEVA_MDL_A_13748277 | TEVA_MDL_A_13748328 | | | | | | | |
| TE-1200 | 04/12/2017 | Chad M. Brummett et al., "New Persistent Opioid Use after Minor and Major Surgical Procedures in US Adults," JAMA Surgery, 152(6), pp. 1–9 (2017) | TEVA_MDL_A_13743478 | TEVA_MDL_A_13743486 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1202 | 00/00/2017 | Corwin N. Rhyan, "The Potential Societal Benefit of Eliminating Opioid Overdoses, Deaths, and Substance Use Disorders Exceeds \$95 Billion Per Year," 2017, Altarum Research Brief, available at https://altarum.org/sites/default/files/uploaded-publication-files/Research-Brief_Opioid-Epidemic-Economic-Burden.pdf (2017) | TEVA_MDL_A_13743926 | TEVA_MDL_A_13743929 | | | | | | | |
| TE-1203 | 00/00/2014 | County of Summit ADM Board, "2014 Report to the Community," available at https://www.admboard.org/Data/Sites/25/2014-annual-report-final.pdf | TEVA_MDL_A_13751102 | TEVA_MDL_A_13751106 | | | | | | | |
| TE-1204 | 00/00/2017 | County of Summit ADM Board, "2017 Report to the Community," available at https://www.admboard.org/Data/Sites/25/18adm04-annualrpt_8.5x11_r8_web.pdf | TEVA_MDL_A_13744453 | TEVA_MDL_A_13744460 | | | | | | | |
| TE-1206 | 10/00/2016 | Curtis S. Florence et al., "The Economic Burden of Prescription Opioid Overdose, Abuse and Dependence in the United States, 2013," Medical Care, 54(10) (2016) | TEVA_MDL_A_13744619 | TEVA_MDL_A_13744624 | | | | | | | |
| TE-1207 | 00/00/2016 | Curtis S. Florence et al., online appendix, "Methodological Assumptions," available at http://links.lww.com/MLR/B262 (2016) | TEVA_MDL_A_13745198 | TEVA_MDL_A_13745220 | | | | | | | |
| TE-1208 | 00/00/2019 | Cuyahoga ADAMHS Board, "Calendar Year 2019: ADAMHS Board – Total Budget Summary," available at http://adamhscc.org/pdf_adamhscc/en-US/CY2019%20Operating%20Budget.pdf | TEVA_MDL_A_13744035 | TEVA_MDL_A_13744038 | | | | | | | |
| TE-1209 | 00/00/2014 | Cuyahoga County Opiate Task Force, "Cuyahoga County Opiate Task Force Report 2014," available at http://opiatecollaborative.cuyahogacounty.us/pdf_OpiateCollaborative/en-US/CC_OpiateTaskForceReport.pdf (2014) | TEVA_MDL_A_13743730 | TEVA_MDL_A_13743745 | | | | | | | |
| TE-1210 | 10/01/2018 | Dailymed, "ACTIQ® (AK-tik): (Fentanyl Citrate) Oral Transmucosal Lozenge, CII," available at https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a (October 1, 2018) | TEVA_MDL_A_13744059 | TEVA_MDL_A_13744070 | | | | | | | |
| TE-1211 | 09/01/2018 | Dailymed, "FENTORA® (fen-tor-a): (Fentanyl) Buccal Tablet, CII," available at https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=8f549d95-985b-f783-1ebb-ef57bd2ecb05 (September 1, 2018) | TEVA_MDL_A_13744090 | TEVA_MDL_A_13744093 | | | | | | | |
| TE-1212 | 02/00/2012 | Darius Lakdawalla and Tomas Philipson, "Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets," Journal of Law and Economics, 55(1), pp. 151–187 (2012) | TEVA_MDL_A_13745017 | TEVA_MDL_A_13745054 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1213 | 00/00/1997 | David M. Cutler and Elizabeth Richardson, "Measuring the Health of the U.S. Population," Brookings Paper on Economic Activity, Microeconomics (1997) | TEVA_MDL_A_13747051 | TEVA_MDL_A_13747106 | | | | | | | |
| TE-1215 | 09/07/2017 | DEA Form Reference ID: 4148977, "The TIRF REMS Access Program: Knowledge Assessment," available at https://www.accessdata.fda.gov/drugsatfda_docs/remts/TIRF_2017-09-07_Knowledge_Assessment.pdf | TEVA_MDL_A_13744147 | TEVA_MDL_A_13744150 | | | | | | | |
| TE-1222 | 06/00/2007 | Douglas E. Mager and Emily R. Cox, "Relationship Between Generic and Preferred-Brand Prescription Copayment Differentials and Generic Fill Rate," The American Journal of Managed Care, 13(6), pp. 347–352 (2007) | TEVA_MDL_A_13751115 | TEVA_MDL_A_13751120 | | | | | | | |
| TE-1226 | 03/00/2001 | Ernst R. Berndt, "The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?," Health Affairs, 20(2), pp. 100–114 (2001) | TEVA_MDL_A_13754806 | TEVA_MDL_A_13754820 | | | | | | | |
| TE-1228 | 11/01/2012 | FDA, "A Guide to Drug Safety Terms at FDA," Consumer Health Information Report (November 1, 2012) | TEVA_MDL_A_13750617 | TEVA_MDL_A_13750619 | | | | | | | |
| TE-1230 | 02/14/2019 | FDA, "Approved Risk Evaluation and Mitigation Strategies (REMS)," available at https://www.accessdata.fda.gov/scripts/cder/remts/index.cfm | TEVA_MDL_A_13750187 | TEVA_MDL_A_13750189 | | | | | | | |
| TE-1232 | 02/19/2019 | FDA, "Drug Approval Process," available at https://www.fda.gov/downloads/drugs/resourcesforyou/consumers/ucm284393.pdf | TEVA_MDL_A_13754775 | TEVA_MDL_A_13754776 | | | | | | | |
| TE-1243 | 00/00/2002 | George Casella and Roger L. Berger "Statistical Inference," Second Edition, Thomson Learning (2002) | TEVA_MDL_A_13747207 | TEVA_MDL_A_13747277 | | | | | | | |
| TE-1244 | 04/00/2018 | George Psacharopoulos and Harry Antony Patrinos, "Returns to Investment in Education: A Decennial Review of the Global Literature," Policy Research Working Paper 8402, World Bank Education Global Practice, available at http://documents.worldbank.org/curated/en/442521523465644318/pdf/WPS8402.pdf (April 2018) | TEVA_MDL_A_13748922 | TEVA_MDL_A_13748936 | | | | | | | |
| TE-1246 | 00/00/2010 | Janet Currie and Cathy S. Widom, "Long-Term Consequences of Child Abuse and Neglect on Adult Economic Well-Being," Child Maltreatment, 15(2), pp. 111–120 (2010) | TEVA_MDL_A_13755785 | TEVA_MDL_A_13755794 | | | | | | | |
| TE-1247 | 00/00/2018 | Janet Currie et al., "U.S. Employment and Opioids: Is There a Connection?" National Bureau of Economic Research, available at https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3149264 (2018) | TEVA_MDL_A_13743985 | TEVA_MDL_A_13744022 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1248 | 12/20/2017 | Jay Soong-Jin Lee et al., "New Persistent Opioid Use Among Patients with Cancer After Curative-Intent Surgery," Journal of Clinical Oncology, 35(36), pp. 4042–4053 (2017) | TEVA_MDL_A_13751631 | TEVA_MDL_A_13751642 | | | | | | | |
| TE-1249 | 00/00/2010 | Jeffrey M. Wooldridge, "Single-Equation Linear Model and Ordinary Least Squares Estimation," Econometric Analysis of Cross Section and Panel Data, (Cambridge, London: The MIT Press) (2010) | TEVA_MDL_A_13744909 | TEVA_MDL_A_13744913 | | | | | | | |
| TE-1250 | 11/01/2017 | Jessica Webster Sendra, "For 1 in 10 Cancer Patients, Surgery Means Opioid Dependence," Michigan Health Lab, available at https://labblog.uofmhealth.org/rounds/for-1-10-cancer-patients-surgery-means-opioid-dependence (November 1, 2017) | TEVA_MDL_A_13750613 | TEVA_MDL_A_13750616 | | | | | | | |
| TE-1252 | 03/01/2005 | Kaiser Family Foundation, "Follow the Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain," available at https://www.kff.org/wp-content/uploads/2013/01/follow-the-pill-understanding-the-u-s-commercial-pharmaceutical-supply-chain-report.pdf (March 1, 2005) | TEVA_MDL_A_13743446 | TEVA_MDL_A_13743477 | | | | | | | |
| TE-1253 | 00/00/2016 | Kaiser Family Foundation, "2016 Employer Health Benefits Annual Survey," available at http://files.kff.org/attachment/Report-Employer-Health-Benefits-2016-Annual-Survey (2016) | TEVA_MDL_A_13746404 | TEVA_MDL_A_13746677 | | | | | | | |
| TE-1254 | 08/01/2011 | Karen A. Goldman et al., "Authorized Generic Drugs: Short-Term Effects and Long-Term Impact," Federal Trade Commission Report, available at https://www.ftc.gov/sites/default/files/documents/reports/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission.pdf (August 1, 2011) | TEVA_MDL_A_13755117 | TEVA_MDL_A_13755386 | | | | | | | |
| TE-1255 | 01/13/2010 | Kathryn E. McCollister et al., "The cost of crime to society: New Crime-Specific Estimates for Policy and Program Evaluation," Drug and Alcohol Dependence, 108(1) (2010) | TEVA_MDL_A_13747344 | TEVA_MDL_A_13747355 | | | | | | | |
| TE-1256 | 01/09/1998 | Letter from Cynthia McCormick (FDA) to Patricia J. Richards (Anesta Corporation), "NDA 20-747" [January 9, 1998] | TEVA_MDL_A_13747307 | TEVA_MDL_A_13747312 | | | | | | | |
| TE-1257 | 01/09/1998 | Letter from Ken Nolan (Center for Drug Evaluation and Research) to Patricia J. Richards (Anesta Corporation), "NDA 20-747" [January 9, 1998] | TEVA_MDL_A_13743326 | TEVA_MDL_A_13743348 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1258 | 08/01/2018 | Marcus Dillender, "What Happens When the Insurer Can Say No? Assessing Prior Authorization as a Tool to Prevent High-Risk Prescriptions and to Lower Costs," Journal of Public Economics, 165(1) (2018) | TEVA_MDL_A_13745841 | TEVA_MDL_A_13745871 | | | | | | | |
| TE-1259 | 04/26/2018 | Maria A. Oquendo and Nora D. Volkow, "Suicide: A Silent Contributor to Opioid-Overdose Deaths," New England Journal of Medicine, 378(17), available at https://www.nejm.org/doi/10.1056/NEJMp1801417 (2018) | TEVA_MDL_A_13755685 | TEVA_MDL_A_13755687 | | | | | | | |
| TE-1260 | 07/04/2017 | Matan C. Dabora et al., "Financing and Distribution of Pharmaceuticals in the United States," JAMA, 318(1) (2017) | TEVA_MDL_A_13745221 | TEVA_MDL_A_13745222 | | | | | | | |
| TE-1262 | 02/00/2018 | Nabarun Dasgupta et al., "Opioid Crisis: No Easy Fix to Its Social and Economic Determinants," American Journal of Public Health, 108(2) (February 2018) | TEVA_MDL_A_13751491 | TEVA_MDL_A_13751496 | | | | | | | |
| TE-1264 | 09/00/2018 | Office of Policy Development and Research, "HUD USPS ZIP Crosswalk Files," available at https://www.huduser.gov/portal/datasets/usps_crosswalk.html | TEVA_MDL_A_13748836 | TEVA_MDL_A_13748836 | | | | | | | |
| TE-1268 | 00/00/2019 | Ohio Department of Medicaid, "Information on the Coordinated Service Program," available at https://pharmacy.medicaid.ohio.gov/sites/default/files/2019%20CSP%20Brochure.pdf | TEVA_MDL_A_13750119 | TEVA_MDL_A_13750119 | | | | | | | |
| TE-1270 | 07/22/1998 | Ohio Rev. Code Ann. § 4729.38(B) | TEVA_MDL_A_13751204 | TEVA_MDL_A_13751206 | | | | | | | |
| TE-1273 | 08/20/2016 | Priscilla Hunt et al., "The Price of Justice: New National and State-Level Estimates of the Judicial and Legal Costs of Crime to Taxpayers," American Journal of Criminal Justice, 42(2), pp. 231–254 (2016) | TEVA_MDL_A_13748879 | TEVA_MDL_A_13748902 | | | | | | | |
| TE-1275 | 04/10/2016 | Raj Chetty et al., "The Association Between Income and Life Expectancy in the United States, 2001-2014," JAMA, 315(16) (2016) | TEVA_MDL_A_13744386 | TEVA_MDL_A_13744402 | | | | | | | |
| TE-1276 | 09/01/2018 | Robin Gertner and Lincoln Groves, "The Opioid Crisis and Economic Opportunity: Geographic and Economic Trends," U.S. Department of Health and Human Services: Office of the Assistant Secretary for Planning and Evaluation Research Brief, available at https://aspe.hhs.gov/system/files/pdf/259261/ASPEEconomicOpportunityOpioidCrisis.pdf (September 1, 2018) | TEVA_MDL_A_13754709 | TEVA_MDL_A_13754730 | | | | | | | |
| TE-1282 | 00/00/2016 | Substance Abuse and Mental Health Data Archive, National Survey on Drug Use and Health: 2-Year RDAS (2016-2017) | TEVA_MDL_A_13743943 | TEVA_MDL_A_13743943 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1301 | 00/00/2014 | The State of Ohio Board of Pharmacy, "What is OARRS?," available at https://www.ohiopmp.gov/About.aspx | TEVA_MDL_A_13751111 | TEVA_MDL_A_13751114 | | | | | | | |
| TE-1305 | 09/00/2013 | U.S. Department of Health and Human Services, "Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities," available at https://www.cdc.gov/drugoverdose/pdf/hhs_prescription_drug_abuse_report_09.2013.pdf | TEVA_MDL_A_13743116 | TEVA_MDL_A_13743151 | | | | | | | |
| TE-1306 | 00/00/2016 | U.S. Department of Health and Human Services: Office of the Assistant Secretary for Planning and Evaluation, "Guidelines for Regulatory Impact Analysis: A Primer," available at https://aspe.hhs.gov/system/files/pdf/242931/HHS_RIAGuidancePrimer.pdf (2016) | TEVA_MDL_A_13744291 | TEVA_MDL_A_13744304 | | | | | | | |
| TE-1308 | 00/00/2000 | W.Kip Viscusi, "The Value of Life in Legal Contexts: Survey and Critique," American Law and Economics Review, 2(1), pp. 195–222 (2000) | TEVA_MDL_A_13746330 | TEVA_MDL_A_13746357 | | | | | | | |
| TE-1309 | 00/00/1994 | World Health Organization Report, "Guide to Good Prescribing: A Practical Manual," Document WHO/DAP/94.11, available https://apps.who.int/medicinedocs/pdf/whozip23e/whozip23e.pdf (1994) | TEVA_MDL_A_13755387 | TEVA_MDL_A_13755528 | | | | | | | |
| TE-1311 | 05/10/2019 | All appendices, attachments, and exhibits to the Expert Report of Professor Edward Michna, <i>In Re National Prescription Opiate Litigation</i> , MDL No. 2804 | | | | | | | | | |
| TE-1312 | 05/10/2019 | All appendices, attachments, and exhibits to the expert Report of Professor Howard Dorfman <i>In Re National Prescription Opiate Litigation</i> , MDL No. 2804 | | | | | | | | | |
| TE-1313 | 05/10/2019 | All appendices, attachments, and exhibits to the expert Report of Melanie H. Rosenblatt, <i>In Re National Prescription Opiate Litigation</i> , MDL No. 2804 | | | | | | | | | |
| TE-1314 | 05/10/2019 | All appendices, attachments, and exhibits to the expert Report of Sean Nicholson, <i>In Re National Prescription Opiate Litigation</i> , MDL No. 2804 | | | | | | | | | |
| TE-1315 | 03/25/2019 | Plaintiff's Experts' Data Appendix | | | | | | | | | |
| TE-1316 | | narne_def_manu_drug_v10 | SUMMIT_000087427 | SUMMIT_000087427 | | | | | | | |
| TE-1318 | 07/01/2012 | "Independent Medical Education Grants (US Policy-205) | TEVA_MDL_A_01261096 | TEVA_MDL_A_01261099 | | | | | | | |
| TE-1319 | 09/24/2004 | Identifying Called on Universe of Physicians in Connection with Promotional Activities | TEVA_MDL_A_11892862 | TEVA_MDL_A_11892864 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1320 | 00/00/2005 | Berndt, E. (2005). To Inform or Persuade? Direct-to-Consumer Advertising of Prescription Drugs. The New England Journal of Medicine 352, no. 4 | TEVA_MDL_A_13745546 | TEVA_MDL_A_13745550 | | | | | | | |
| TE-1321 | Undated | Anne Case and Angus Deaton, "Mortality and Morbidity in the 21st Century," Brookings Papers on Economic Activity BPEA Conference Drafts | TEVA_MDL_A_13746984 | TEVA_MDL_A_13747043 | | | | | | | |
| TE-1322 | 00/00/2016 | Moghe, S (2016). Opioid History: From 'wonder rug' to abuse epidemic | TEVA_MDL_A_13746809 | TEVA_MDL_A_13746816 | | | | | | | |
| TE-1323 | Undated | Khary K. Rigg et al., "Prescription Drug Abuse & Diversion: Role of the Pain Clinic," Journal of Drug | TEVA_MDL_A_13747631 | TEVA_MDL_A_13747651 | | | | | | | |
| TE-1324 | Undated | Natalie Mizik and Robert Jacobson, "Are Physicians 'Easy Marks'? Quantifying the Effects of Detailing and Sampling on New Prescriptions," Management Science, 50(12) | TEVA_MDL_A_13744241 | TEVA_MDL_A_13744253 | | | | | | | |
| TE-1325 | 04/30/2011 | Federation of State Medical Board House of Delegate Meeting | FSMB_001590 | FSMB_001591 | | | | | | | |
| TE-1326 | 12/03/2018 | Federation of State Medical Boards Report of the Board of Directors | FSMB_001389 | FSMB_001396 | | | | | | | |
| TE-1327 | 06/03/2009 | Attorney General Janet Mills Remarks to the Maine Medical Association | FSMB_001931 | FSMB_001939 | | | | | | | |
| TE-1328 | 07/29/2011 | Letter from Virginia Board of Medicine | FSMB_001966 | FSMB_001967 | | | | | | | |
| TE-1329 | 03/04/2004 | Medical Education in Opioid Use | FSMB_001357 | FSMB_001364 | | | | | | | |
| TE-1330 | 02/16/2017 | Email Explaining DefOPS Process. | TEVA_MDL_A_13757937 | TEVA_MDL_A_13757938 | | | | | | | |
| TE-1331 | 04/27/2017 | Document explaining the benefits of the DefOPS implementation. | TEVA_MDL_A_13757946 | TEVA_MDL_A_13757946 | | | | | | | |
| TE-1332 | 04/27/2017 | Document explaining the benefits of the DefOPS implementation. | TEVA_MDL_A_13757947 | TEVA_MDL_A_13757947 | | | | | | | |
| TE-1333 | 04/27/2017 | Documents explaining the benefits of the DefOPS implementation. | TEVA_MDL_A_13757948 | TEVA_MDL_A_13757952 | | | | | | | |
| TE-1334 | 1/11/2018 | Document describinig Suspicious Order Monitoring process. | TEVA_MDL_A_13757963 | TEVA_MDL_A_13757965 | | | | | | | |
| TE-1335 | 04/27/2018 | Email regarding DefOPS procedures. | TEVA_MDL_A_13757990 | TEVA_MDL_A_13757993 | | | | | | | |
| TE-1336 | 2/10/2014 | Document describing Suspicious Order Monitoring Policies and Procedures. | TEVA_MDL_A_13758027 | TEVA_MDL_A_13758042 | | | | | | | |
| TE-1337 | 9/11/2014 | DefOPS Process Flow. | TEVA_MDL_A_13758082 | TEVA_MDL_A_13758082 | | | | | | | |
| TE-1338 | 02/12/2015 | Document describing DefOPS enhancements. | TEVA_MDL_A_13758155 | TEVA_MDL_A_13758173 | | | | | | | |
| TE-1339 | 08/23/2016 | Documents describing DefOPS workbench. | TEVA_MDL_A_13758326 | TEVA_MDL_A_13758329 | | | | | | | |
| TE-1340 | 04/27/2017 | Email regarding DefOPS screen mock-up. | TEVA_MDL_A_13758575 | TEVA_MDL_A_13758587 | | | | | | | |
| TE-1341 | 01/10/2018 | Powerpoint regarding SOM Process Flow. | TEVA_MDL_A_13758672 | TEVA_MDL_A_13758674 | | | | | | | |
| TE-1342 | 03/14/2013 | Email Describing Teva SOM System. | TEVA_MDL_A_13758721 | TEVA_MDL_A_13758722 | | | | | | | |
| TE-1343 | 06/02/2016 | Email regarding DEA order hold system. | TEVA_MDL_A_13758909 | TEVA_MDL_A_13758916 | | | | | | | |
| TE-1344 | 04/10/2018 | Document listing DefOPS scenarios. | TEVA_MDL_A_13759200 | TEVA_MDL_A_13759200 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1345 | 05/03/2018 | Email regarding DEA Customer License Information Form. | TEVA_MDL_A_13759209 | TEVA_MDL_A_13759210 | | | | | | | |
| TE-1346 | 05/29/2018 | Spreadsheet regarding DefOPS computer system test script load. | TEVA_MDL_A_13759218 | TEVA_MDL_A_13759218 | | | | | | | |
| TE-1347 | 04/02/2014 | Presentation regarding Suspicious Order Monitoring. | TEVA_MDL_A_13759578 | TEVA_MDL_A_13759589 | | | | | | | |
| TE-1348 | 05/14/2012 | Memorandum regarding DEA Suspicious Order Monitoring review. | TEVA_MDL_A_13760784 | TEVA_MDL_A_13760784 | | | | | | | |
| TE-1349 | 01/25/2013 | Project Plan regarding Suspicious Order Monitoring. | TEVA_MDL_A_13760810 | TEVA_MDL_A_13760810 | | | | | | | |
| TE-1350 | 00/00/1972 | 37 Fed. Reg. 16,503-16,504 | TEVA_MDL_A_13762429 | TEVA_MDL_A_13762500 | | | | | | | |
| TE-1351 | 00/00/1975 | 40 Fed. Reg. 15,392, 15,394 | TEVA_MDL_A_13762501 | TEVA_MDL_A_13762942 | | | | | | | |
| TE-1352 | 00/0/1994 | 59 Fed. Reg. 59,820, 59,821, 59,825 | TEVA_MDL_A_13762943 | TEVA_MDL_A_13763210 | | | | | | | |
| TE-1353 | 00/00/1998 | 63 Fed. Reg. 31,143, 31,153, 64,556, 64,579 | TEVA_MDL_A_13763211 | TEVA_MDL_A_13763243 | | | | | | | |
| TE-1354 | 00/00/2003 | 68 Fed. Reg. 6,062, 6,071 | TEVA_MDL_A_13763244 | TEVA_MDL_A_13763263 | | | | | | | |
| TE-1355 | 10/17/2017 | From Teddy Roosevelt to Trump: How drug companies triggered an opioid crisis a century ago - https://www.washingtonpost.com/news/retropolis/wp/2017/09/29/the-greatest-drug-fiends-in-the-world-an-american-opioid-crisis-in-1908/ | TEVA_MDL_A_13763264 | TEVA_MDL_A_13763276 | | | | | | | |
| TE-1356 | 12/05/2011 | Letter from Susan Franks, Director, Regulatory Affairs, Cephalon, to Robert Rappaport, FDA, Amending Actiq REMS with TIRF Class REMS, | TEVA_MDL_A_00297176 | TEVA_MDL_A_00297176 | | | | | | | |
| TE-1357 | 02/08/2012 | Letter from Susan Franks, Director, Regulatory Affairs, Cephalon, to Robert Rappaport, FDA, Proposed REMS/Modification for Fentora | TEVA_MDL_A_10687983 | TEVA_MDL_A_10687983 | | | | | | | |
| TE-1358 | 06/16/2008 | Speaker Program Presentation - Fentora Secure Program | TEVA_MDL_A_06384848 | TEVA_MDL_A_06384951 | | | | | | | |
| TE-1359 | 05/00/2006 | SAMHSA Substance Abuse Treatment Advisory: News for the Treatment Field (May 2006) - https://store.samhsa.gov/system/files/sma12-4175.pdf | TEVA_MDL_A_13763753 | TEVA_MDL_A_13763756 | | | | | | | |
| TE-1360 | 01/00/2012 | SAMHSA Review of the Literature: Managing Chronic Pain in Adults With or in Recovery - https://store.samhsa.gov/system/files/tip54_litrev_jan2012.pdf | TEVA_MDL_A_13763757 | TEVA_MDL_A_13763827 | | | | | | | |
| TE-1361 | 04/09/2019 | Statement by Douglas Throckmorton, M.D., Deputy Center Director for Regulatory Programs in FDA Regarding New Opioid Analgesic Labeling Changes | JAN-TREX-00031928 | JAN-TREX-00031931 | | | | | | | |
| TE-1362 | 11/26/2013 | 2013 Email from Randy Spokane to Teva Pain Sales Force | TEVA_MDL_A_01086537 | TEVA_MDL_A_01086538 | | | | | | | |
| TE-1363 | 12/3/1997 | FDA Guidance on Industry-Supported Scientific and Educational Activities; https://www.fda.gov/media/70844/download | TEVA_MDL_A_13763277 | TEVA_MDL_A_13763284 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|--|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1364 | 6/1/2014 | Perspectives in Palliative Care: Managing Breakthrough Pain in Patients with Cancer June 2014 | TEVA_MDL_A_03524429 | TEVA_MDL_A_03524429 | | | | | | | |
| TE-1365 | 3/19/2013 | Perspectives in Palliative Care: Managing Breakthrough Pain in Patients with Cancer | TEVA_MDL_A_03524429 | TEVA_MDL_A_03524429 | | | | | | | |
| TE-1366 | 7/12/2012 | Abuse/Addiction Screening in Chronic Pain Management Patients | TEVA_MDL_A_11701437 | TEVA_MDL_A_11701437 | | | | | | | |
| TE-1367 | 9/10/2012 | Email from Meredith Taylor to Jim Reilly and Robert Bobrowski | TEVA_MDL_A_00400237 | TEVA_MDL_A_00400239 | | | | | | | |
| TE-1368 | 11/22/2013 | Email from Mike Derkacz to Jim Reilly | TEVA_MDL_A_00968021 | TEVA_MDL_A_00968022 | | | | | | | |
| TE-1369 | 12/17/2013 | Email from John C. Jacobs to Randy Spokane and TevaUS_TP_Sales_All | TEVA_MDL_A_00968023 | TEVA_MDL_A_00968025 | | | | | | | |
| TE-1370 | 11/21/2013 | Email from Matthew Day to Jim Reilly | TEVA_MDL_A_00968029 | TEVA_MDL_A_00968030 | | | | | | | |
| TE-1371 | 8/24/2012 | Email from Randy Spokane to Chris Brown, Geoffrey Merris, Joe Haygood, John Harold, Michael Morreale, Randy Smith, Shawn Lally, and William Sweet | TEVA_MDL_A_01118126 | TEVA_MDL_A_01118126 | | | | | | | |
| TE-1372 | 6/28/2012 | Email from Jim Reilly to TevaUS_TP_Sales_ALL | TEVA_MDL_A_01505115 | TEVA_MDL_A_01505116 | | | | | | | |
| TE-1373 | 6/29/2012 | Email from John Harold to Michael Collins, Meredith Grim, Kathleen Haven, Thomas Robb, Adam Jacobson, Marc Oseroff, Ana Esther Jacobo, James Henning, and Sherri May | TEVA_MDL_A_02047315 | TEVA_MDL_A_02047316 | | | | | | | |
| TE-1374 | 11/21/2013 | Email from Michael Morreale to Corinne Gillenkirk, Greg Hadaway, Gregory Garner, Kathie Glick, Kathryn Schick, Mark D. Morris, Michael Warken, Sara Putz, and Valerie Kaisen | TEVA_MDL_A_02071767 | TEVA_MDL_A_02071768 | | | | | | | |
| TE-1375 | 8/24/2014 | Email from Randy Spokane to Joe Haygood | TEVA_MDL_A_02174965 | TEVA_MDL_A_02174965 | | | | | | | |
| TE-1376 | 7/6/2012 | Email from Randy Spokane to TevaUS_TP_Sales_All | TEVA_MDL_A_00693483 | TEVA_MDL_A_00693483 | | | | | | | |
| TE-1377 | 9/7/2012 | Email from Jim Reilly to Randy Spokane | TEVA_MDL_A_00694333 | TEVA_MDL_A_00694333 | | | | | | | |
| TE-1378 | 5/14/2013 | Email from Randy Spokane to Chris Brown, Geoffrey Merris, Joe Haygood, John Harold, Michael Morreale, Randy Smith, Shawn Lally, and William Sweet | TEVA_MDL_A_01319597 | TEVA_MDL_A_01319598 | | | | | | | |
| TE-1379 | 1/27/2014 | Investigative Report 2014-21 Greg Garner | TEVA_MDL_A_00404212 | TEVA_MDL_A_00404215 | | | | | | | |
| TE-1380 | 4/18/2000 | April 18, 2000 Statewide Increase In Heroin Use, Especially Among Younger Population | TEVA_MDL_A_13762249 | TEVA_MDL_A_13762249 | | | | | | | |
| TE-1381 | 07/00/2017 | July 2017 Treatment Episode Data Set 2005-2015 | TEVA_MDL_A_13763285 | TEVA_MDL_A_13763516 | | | | | | | |
| TE-1382 | 09/00/2004 | September 2004 – Treatment Episode Data Set 1992-2002 | TEVA_MDL_A_13763520 | TEVA_MDL_A_13763752 | | | | | | | |
| TE-1383 | | 2009-2013 Ohio Behavioral Health Module: Prescription Opioids as a Primary Drug of Choice | TEVA_MDL_A_13762244 | TEVA_MDL_A_13762248 | | | | | | | |
| TE-1384 | 08/00/2014 | August 2014 Treatment Episode Data Set 2002-2012 | TEVA_MDL_A_13762250 | TEVA_MDL_A_13762428 | | | | | | | |
| TE-1385 | 00/00/2001 | 2001 National Drug Threat Assessment | TEVA_MDL_A_13762148 | TEVA_MDL_A_13762243 | | | | | | | |

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------------|---|---------------------|---------------------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| TE-1386 | 00/00/2018 | Substance Abuse and Mental Health Services Administration Website: Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health, available at https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsRe | DEF-00099217 | DEF-00101726 | | | | | | | |
| TE-1387 | 8/21/2019 | Reason Website: New Survey Data Confirm That Opioid Deaths Do Not Correlate With Pain Pill Abuse or Addiction Rates, available at https://reason.com/2019/08/21/new-survey-data-confirm-that-opioid-deaths-do-not-correlate-with-pain-pill-abuse-or-addiction-rates | DEF-00101727 | DEF-00101729 | | | | | | | |
| TE-1388 | 09/00/2015 | Sarra L. Hedden, et. al., Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health, SAMHSA, September 2015. | DEF-00096558 | DEF-00099025 | | | | | | | |
| TE-1389 | | Trends in the Heroin Use in the United States: 2002 to 2013, Substance Abuse and Mental Health Services Administration | CLEVE_000118926 | CLEVE_000118936 | | | | | | | |
| TE-1390 | 7/21/2016 | Email from Matthew Paolino to Pam Murray | SUMMIT_000023243 | SUMMIT_000023243 | | | | | | | |
| TE-1392 | 6/8/2012 | FSMB Letter to Senators Baucus and Grassley re response to letter from the Senate Finance Committee | FSMB_001030 | FSMB_001057 | | | | | | | |
| TE-1393 | 10/28/2015 | Email re: Publix Anda weekly call | TEVA_MDL_A_01462200 | TEVA_MDL_A_01462203 | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | Teva, Cephalon, and the Actavis incorporate all other Teva, Cephalon and Actavis expert witness materials given to the Plaintiffs. | | | | | | | | | |
| | | | | | | | | | | | |
| | | Teva, Cephalon, and the Actavis incorporate all exhibits listed by any other defendants not otherwise captured on this list. | | | | | | | | | |
| | | | | | | | | | | | |
| | | Teva, Cephalon, and the Actavis incorporate all exhibits listed by the Plaintiffs not otherwise captured on this list, unless objected to by the Defendants. | | | | | | | | | |
| | | | | | | | | | | | |
| | | Teva, Cephalon, and the Actavis incorporate all documents yet to be produced by the Plaintiffs and not objected to by the Defendants. | | | | | | | | | |
| | | | | | | | | | | | |

Teva, Cephalon, and Actavis Generic Entities' Exhibit List

| Ex. No. | Date | Description | BegBates | EndBates | 901 Stip | Admission Stip | Plaintiffs' Objections | Defendants' Objections | Offered | Admitted | Not Admitted |
|---------|------|---|----------|----------|----------|----------------|------------------------|------------------------|---------|----------|--------------|
| | | Teva, Cephalon, and the Actavis reserve the right to use any document or exhibit not included on this list for purposes of impeachment. | | | | | | | | | |